var title_f34_18_35104="Circumcision complication - Meatal stenosis";
var content_f34_18_35104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meatal stenosis with ventral scarring (black arrows) after neonatal circumcision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35104=[""].join("\n");
var outline_f34_18_35104=null;
var title_f34_18_35105="Urine sediment showing squamous epithelial cells";
var content_f34_18_35105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing squamous epithelial cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A group of squamous epithelial cells in urine. The cells are large and flat and have some granules in their cytoplasm. The central nucleus is approximately the size of a large lymphocyte. (Bright-field microscopy, 3160.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McClatchey KD. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35105=[""].join("\n");
var outline_f34_18_35105=null;
var title_f34_18_35106="Toxic epidermal necrolysis - bullae";
var content_f34_18_35106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bullae overlying diffuse erythema are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35106=[""].join("\n");
var outline_f34_18_35106=null;
var title_f34_18_35107="Pulmonary regurgitation short axis color Doppler echocardiogram";
var content_f34_18_35107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/79177/prssaxbc_conv.mp4?title=Pulmonary+regurgitation+short+axis+color+Doppler+echocardiogram\" style=\"width:360px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The basal short axis view from a 2-D echocardiogram with color flow Doppler shows significant pulmonary regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35107=[""].join("\n");
var outline_f34_18_35107=null;
var title_f34_18_35108="X-ray fracture of the coronoid process";
var content_f34_18_35108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    X-ray fracture of the coronoid process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 576px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJAAbcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwZzUbNT39ajPUAelAChsmlLc8VGDn8qQntQBIHOfx6Uhc4FRg8k+9IewNAErNgj370gc5H161G2SPp0ozgjvigBQ/X60B8sfwqPjYefpx1pBjcaAJS/8AKkMhqI5HekJoAm8yjzOOc5z1HTH+NQnpijPFAExkPFHmGos0dqAJN5p3mccd+DUIyDTs5JzzQBJvo3kjioh9aOhoAkEnNKX96iI70ueMUATBztB/SnB+agU4IpQe1AFgvx1oMnQd6h3cc+uaUEbuuOaAHl6VXJPXFQsfw4oQ9s5GKAJw5ypOT0z9KXd83GcVAG5pxPNAEgfqaN5yR3pjHdg7yxKgnjGD0xSDJzQBKHOOtIXx0PFN9eTimmgCUueeO1Ac9zxUeeT/AFoHTtQBIrnrnml38A8dcdaiU0uTjtigCbJ9acGPr2qEHHvTsce9AHa/C9DJ4j3Z+VF3V9CaWAseVGNv514F8KIPM1S5k5JCquAccd69/wBL5UMhBB4GR1oA6Kz5AB2nBAyPpUtydw4Bzxx71BartA2r09Kfc4LAs2McknvQBFNuBYqu3Z1qrMPmUMcqT2pZG5JJJwuBmmkFd20jOMgfyoAGXAyCBk8nuB6U6IguY3BIzgH19zUZyAT1JHce1LERlMk7mXHPNAGhD3YY3YB+tXIFUKAc7hyeKzYnIkPQLkAYNacQVs7gc8gc/rQBYLMCFTkN/KrOCwDEcjGOegquvygMcKT6dcdhU1q+2EgnvkHHSgDRhPyc9T3p5PHI6daZESU56+lKxwvJyV60AVLpyq565OAR1oqHU3wpJJyaKAPgWSouh/CpH61E3WgBrd/pQfc96Pc9cUh6mgAT88c0hPK5OOKB932oJw2R1HegAY9McHNHBbApCc/WjjJOKAG9QOwNIRhmwc4OPSgcAUnY+lACk54pKXrTe4oAUZwT6UUnp+lLxnjgUAGaM0lKKAAUoOKTmjvQAo+6fWlzkYo5B470Y4JHYc0AAznHrSU49c9jSYyKAFOOMUo7e1IO/oaUZBxQA4n5hkdqQdTzS8biR06Ui8ZxQAN39KBwCaVmJGD0GccUmflI96ADufSl7+lNz60pxQA5D2pwPXHeo1p6nABAoAeO9MJw2Dz245pSeOM038aAFzkt6UdBimjofrSmgBR1yacD6daYOgpQeM0ASLxTweOf1qMH9KkVsBwADuGOR75yKAPRfhEv+k3LFCTlRuB7V7vpiEwg7j2JGOteJ/CC382Gd8ceYSCDggjivbtNLKikjL5+Y4oA3rbIGOduep70ydmJOSCeg9iKltgdpOAQBxkVXuSdxBOAPwyPWgCDIYFxyvVhjpTC4LMQoznAHtilCjDIxcLnPH8R96YSFUbeGOcEDkUAOX5jyVbJ6f3aUMUztIxjOSOtMGNobdyTggdOlSSINg29VycDsKAJFP71WUEDGCD3rVs2ZmUHB45J7Vk2z4ZSRmMcgN1Faaq0aM4UEkY60AXG5UqME4xn3qzEv7lRn73Qiqtv86qCBkKM881oQgArtxgdjQBcX5cA8imluo6j1NKpwPbqaZIQAQMnI7UAYHim6+x6XPKcEqFznp94D+tFcr8a9Q+xeCrl9zF2ljTAOCx3Dp+VFAHyAwyTUT/eqaQ/OxX5QewPQelQmgBo60jA04ZzSN0oAQD5aQjBNOHamnvmgBB94exxSHoacMbufXNNP3WOeQelACJ97OAQOcdjQOh+tJ1IoU8/jQAH+tJQOnvSjqKAEI4FJSjpQeOOM5oAOuKKSloAUUf5FFHT60AKOnvSikJ4B4HbilHTNAAMZxQMg4NHbtxS4796AExzinj5iD3pvYGnKPm6j0JoAB/9akUdzS8YJNKnA696AGsvb8RR0UdeaOPx7elLjpz1oAQY3Uv8XH60AfMBmkP1oAVRxTx0pqjqSeKVTx60ALRgbepz+mKVVLNhQScE4AzTWOBxQAAcHHFIcikTBoY/MeaAHKMjGB9aDxwab9Kcp+Ug8jtigBRUobJzxyMVEOuKevf6UAewfCGEnRjwSHlPT0r2WwUAA7SBgYGe4ryr4UR+ToNqwL4PLDGBzn8+1eraeuVjyMFhnrQBs224DJO5hz+BqJiu7LfMvTkd6mjymN3TbgCql25wMHljjkdqAIC5CFX5B5BHc1H1JCgjOAd3O2oyWDlmk4B4A70qEqx5JOc59fSgCyhXftIyc8EVOy/L8uNuMdPWqMW0E4J3E5PHSr1uVdCDlcEYzQA6KMB1zjJ7E9qv2rn5A2MAnk/1qrbEqH5IYdD1FWztGCAN/UYoAsQBUkLZwGOzI/nWjCpwo3ZYcHNUAWRQSACeB+dXoMvhSScHGaALa9snr0z2qKZsAF849QKkX5gCO/ANQXLbVOTgc4HvQB4x+0VcMPD2n25cbprksOccBT/jRWN+0TdB9R0OzkcnZHJMU+uBRQB8/P8ATmoT1qZ8VG4xQA3vTW9hTulNbGRz3oAD6gU3+E8dqcRgY+tJj5RzQAmOTxzTWpe5NIeooAb3oHFC/e60JgsM5oASge9AFA60AHTFFKRxkDgdaQYoAKB3oo60AKRz2/CjHpR2pR1oAOv40dPpSkevek96AHA/rR3pO2KUe5PFACjjGelKO9NHQeo/WncYB/CgAH3Se/elHC0znFOAyvPvQA0dR/WnHtjHSmjrmnsOg68UANXGRRwTSgY556U0nnvQA9e+BSr92kUYHBpVGFHOc0AKCRyCQfUGmt09sflSmkbpQAIOR0xSjk801SM+2KUH5sUAAHNO6GkpcUAA4INPzgHjPFIBzilAzx68UAe+/DlHXRLPAXyhGOp6nvXpWncKm7Oxe/vXB+CY/L0y0QDkruc9AcAV3+n8KAo+Yc49TQBrxFweD749TVO7XcpAY9ME981dGRGTgE8H68VnSnuV+XPC9xQBCiYVdrAsq/MO31pZTtwwIO4gNxTDliT1J64GKJSq7tuQWxgDp0oAQ7kbBUYzgA1ctuwLDj5j74qlFkv0yCMn/GrkaspwiqT29qALsIIYcY3DOTViNcgLtII+XmmxYdB2x0PrTwdmQw4z+ooAuyKGCMcg9CD/ADqzYg9B1J65qorebEOVyxBHPGB1FXLUZOQ3IP4ZoAt5+Qj3xk1VuM7CpJwc9B0qy2Ao549Kp3TbScnI5I96APmf483rXHjqOAEYgtlAJGMZyTz+FFYHxTuBdfEPXJQcgSiP1HyqKKAPO3PBAphON3TB9qc/eoz60AIfU9c004yB9ad06etJjJoAQ4/SkONtOI6/lTSMECgBv8Tc4yaD1OR2oPTrzkUN1PrigBgHIFKOCMUDqKOMA9sUAJ/Kkpego45x0xQAemaOhzmkPanAZH1oAToKB060D0ooABwec4pcc+lJ2pfegBT15+tHrjpRxRQADjFHGTgcUE4HH40AcUALnmlHAFN7nFSNgAYz05oAb2waX+EetIegNO6gdcmgBv4Dilb730pF+9+NKfvUAL6/Sm8Z4pcDknNIOtADl5SlHCihcFMHv+lHG0UAKelRt1B9KkPFRtyw9aAFXr0o9OtKvTNL3xigBRyMDrntTs88cU3HFLQA4emKkgXdcRLwQZFBz6ZqMcjPpVvS4xJqVqjHaDKuT6c0AfSXh11aKHZGqxqoUAHgV2FjnHoBj7o7VyXhpPkRHVcgA59eK62xBYAMMHHUHr9aANVAPI59cDPes6RstxkluWz1FaDn5GyDhsHAbms+4JXc4DZ5IA60AVQxLqANwCnIPfnpU0cY2gEjCtuwewqK3UvJuzlVGSfc1YKhm2gH0Pt9aAGjkKM8KMEd6nicKoAxwO9QbSTtAwTgZ6YxUuP4mxleBz+tAGnbsFcRkg/1qxIpC7gQVPr0HNZkUjSHd3xjOP5Vq2p3RAHBwOR/WgARgpGz7vUH0Poa0oeVDMc9sDvWeVLHceinPStG3wYkYZwTuNAEzEYyGyc9cdKzrxwgYleAMnH0q8xByQTgHp3rC8S3HkaRezMwCLEzdfbpQB8f6/dfa9c1K4Of31y7gE9OaKoSO0rNIQMsxY/UmigDHfvTCeae9Rt7UAB6fjSA84pfamg/MR70AKTwTQQCp5H+NIeCCBR0NADD0pH+8xFS/wAKmmFSC3v0oAYoG4c4B70i9QB3pwHTt6U3HFACHoRSZ4pxyQD1x/KkxQA5VRkYtIFK4wuOXyecHoMe9InXBPWk44zSnrmgAPAzn2oPcinqc8nvwTjNNAyPpxQAgpelAOMZ5HoaU/TkdqADvR3IpRyCPxpOx9qAAfzFC9jnkHFH0pe4z0oAOOeaefx5FNBwp7n+VOPTjr1oAQ9MdiKOwofqKc5AbIoAavLZ7UppFHPuOaXHyjnNAARwfrSKMZ/3TTmHNIv8XrigBQOn0oUcDvSn7uenFHp29KAEPX8aYfvDipGB/PrTe/NAB0oHegfpQvUn8qADqKd2pq54p3agB3pWn4btzda5ZR4yPMDHnHA5rMrovAdv9p8S26k4wrNQB9C+HBut4yyhQeWP+NdVYjER5ycjkDpjtXPaMmBGAR5YUYOOMe9dVaLjC8ADnIoAn5OR1z0x1/Cqt2pBxyW+YjH8qtrnkjbg9eetU7mZdjFeGGAF9PWgCsgWKMlx8i9MVYiVWizExB756g1RklYOHBGeTz0FOgfdhosHgBhQBPI4yNvLck54qbYrWzSJyMYxjoaiUAuAVJDH0ycVbgXbFJnGG6kdCBQAiIqICVYDgn6VctXCnGVIxgc1CsI8oEHr3PSlSExzZIwq/Kc/nQBrIp2jJI6A+9X4VCKuOFAwCKo2mHjXGPx7Gr65CjGM9evAoAZIBjA6ZxXEfFK5Fp4K1aZeD5DAHHPpXbS8AkZODXmPxwuTB4H1AbsMyADI65I4oA+XlyUU8A4zRSDgAc5ooAzX61Gc4qV+tREUAL9aYOpp7cU1f/r0AIaUntik9KD0oAUHhaQ8hqUfdFIen1oAaozg0h4fOOOlOXqPegDLADHPr60AM6HGOKaOMjA6dakb7ox26UxsYBHb+VACN24pRyMUHrg/nQpoAFPGKU8HtjpSevHFKOnI+tAAenSlzzkcD86TPGDQOo96AAcdfpR3PpR6Z+lIaAF/SlyTjNJz1pw6igAUnA/WnnIGPSmEcdOvanMR36GgBPUYpxZlB2nHUU0fe56g0p6/WgBUPI4GKFOMDFIvcelHcY69KAF7nNC9GoPr7UoGMgkE57UAHYUopO1KOtAByaYe9ONNzzQAvbjrTen8qd3pO3Q560AA9RThjtTR0p/0oAUda7X4WqTrkvH8HXuBXFryRXpHwftRLdXbOCEJAJH8qAPctJQxRmORc7cY75FdFaqyL8vPfFY2mR7Vxt46qT29BW/ar82QMnI3YPFAA6Hcy5yT69qyZ2UyEL/eyP8AGtR/4uOTxnviqNzb7m2py3Qj0oAoSRMcMmGJ+8vrUlopSYYHXg/TNTPG4Jx8pB4I9fSk8xYWO4ksOTjmgC4pKOCBlhjpwKmZ08vYTnPO0cYqnDmaN2B6AYxRcBs7m9MgA0AW4naR9hHKjI9DUsMvmM2QCo654Jqrb58nLEljye2Ktllj8vIyCSMEYyaANKwwI9pX5Qa0x0IJzngnHSqFkd8mFUDjOM1fHQ569aAIJeFG4554Jrxj9oq62eG0gQf62ZAW7YBzXs9xnkkBeprwH9ouUfZbGPPJnyOe+OaAPDiTvPvRQeSSRRQBnv1pn509+pplAA+CpxTV6dO1Ob0pQvPXAxmgCM9RSH7tOwM9TjFIe30oAQDBFIT8uPwp3rTGHyZoAF5wPTFKOTmmjA564P6U7+Ig9zQANwM+/rTfXPTFOPXHrTOgPqKAEOenpx/hQfXFDdR6dDQRwPpQAfrSDrmgfypec+9AAaUdKQ8rSr/9egBBR0OfalIw3HWjjNAAOMgilHSk4xnNP46+tABjgUN1AxwaXpikbqKAAcsCR14oOdtAwScUvB6elAAvr1pQOfwpFHDDpTuq49OaADI5+lC96T+WKVeAaAAc5oHehRwPSgdKADODTfWncZpnAAHvQAretIc8d+cUp+8KOy/nQAo796B1/CjtSjv+VAEi9q9h+DVsF05pGQENISx7+xrx3OFNe/8AwvtGttHsoyg5jDEf3vf680AemaYgwM5xjAWtiHAAUbvyrPs0UYz1I+ma1YgEU55x2/8Ar0AMnO2EkgbR+YrPBRgMbi4J6cZ5qXUULKN2SFbfwehxWepEZyN2/oM9qALkkyYPmE7s5I7kVVljzsaMHAOV9z71HFlv9aMvnhwetWZZorcgSMC+AcCgC9YQhVbK7Sfug8029h/iHC5zj1qKB2KZ+8v3ifSrqt5gIOC/fP8AhQBQjcghvmwxxirkUomALAcHpn9ailifbtQAheSSeQf8KkVATkcHHTPOaANbTQMkkEMo6n0rRZsBjwD1xVLTAwcuQBxgg1efoufXnFAFO8+7Ieox0NfNv7QMwfWNPhDZYK7n2HavpC6O2IsRnORzXyx8broz+L4AM4jgPU+poA886gCihcZBOOaKAKLg4Y4OBio2/GpXPDDse1Rt1x6UAN65px+6fXFB6HtSkDuTQBGSOcUOfalIG4/SkbrigBP4zTHHyHFP701s7e3U0ANPfPcUD8cikxx0pRngnHXmgBz/AHj+lNzznHFPPVc/SmcZPvQAEDOO1J/Cueo4pzDkZHfBpABx/tfoaAGt04owA1KBkEUi80AFL3NJjj6U73FAAe1J1+lO56ccUAYPOOKAAdBSjpQDS57mgA7Uh6g+1OzjpQOo9cUAIByenekHX9RThjnIHpQflI6UAHvilHU4oHTFKORmgBp4NKv3aG+91HSlXoM0AIOtA649qUdRSg8n6UANPTPrTeKeehpo64oAG75pP8KU47d6O/tQAcYpfX60gPvS570ASwr5kiJ/eYD8zX0x4Etlg0+GNoyGxjcD1A6V83aVF52pWcWM75VGB35r6m8NQGG0jDsMkc46D2oA6m1TgBQcjHPQVpMD24GMZFVbRRtBxgjjHb61cwQoCg9OnT8aAKV6SgGCCTzjHIFULePcd0m3axxn0o1EtKe+3bgnrioLOf8AeooBKLnAPegCO7cxTsicYyM561RkYynzHb7vTHc1PqAaRi2B/WoNhYYVcdPoaANLTrhoZEBIYdMHpmte3PGc84PHU1zKXDpdhdu6MjjiukhAyrxkLjLHPTPYUAIkhWRQ5DE/rVtQWZuNr459qyo0lxGbmWKW5jzvMabFJz2FbNuyyLuJwx4478UAaenr/oybpCx65NWnOM9fqaZbcIm4cbfwpW4j7Dkc0AZ2qnZbvICRgZYHvXyR8V5/P8b3hJ+4irx9Oa+sPEJAspC2ecg+or498dXKXXjDVJFI2ebjGOmBjFAGCrckUU0YJyMgUUAVn70wipG7imEDIzmgBvrQcY6UDmkPFADe9BA3ClGMmg/eA9qAG+2O1NcdfY08j6dKRwMt9aAI/wCAfSjHHFKPuEijGV6c5oAU5IU+hxQwHJyPWkPQZ+lLigBDgn2NIRlfelPfHODxQOnH1oAbkEZ9aTuM96UZwR6cigjj9aAEx69DTlwR9KTGVzTh+lAAoG2jHOccUnb0zxSjJycgA0ABGcY9KcBwBSYOV9xSr0GT1oAVeQKAOeaMckDp2zTgDznsKAGjHNKfvdqUA45+vFH8R+tAAMDFA7/WlxnA9TQeB0oAa3X8KdjAFJ/FxTv4j+VACDApAMdKUUUAJ600U89DTaAEIHA/Gg+9K2c+mKU9cGgBo+mDTu1C9RR2xQBveCbY3fiexjGMB9xye3T+tfUGhRlIY1VRtQbSR0xXzx8JrM3PincciOOPLHt9K+k9IXbEFACgHqfSgDcth+7XGR3zVtsiInOR0I78VFCu1QMYGMU+U4Rjkbl6DH6UAYt2QscgU4XPFZjMI1IZCMZwR/FWldZZnUe4Ge/tVG7QmPylGGT5ie4HpQBFBKGysi/MuOeu49qrXjfZrguMmILuPNO2kSyGJmU7Qw9R9Kc0iXELRyADoPrQBQkuH8tJFyC569cDtXU6ZKJ7RHZdrEdu9ckLfE0kWHjII2svQ89K3dLuVM3kOwBK8cdSetAEn2kyXUi4wueCOldBp5LJsJUsDkDHT61jPCpJJxiMYAXvWzYReWQ4BXceRQBvwgJEvBBH40Snb1AwOKemfKTB5PvTJsFDgDdQBzniqYC22ByGI/M18b69KZtc1ORsZe4cnH1r678ayeXA5zgopJJ7+9fHN4/mXVxICSGlY5Ixnk0ARgZxgUU0ZJ5ooAhcU09OakeozQAzOaDSikPf60ANx1pSMMAetKeaMfhQAwnBA9c0j8U8gbkpp5b8KAGdj6Ui8Ak/WnAfKeaaPunPYUAOwSrYHNJnofalXow/rQeCBQA3HPHrQOARj3FO7EdxSKOnPQUANOAc+h5pR8oOeo6U7sRikXG0nHPegBoG047U7HUd80mMEe1OIA55yKAGjlad1FHGfak55470ALg9jj2pVGBQRluBThwOaAEI7+1OHf2pO3vS7WHVWGeQSMZHrQAAH+tJ0PTHWlXrR1BzigB2ec0mOMe9HUg0D+tAAe2cDnr6c0pUK7DIOD1HQ0jcN2IzTvXjHNACbW2b8HZu257Z64/Kmgcn608cDHbOcZpB1GaAEI64pMf4U8KSrlR90bjz2pMAAUAMPf60N1OAKewAVCHDM2Sy7SNmDxz3zSdzQA0cds8Uo7UACnAeooA9N+CsAa6upHB2l1Xj2Gea+hNLUMuSOD1J7+1eM/BWy26OZ1VsyvnB/i+le36WrCFOOnQj19KANMDheSeOvam3BzGFA3AdjxU8Y2x5GMA8d6ixjLk8dOmaAOfnbEvQYX5s+ntULujM+CQx45+lTakwR8ZxtGc46VkF/wB45HAbDc9xQBNdLvg87CB8BQAe9Z/myRoAwBO7avFW1DCZImI243YqhcjEnmRndECeQMke1AGnGiT25Ylg2evoaksIw985G0yLkZYfrUMJeFSCS4JBA6AD2qfTlWa+C/MkxHIzxQBfDqlxsHzDoQT1rorNQ4BB3Kvb3rnZ4is7x4yx5Uj1+ldHoKkW2xySe/1oA1xkIucZHOKjmIIyPXNTD7vPNQtwGGAQR1oA87+I9wIbDUJVP3YWbnkj5a+SQeOO/PWvqH4u3Rh0C/mRQHETLk9u1fLhHyjntQACilUZPWigCNuc569sUzpUjDP1P61HzjkHHYmgBozgUHp1pR0PIGKae+Rg0AAHNA6nvQcjA/OjrmgBO4pRs3OZWcYjbZsUHLdgc9B1yetI3UegNNbqfQd6AEXhevamjgCg9DzxStye3SgBU5OCRyO/amH7o9KUdR+VBHymgAz1GaQYBI4570rdTSduvSgBfx9qDwxGODSNnLDPelPOKAEGT19KUnK4z7UdPfvR0YjigBBng9eope+B0oGcnPpkUHJGc0AKOv4Uvp70Dr6cU7oKAD+LnnijJwcsx7cnNHPHFC96AFUdM0Y9eBTlPA4owe/p+dACHsSMClxgilwRjH5UDIIFADX9DTsHkk8004yPXNOPXrQAijJx3oH16dKM/McUD8jQAEfpR/COKB0o7UANHJpSOTikHBpD1P1oABnBpzH5ffHFNB65qSJfMkRBjLOo/WgD6M+Gdh9l0WzDDAC5wT6jOfzr1TTYyR14PJHpx6VwvgiEpplsGXJT5emAw9QK9AslJUgYGQQcUAW2JaPAzjGM00kNgHnA/OlT5iMHIGenQVGGyrqAAFPFAGDfwl7l1IOG49M1kXEI3bVdguQApHQgdK6K/AP+s5PY+gx3rKkhZNq5DsvOcdaAKMS7rhWZsOvRj0aqs5e2vJAF+VzyO31q1dqftwWNsqBgdsVJcxk5OB8xH3uxoA5nxBq8tkiiF/3Mq5UdCpq74Y1gyS77mSKScf3Tz9MVl68r/wBqxxOivCV24IyC1ZtgH0vUpEuIBvGfmPAOPukH6UAesjy57oMwYHI6HpXU2UZUDA4J4rkvDro7b9x3BQAM5612NoMEkkHA/pQBY7nvjmq12+yGRmODtJyKsj1wPWs/VZNtnJjg7eTQB4t8Z52j8MXignaV2ZzyCSK+dmPPtXufxwuyuhGMKNssigHvkGvDthIY5AwM0ANXJNFPUbSKKAIndjIW/iJznHQ00ZKnPQetK3Wmnr6UAMY9qRiSTuJz6k0rAg4PrTSD8x4496AA54ySaXoOD+GKQnj2oYMuQylTweR2NACNnNNP86VuhyKQnkGgBMHB780DnBFA7/WjsRn3NAAowBSENg4PBpeh5FIfyyKAGkHINLztHvQ3B44oz6nmgAOe1KDxk9qTkHtinYwccECgBM56dutBJUjpS5wPrSAZye1AA2Rg/wCcUpyCQaQZK0q/NznB6UAKD82cfhTsnCn+KkDY7fSnA/KvHXvQAgzj2pQMZyPpR259aX1xzigBVOcgdaDnA70in0pR0HY4oAV8DyyGyWzuXB4/Gm5J/PpTgcEfKDj1pvbPP40AB6+/SlGc8005B/GlyRg5oAX37elApM4A/Q0q9aADnGe1DDAHNAoGMdPrQAg60nJ496UcHHrQOBnvQAgH51oaFB9p1qxhyBvlXk9hmqIIrpPh7bi68UWwb7i/M1AH0r4et2WyiQBgFXB9fauxgP7vIGDjJHpXPaQG8tBjnv8AhXQwA+VtB989aAHj5Rx37jpU0hVYCcDOMYI5+tQMCfk7DqalZi0BDNgkYGetAGVcsHYrwHA5B796zZVZAmTxzkg9RV67U/aAZcAY6+tUZJAGdSPlz1PagCjcsxlbYFwAP/11Dc3O6DaijzQPlx/FWsLeOQ4cozyAkg1yGv3H9nS4KNscngdgOtADEurbzG+1nAViFI5/GnapA+oWTmII8yj5HH8Q/wAcVRC2987IoKv5e+NgcBhjqaz9Ck1DTdSWFj5sTuuUJztBoA9I8FxP9gg3oUcqM56iu7tkUA7eRmsaKBIyDEuAF7dhW7Au2MAgnpigCRsbR3+tZOunbbOoyFxk55rVbcM45GOawPEM5SHCgbu5oA+e/jk7C0tUZshp93XHQHtXkiucEcHIxzXqXxwlLy2UWA370uCfywDXljxOpwVIIOCBQAufXpiintHJG5WSN0YdVZSCPqKKAKz5yaRuBnGM08jnnpTGGfp6UANxlTjHA9aZ1NPI4pp4bHB9xQAmcduoxQe/9aTvQaAEb2NN7CnNzTSOn1oAdGwUONoJbHJ6j6UiHBB6nryKQ8HsaOmaABvmIPHfikb7v0NKTx0yaQ989O9AA+QRzwKF6UP9wUL0HP6UAAPBFKSeD60ZHNHUEevNAB29aMcY9aQHH4UoOPTIoAAcA4x0xS5wTmkPWjPt70AO4+tOY8jHSmZ+9+dP7CgAHIPXrTlK+XIGUliPkOcbTnr70gwMgUnQE570AKD09aXrj9aTOB15pRwvFAAPvA80nb8KQkjGOmKVfuD3FACkncPr3pDx+FOPHfmmk885oAD09jTh0yOvpTO/P1p3agA7DrR3FJ246UpPNAApHPNIPu0mfenZzmgAFej/AAYsY5NSub6ZcrDhVJ9a84HFe2/BqwaPQZGYLiaQHkdaAPZdHULDGecYyOM4rdtwAuThee3GaydIOYFwAccZAzn1rYgBEa5HTnPtQArICcjG7OPqKWTPlNwME9cUD7xA45HvmllU+Xj+Hdn3oAxNViUOsjclcAD1/Csok+Y5dS2MhTnp9a37iHeJFJBPGM+lZKKVEisVBHPAoAqoisks8Y2mNcKpPOazne01f5Llf36EqFPb/Grc7OkM+Sct0C9R/wDWrINrMlzDcq4MJJ3/AFoAgksPs9m0SqQwPyOvO5ehBrR0fSkvb9LiOIFYtoznBXHapreVJEe3lYLGCAcdQe3510mmWfkFRCgCN29D70AbFjGdvzjK8gdz+NaqKfMX5ePaoII1RVWPJyM+lWh7dOvFADJDjhcj3rl/ETk7gcn5eR7+h9K6W4J24yf/AK9cn4hdWmYYwSOTjpQB85/GV3bUbRGHyDcQPfvXnjA4BGPw/lXe/F9sa5Z7nDkKxI/rXBqcDOSTk0APUtvyzOxxySxJP40U1CQR3OKKAIX6mmnjrT3xTD0FACdqYwp5xtHrTT60AMI5oFK1H50AN70KSuDgHDZGaXo2aB0NAEbDLE4AzzgdB7UHG4/rT2I3sTjJPNN6UANYZOPype/1GKU9s9KGGO3SgBrEkZ7g0idPXNKec54wc0g5HI4oAUgg4HFLnvikwNvuOKMYyR+FACgfNz1o9MDr/OgYz3zQTyQevWgBcHBxS59hgcUgxux1BFL1HGaAADjPHoaf1/lTRzmlU9BQAv8AD+NAGQc9qF5H49KAeGAHJoAUjn1IoB7HpSNjOOc0q44zwDQAcZIBHpSN2HcUoxzngdqCCOMc0AJ2+vajacD264pMcAY9aefvHjigBD2xQOaPTHSkPHSgBSB+lIaccYpCOaAE/wAKXtSH7tKOgoAeiksABnPGPWvonwFbi20e3gGQqLg59TzjPqM14LoESy6xao8ZcBwxUeg5r6B0Fs6Yu1SFL9AOcUAei+HAFtyGzsJIU+v/ANet+2wIXGSVPJBHT3rF0MbbYAhvu9+3vW1AnzHJPJwfegBFXbMCMquOMim3Rw6behzz6HrUyEsGA5APHvTLpl8j+8cZ4/LNAGbdvkuCSM+g4+lZyDykPI98/wAQrRuFXdlmxjuen1rE1KZX3xoCADk46UAZ93LiaXzDgSZ6dBiqtriO3aN8yLM+cMOnFJPL5kgRXyoHHHXPerFvGsUvluQjvkZIoAn0/S2ubp25RPzy1ddYwvGCr5xwOnB461R02zMUMce7BVfmOeetbtmPNVdwYc8g0AWoFwiE5zjufSpjgDjr1wKYDggjPHFDdDgcfqaAIrg4AHJJPXHauP1z55JizsFwRtz1rrL5sQkhgoAzk1xeqyLtY5OSpzjqDQB86/GCTf4gtxt27UYdPeuFB/Su0+LII8RRMQQHjLDnj0ri05NAEq88Z7UUpOEU9BjsaKAImOCcdKYfu1I47g59aibpQA0npmkBOOBzSkYx3pMdaAEIz+VJ0zTzjPWm96AEYZpoGdw9jTj0NC8n2oAI3McscgCMVPR1yp+o70zHA5496V+lIemcUAAzjpSvgKuAenzZ9c9qQ8Egc/TpQRnPBFAAR81JgbPc05iSeBk0c4+hoAYMnIxxRg4zxTutAwOooAEQv5rB4k2J5mHfbu5xhfVvakPPvinKvGcjOcH2po6nHagAVT2OSDihQSQA3fr6UHr/AFFGT3x1oAD/ABc556j+dP6expMqe+eO4xzSjgjmgBR90Y9aAM/jQOg9emaBnPFADuaOmMfWg9u+KQnIwe9ACkEx7wVKFtoweePahegyec4p9zPLczmS5kaSXasYYgDCqMAcdgKYOVxQAdhngUnqeenWl4+XPIHbNDNlmZUCKTwoOQPbmgAUdfpSdyKXrxSngfjQA09M05hwSDSdh70p4zxkUAN4K+lOUHigdAD0pwQlgBzmgDpPAtu0usGRPvRoSCele3eGQV8uHdwFLEeue9eV+BI0gtXnHzFz8wHXjgV65oCBFA7qg3N3Ck0Aeg6OQLaHZwCuD9fWt2MHyy2Oc/pWDpLP/o4xjIII9vWuhgxhgDxjvQAyMMqO42jnOKqSkpJnaWUgggHjmtBlKxNgZPX2+lUpdphDPxnjAoAz9R2xbgcFCgI+n+NcoJWW6Lk53de2fpXV6hJuMXHyn5Tx2rI8iOOeRm2lsfKMcZ9qAMgWDC4Dx/fc4YHkAZrXtNKJvlmmwWI+UZq7pidmTLseQa2YbcI27gHk/SgBbaFVb94vPUj1q8Tg8AEE/wBKjcAbVwM4yT6ULuD5Prk/0oAnV8cDt1PqaeOAVOetQqdxXI4ByBUxJ3HkHBxigDM1gr9jfA524znmuT1Rl8pxkZHUnriun1vHkqechs4J6CuLnlMiT5GSf5UAeAfFkAa5b4bcqJt46CuIGBXf/FqL/iYQzhsA/KVHI9jmvP8ApQBNuDKABjFFNU0UAK4wOlRkYPpU7jnmomHX68UAR4Gabjr2p3ODQchiO9ADSPWkxz9acRzSc+tACYpi08d/rzTcZA9KABxwaTt1px5OCMim8UANByDzzSnJyB3oA6+tAyaAEB6elKoODnOc80nc469qUffyDweaAEAyOeKUf/WoHpnjFIPY0AIAQT604YHSkAPOP/1UoPUH160AIQOcdc0FSDwRjNOJz9M5pFBwM9cnrQAgGQcU7GBRjHIGKcQM8etACBQMAd6VegNJ09+TS/wjnntQA5vrTVAHWlOOMdcUYIPSgBCMNnPWndOKQcOAaUDrk/8A16AExz070uM9M5A5pPx6UDIO4dRQAuOtHfjp70p6UnAIJoAByPWl6ZNJ604d/pQAAc47VYtY9xy33QQD3qDjFaGmorRlGGTyQR2oA7rSotkEkcCOgGApXnjr+desaCuYQyuAu1RkdjXm2g2rPaBUZvm2lgPTFek+FV3QsAxzvw2R3FAHb6Nue6Ru4TiujhGQDgHPAxWTokBCM4JwCAM9a3FU7jgBvp0oAWVfk4PY5qlJho/nyPRavvyuPTv6VnXAKyKSflPGD2oAzrvBRjjBx27VWgssAM+1tp4z79DWg8XlHysHGNxPWltoWZ2CMfL459KAFt7RFf8AdnOTlvwrQIEbAkA/QdqWKFY49hA4G5j70ly25QFA2kbc5oAi3BnYMw9frTySwPO1Rg5x1qBAhO3O3HQsOtPlDeYg42HtmgCaM72XcMjOPSpJefmHy88VFHtVgDnI5HbNEjED5zz6DvQBk64R9n6/xdj3rjGJWSbON3GVxj8BXR+KXP2Y7chlI5A6nPSufmIe7lSTBVQNueuaAPHPi7bkRxOchD83Xjd6V5cc5r2z4mWT3GmXYKhwi5U45zXiY5GaAHoKKcmQaKALDgN90E4H/wCuq0gyM4H1qxI6hHBQEsNu4jlOeo9z0qFsE4Geo49aAISOPqM0386kYdM+tR84HtQAnYUnenN0pO9ADCeopDznjHFPJHfpTTxzQA0/e96CecgY56elOPU0Hk+5oAb03dc+9J1zg8Uv9PWk4z2OP1oAD0zwMil6gfXtTWHygnkdKcoAJHJyKAG98dKUdulGAevWlAz7E0AIwznHWlxzgfrQBzk4zS49T70ANwAODxSkYpemKkhRpJFCnJzkjHagBmQcnBx25oYc1bFso3Akk1J9jDDKNyD0agCgR+dHIwOKstbHswxk8mo/IfaSoJHtQBGcYGKVuSMD2pWB4+lNP+RQAEndikLYyPwp5HzcYHFNA79Rjp6UAHc5oHU0nH8qcBzQAq5wQBj/ABpPf2o7H3p2N3scUAA5oH0zSqPzpQM4xxmgBRjC46960dLB81eAV6HPNZzDAAPrir+nAmWMKSBnqO1AHrfgsSzQl7j/AFZJUYHfFehaBbeWVVDnLYY+p9a4nwTDMbBJMEMwIAPTH09a9X8G6YIys8uXbsG4IJoA6yxh8q3WM4+71HSrDn+ADnpmiIbRtJ9ajlbay9Dg5wOtADx069R1qvcQNKcnGQBgD1qUkfwkfL1I7f8A16khGQcfUnPWgCq1s0gKlsDAyT1FTJEIVCRjAHJzVlx8vBwfWqsqF/u557+9ABPIAh24wRg57VWV99vtjYBQOW/GnuGEnytk4xtHSoWl8s4KAs3XHTFAAuVZSScHgVLGipG5bJLe/SmMN4wnU9qJZcbVHIJ5WgCYkbR8p9wetR3ZO/PAG3jPf6UiSFsY5HoRxioriVSCN2XHPPpQBg+IQGSNV3HJIJB6muXkkYzlSRuMeRnqMda2tXlJa2dTkBz35I/wrmSdrPJ93flVz6k0AY+uqs8VzGVJJXBXr1714Bdwm3u54CpUxuRgjH6V77qjhngYDd1Vxjoa8h8eWnk62Z05ilAUt33D1oAwIuuKKap5/pRQB6BeeALgBvImJJ6Bl96yZfBepqGwFOzruGO2a93kWNTtblT69R71G1rCwLc5YY6YB9qAPnuXw5qUW7NuXCjPy88Vlz6fcwOweCTK9cLmvpCfS4HBATacFRt9OtZ1zo0Uhl+RQzHKrjgjuSaAPnqaPy0jLOm5y37sE70A7sMcZ7etRgDk9Rj8q9vvPCdpJCsawhotmBGwyQOvWsW/8BQSD92oGQAGXj/JoA8oIpGH512t34HnUlYZGyGCtkdBWJqHhzULV5MRmVU6lR0oAxAMHGO2abtznFTyRSRsDJG6g55Kmoyo2kjigBmM5/nSMMHjpTyOOeeeaCPp70ANYbh19+lGBj0NKRxgDNIn04oAcRhvwycU0HscinYGPoab2AoAByT1GacT0yO9IAQw+uaeAWbAGWPAHegBApLYwSScV0FvZtbabEwJ8yd+XH8AH8NS6To80J3tCXdwQrH7o+nvWqminywrF/l/5Z7uCev50Ac6yNKyBEc7RtBA6t3qaEMoBVd2/IK46EV0Vvo8lwZUiL+bGrSBYz8oPZTSSaUyQCRYWh81iDuPT3x2oA59I2+z/IpbOSwA/wA+lSm0VmjKjBYngHFdDPpDw/JJthzhmbtmrEmk7pFERR4WXLleuc9qAOOv9K3Az2yseTmPHOPasUjkHHFerJpxitA+3apDIM8YP976VwnibSvsFwsilvKlOOnRu/4UAYRHzD0xSEHFOcAN149qQjjGKAEJzjjtSjrS7fmH5Uqqc4AznpjvQAD37Uo6AgdKuxabcNGHdTHGQWy3XArQs7K2DR+VH9q3JkiQ45+lAGQsLuTsUkdjVmDTpZVymGycACtlPtE0e6KP5B8hj249eRWlpWkz3c8bQIQmVyCMfnQByM1nNCdsqMMc5xniuj8G6HPq14ogjdjnIbHyj6mvStC0JbqeOEok7M2DFs6r35r1jRNAtNOiaKC1ihX0QY/GgDG8K+Hfslvbich9qgc98eld/YQeWoyMkc5Pekgt0jICqdo5q0jfIAOnXmgCRjtQZKjPFVrmQ7VIG85+mBSXE6xgHgtn8KiVvNdjhgMDP1oAfZWqRrIYyQZZTK+TnLH/APVWhhVHoKrWmAoXHAHfv9anY8EEcGgA3Z3Kc9P61XkkKDI4J7fSpR90nJHHPFV7wM4VQBjqT6UAQjcj4ZhjGQT1NJNC0oCRYB67z3FOYbgpyPk6/wCNMldmRREdyp+HNACvKBNsZCAq8t7io5Au4E4JYY56+5phJUqAucjJaopGO0YPLHP0XuTQBYLAjBf5D29qqXcxDNlsqvy4A6cU9WzHvxuPIGPyqjqjmO3IDlAo6Y+8TQBgXoE7wxp+83rkA8cZrmL+4KQzM2XkWUKD6EcitPUpvs/2yf5iY4mAUf3u1YNwwhtbTy1MjSAE7m4DbeDQBQknJvroTpthmUTe+/oRj071xfjizjuLK4WIEvFmUYPBx1rsLISLPBI8jl13A5Xh+On0rB8RW5nYzxKDHg7iP4PUUAeWRn2zmipJohDcOnVQeM+lFAH1S1s5LM7Jsyc4/Wo5rSPdnzPlBzhT7VP9vtGiKSBduznseKhe3gk5hmAQnjnOR6UAQSRRhz/pO1fcdKYYZlwsbRODkHB5HpVlopFf5gCv3fmGeKY0BwTC6IwODz1oApLHIFcTREhPmyO5qFxGMFhtyD8uOK0lW5VG3FGO3HHGakUJz5iEHB+8M80AZLWKOVbcCnIJzjn6Uj6PBIWCYwBgjvnqM+1bMdpG6okRVepYqc9aVrKRVbyyuFAAOOQKAOK1Twxb3KljBGpI+dc5D+xH61y9/wCALWSZfJUw/KR9cdx7166ts4jP3RgYz35pPsJdQCgK4JbJ5PoaAPBdQ+H95boZIpQ20kOGXoO31JrEufC2qwrua2J+by8Lyc4r6Oa0O4sAHRMEKRzjH61E9hFJGd0Ywx3EH1zQB8zy6TfxIWmsbgBSQcJnpVYQSk48twT0yvGa+nJdLjJYMvy8nK8HPpVN9Ast6ExR5A+5t754P1oA+b1ik2n905Of7pqe30u9uJFSC0nYtwPkPNfRc2hWuADFGqIVPyqM4Hr+NTm1t0mZQIwu0gseCM/yoA8LsvA+sXAUyQmI7Cdp6/Qj1rq7HwdFaFY1hIb+KZsEuuOceleghzHKRGSyhR1x9cg1BI946StDBFnJwR1AoA5x4IbdFht1iSRVIJLdD6flWdIlqJmWKQnYu1wp4BNbN9JO/myOFeRvmG1cHPSqULsr7Wt0EpJxx9/60ANsw9mwks7cD5cuckht3fP5VPfWd3JaBGaON4jzJ13A9Dj6VZMbC3V1bAK8qM8MT0xVtNrRBvLZvmBb6dDQBmQxZuWeTYwOA6EdfQitW1sXm82RQNyOMEYG7OO3txSNp1s94kKBjGejsOg9PpXR6bpZt1Cvhw0hwc5GD0oAyru0S3jZVj2IVO4ty34CvPPF2nF9PuwuRgCQAnkd/wDGvW9Sib5dzBdhIYEcHivM9flLyPHtjQtlQTz8o60AeTdcH26UnVc9MVPNEUlePGSpIGKS2gkuZ44bdDJJIQFUck0ANhiaWURpyWNb2m6cFkKDBcrnLcFK2bDRo7DdbuiPcMQryg5yT/d+lasWn+WQJEWRiMFiOf8A64oAybSxJuJPtJk2AYZjzya2dL0m289beYsJWyyOvykgDrV0WiiW22LiNCWKtkgHv/8AWras9MiuAJd379ydhB/1ZHYUAU7HTkDeU9nvMeA8inqOx9xXR6RpS3qEkHzS+TtGFwKsW+klHVvM82ZVAVweDzyCPWuu0eCSGCLaixkP98LweP8A69AFjQ7CGzhaSP5ZC2ST256V0EH7s+YSWDHNVIiGY71AJb7uMfnVqJQ8ih+NvUfU0AWlkVQA3AH3jnrTi+I1Kg4IGOOlRYEYwenJAA560ksuAgc7RnoO2aAGXZLqhUZXocdc1PFGAoblXxhvrUHlicJhtpJ34+lXItyygnBB5HPWgC2CH/l6YpkgUtjODn1p6jpjOelNdNxHAyOeaABUKZJPUZNQXBZnBUfKePwq1njbnoKqzclgQQBzQBWZAkqEqSH4J7U2Rz0QjzAcKgGM1NIoEQzxnoQefrVaSRIm2AEyE/iKAGuCAVwASDkeg7iq8gw6lDlnyoBHT1qcjaRuJaVhjPvVdiS2WU7+Tx6470AHEUaoD8wOMe1YPiK4cBM/NgghQOorWuGUlI9+3jcxzySK5nxBJmfI4WOPe3OMelAGBrM8m6Usq+SU2gn+PP8AL0rLvpreYIdjhQwxGo74wT9BU19L5jQ2rPkMxLN6L1rOueEbc5EcM4kJzjdngjjtQA+wxDIhlnR4fLaSLv8Agax7gBtK2IBGzK4bjvnOau6ekii6kkJ3Rv5UbEY6nIIHeqEwk8qVicSKrJIh67gB/wDWoA801m3MFyVY5P5/nRV7xBiW9YrhlPzADtRQB7TDcLHI5lcFmB+oOaQ6gIpDwQh56Y28VRLWyfLNK5Zf7o+8fX6VEs6iR4sM6qfvFv6fSgDQi1+dHKO5EQ7nufStC31qK4mCPGM/dJJxzXNTyoHy2MSKFXcvb/69VN6wrIjgh35BwcZ9KAO1a8soWAJmz3PpxVk3sHy7ZW2jkbhzk1xbNKoLlhkDjjORUrXrxW/nlsTK3IbkD8aAOvivovmZACxXO4DBPOKnW+H3RuTIxg81wh1iSQFYYiu4nknGenSnz61OqyyW+xvJGCp7jt/P9KAO7GpJgxuuApxkinC/jdiDj7vBHf2rhLHXZpJNlzErMRkbT0x1xWot3FujEUZXk5JP9KAOojvEO3bHuIznnp7VXlvYt5LgICxbPUdKyUuHiE4YFk4C/wCAoXU4Q5R4iqE855GAPSgDSkv4nVwCoycDI/Oka5CsVCqx29h3rMmnjmRkgaJw3RTwQBUaT3EKuPJ2gNvPOdw7DNAFqfUhEmVbls53HoPT65qk+owPuHlSMScFscED1pr6g7oDJFCVPKgjkg1DPdEuC6lkZdwwvJOf5UAI8Ucg3uUVNoXknueBiqLRokQhF/sCEhXBxzn+VObUIirPJbMFUbnjbuRwBmolm0jUpfLYTWsijkFcg+woAiS2SKSILfRnI+VixYk/5Jqs7PEj+RKoKPs3OecDofr2q+iWMULyguQNxUbMsPcGoNOitGkQpHIdg3fPyST1+lAFqJLySRY1EcwQAuVfGc+tWrSWQyqkR82cbiqFcDAHTPtVS3jVVaKCMI55ZkbjA6H+lbNgZ7aWPz0Zxt3BV5ODgHH1oA2tNs2miLnynYgvwM8ntW1bQmO3iVgMgEHA4NRaAqvE6QoykEjDdVx0rYWN28sBE2DHXkmgDkfE8nkxJG6P84OCDnIFeXa0+6Yb4z8p35Ix8v8Ak16H4wnxqFwSWDKNq7Tk7ccgen1rzu8BMx8hZZCvyZk6g46Z9DQB5peL5V/cJhsK5xxyfT+dd/4T8Py6ZppublNl5cpwccwoeh+p71D4Y0Rb/wAWy3d1A5tLb97t7M+OBn6/yrvbaMyIxndkdtw+bnbj+nSgDN/s9oQkP7t3YDcp9Rz1/Wkighumy8UgMcnOzoR/hXU6bo899JGeGhQBiR8p47V0dvokCyljbttkfcQOo9/pQByljbq5kNvtwSGUyDgkda1be1SGSVI4wshfqBnBI7Ctm80koPkKbACc9MA1JDb4ZWYoQDkMDjJxxmgCO1sFimYH59y4yO5/pWxDmIksh6jZzkelVkhHmhYiVXblm7delW4g5KMxGSOfQ+9AFqLEsbylCr/zq9bnEZABJ7n/AAqKFGEK8gAdAf4s09FCRIu0kH07mgCSLEtwo43j7x6Co3Bk3bQBjOPYj1p8cX7skgFscZ4IqaO2CwZc8dc9zQA2GMrGu/O88kirCD5lKA/KOQR1prbd6lvugYIz37U5TvRWxkk7Tg9KALKHjB9elSAAjB7+tRxYIIwcg4xipFOTQAx1I2nuP5VWl+bqSMjAxVzqOvUVCsezIA56jHOKAKoAYoGGMDOfSq00YDb8DI6571ZIHDP1ycD6VDOCfvEeXnPPagCq8m1x5nzZPOO/tUe4R73IyBxjvzTJ9qHcSQOSPr2FVp5XMkKDJdzuwOMCgCrPJkhkPuQfauZ8Q3SxP9odfkQYLY4kz049q3ro70eNBmLo4PU47iuPvjJLfStcOZLQkSRAfwFexoAy7lI1KRs3zzjd6ZIFZl9Bi1ihjAMjozGTPJweRWzfxw3yx3THy2RgyEc5Pfiq93bKI3KiSJnYLE4HCqeSDQBQuHdDHsiPlOBIWJyFKDjFUXvEmnuBMfLlkJ2yhfvMRzUt354mlIVTDEioiB/veox6+9UHvFa1jkbBUyOy5HoOh96AOK1NZPIVpB88bkAjk7e3+feirWtKITF9nwQ4LkkfNzjI+lFAHpssoMhZkQnG3gYzTJHikYSFRk/dCj7xp92shgcE7gCTgdvb8azWSN/mTeqgAKQeFz2/OgCeULbIXlzKSQQucYquZyY8T5jO3qB8wOeBUM87pIsjl3JOwgH7vof51Vu5YhGgmOCo3MMnk560AbLSRuY1YkIGHzg8HPTI9aLkgSFYVRxwpxxwD1NV7YbE3zuA5ALDHXuD+tOtJIZJ1QsWlUHjGVxQBMbaOR2THlSRk4/KoEWwgypXeGj28d+ozT72TEX2eJ8M+AxXnj1zWM+0XTlizMwJKkdhx1oA6G0e0WSIxqmJVwMnoRxUwdlldUVSy4cd8j2rn7GUnJ2nYfm2js3bmkkeUXG5naPI5Pr6igDp4tQKLGzsS2CTnvz6U25kW6hEtrHGwZdrKflxjk81z32540Dl/MyBtHbOamXVGOIPKBB5PYqKANKK5Y3AHlBZZAPl3AYA6GnSahdIsqk+YdwIKHOQe7VmpLYXKSvcSuJFQArnHX0NSvb2UFvmK6ZC5+Zt33qAHi9W7mZvLMcgwvr9PpRBf74JhLuzGSu9vlx3zVa20+ZzKba6gIcAIQduefSnz2F64mijuLN5Q2GVz14/WgAtJrjzHePc6k7yWGRgdgPwq2l0twlwz2sUZBwCoyfx/nVaGLUl0pxNGmxcLuVuTzzVPdPH5scckZkZ+GPboMfWgCxJJeQPE0dxGCGLAbcqc9iPpUlvNNFOFcLLAc5ZfX1/CqkAunnnZpJMRDcUAyDj+7QZoojN5Al8iTBKt0LdzntQBqx2yvB9ozLBIeN+chl9Mela2mWvkMJIGkFyF4R24+tZECAAfaJoYIiMqZG+79PpW9oTSssahVlJY/PnJIHf6UAdxou8rGpI3df/ANda8ShZMg9Mk5qlpQxAgIyd2ODVy6yiS4U5C4X0J9KAPL/Ek2ZpAQu5ZGxIB/DnnIrjNQVJo1LD5yxxtOAR2rsdbik3TMGUed8vzdAAec1ztpE815aRXEce4zbT+fGPUGgDoNJ0+PTbSCIIwmnUNI3UZPXP4VraXpb3EiiNVKKc5xynP+FT30JuL6KOHAkUFcY4x3rqrDTRZ25LZMzLlie1AEEEMcUiKQwU8gY/StkRbipzgKDgZ5pix5JR84HQ9M1bVF+UdT6459KAKstojRMpXcGO3Fc/JF5MnlkEwoeB9OhrrH2hQHOADwax9QRfNl4Kqw25HIPOeaAI4/8AV+amVd+SD6VagHmKQeVcjAxjioI4ZJJEYOyoo+QN3NaGnxtLOpyVHGeOAfagC5FFujjBQkZxnrVxLcZA+YgcfSpoFA+7wtSqMDrnFAFdkHRfmA4Of5Usaq+CwAHQ47/hUrR5zzg+1G0E5PpxQBDHDgfNjg8nvT4lK8EKPrT2KgjJ57D1qpNcHzGRTsQpkN6UAWpHCc55x+NU2vXMu2FAyg9zyfeoHupInVC6lgB8x6niokZWlJfg43YHFAGrBP5uc/KQMmpScoCBzmseCdFnX5wBnkZ/nWtHjYMHC4yAaAIZY1JDtwOmKqzhPlAG4AHjPWtIjcMEcmqF2rKqlRwM5oAzZCkmPMUBM9B2PY1nSECKWWFvmzz7fStC5dc7VDZAySO5rKu2aO3fJRZB1A7+maAMW5lk8uRoixbeNoHcd6y5oF+0SShmVAvK9QfWtW8MQBUtsPQqo559DWdcwyNIfKZtmMKM9T6mgChcWcSB4bfCmMZQAZ568/nWbO5jQxyh0lPRQc8+1b7KYm2Ph2B3yFeucc4rmLuKIh/mQvNMXVmJzk9/06UAYEzywPPPtBkyU4O7OeD9KyxIs26HhQkYhZMfecnOQfWtHVZWEKQO5iJlMjSr3x0P/wBasSWcSNfSbsxO3mxzAY28YzQBleIQSbdoxgqGUjORgHGaKpa1Pu1I9GEcYHXgk9TRQB6/dqY0ZdhXaeoPUE9RWTeh9sgO4k5I2+g6ZFdNPEzxsmwFipqi9pIZZGjHzrkrgfrQBzDQErksVXO75jyTjke1IbRZXeV5GAIyoI5+ldEum+Y6o+HAbD9scdaht9KSVWYRyq0b/IA2SRnr70AVbeItZqxLk9cN1xjgVctEQoNsYBKjZzjnHepmsJXaNLcMu35ueOP/ANdJe20lvJlAEygJPcGgDM3mBjE4VmTGQR1981DfQg8MSxPJReQF64rSmgg3lGJL58xQT19iaoq0PnCOH5sgpnOd3rQBTj2RbljijAYZznkZ/wAKbLdM7udoYhsEY6gelaKRBJIhHGEYH5W67vXiq8gHlKqeUW469j3oAozzqY2MECRq7ABCOD1/IVGD5TkW7/IwK4Izj6+opGll89gY1Y46gcD2qG3ljt5l3grvTAOM/SgCCSCaZEjRdkqqdyHpz0NXLWyUQhpt8aOd+4jIyP5ZpvnW7Fm3FGVPu9DnsM0x7nYEjDswf5TGOhP+cUATSta214YpXlaSQZwq/kwpyF5ZRcwXUsewlfL25DYPf04qK0ltZEZ51ZpIccLwwB6HPpTGMsF0k1vOvlsNrqjZzz0I9aALUc0zS4S4R025RS3LEmpodQeN1SdYzCz53qPmQ45qCO4so4TLIFMyvsjO37me+auSmyk8yRlV50G7cnRnH/1qAJbR5ZCXS9IXzMFFbhh6YqeLU5ks7iFYszElT5gyAueo96oRuhlj3RvLEfuKqbSD7n2q/Bd3CIyogwePnXPr1P8ASgCZbn7XHApaNXwEZioIH+HNdDo1tcRXKvMyGPd8pBwTkAYxXM6Zc2ct05lBQxFXZlXq30ro9LubSe6UoCW/vk8DvjHrmgD0vT0wgYDI6Y9DU19kxMG5QEDg4xTdOw6BlJ2yKOW47VJqW17V95Gcgf8A16APK9YHzypuZRJLnB578jFUvDQSXV4MR4MbMfmPIGODj6Vt6zG5lkMYXKuN24dFzz+NS+EtOJ11G27lQ7Qc9eO/rQB2ujabGsomfLO2OSOme341qSbeWI3c8Dt1qxLst0wxwoXHA5Jqgs6vOTEAT0x29jQBbygUAhdwOD/SmicKSp2l9pGB29qx/FGqPonhnVdXdQ32G0kuDGeN+1SQue2SAPxpng69sfE/h6x1zT2823vYhIPmy0bZwyN7qwKn6UAX57krIoUNtOevcjrUJcXkfyrtKjd83pWgbctuHG0HILDJpk1mscoKnGQPu0AVYEcO2H3oGwvfg1t2sCou2NixY/MKpW0H7xUXPyjBI9fWtRE6AZU4yWxjNAEyjAVVHHt2xVj+HjNRJjGR+frUnU8UAIfUdaa4yrL0BFPzxTWOMluFAzQBTmc8q7cNwOPu+9ZIVAHwS7McnPStdyqIXk5BGQKybo+XOkiIu0/ewf0oAako+0qQoyfmIIyPpmluSon+ZgXX5sHriopGQJIFbK/e3LRHGZJGkEWd/djk4oAsxQKpUxsoBIB3c571rwsGG4nt07VjbQzKW2jHQL/FWnZuvlDBG4fKRQBcyMdfeq14oVAcAs3YnirIGBVe8bARsE88YHSgDGuyPMyTtOO3Q1jX8sMLCGVyzyZKkDt2zWrqE33Ru5YYAIx+VY2oXABxcBMcbSRmgDNuIxFHIThTjOeu3FQW0cU8YWOZgwGSuOSTVib5pRHJtQvn5h3BHeq2niFbr907OAAMdsigDP1MOjGKLHnAOryA8g4xnFc3f+ZHDZpHIPN37SzD7nqT6A10usTwRSyu6GO5wdnP3s9PrXG69qUS/uTGQGhLyHdhi349vagDnNWuJY7u5+aMxxxMVAIIz0Bx+NYDTxPblpHKxkKjBONxHXiqV6+50gMYTDhg4flgecGqUlwiyDy1yFDKCT9cmgCC6naeZ5W6yndx2HpRVUHLZooA+oprYGZdy4VcjA6Yqu8LK/7l1D9vl6j3rr5baBmVSOPpUEmlIXAG0H/aPH0oA42SzmI3qMjeXbnGaYEmtbZdmFIYDB7A11hsGVmJwOfujvVG804sWWSESK2Oo7UAc59ouWjYh1ePBUEd+/FUnEsjs5ZiWG3g53DHGf1rcuLNkmJSBlj6BVHA/CqtxaSsXjjQor8KTweOaAOdW2Ekqgg7WJDNnkCorm3itYJIjGVRTwAMn1yPrXQz6dIxCtjbwxbs3qKqXFoGiKHII6EDoP8A9VAGFGZBH5gcrkbWj25OPf8Axp00EkbIREJApDbwfXsfwrQSwWLHltI+9jwey9qkbTZGVwkvJPKKeaAM2dERsJFslYEgAcEe9Z9y7G52x2yAkAFivtya1ZIJQrMzOz4Ix7ntVGd7o7CqbVwBkHn2z7UAYk9y6M0flOxAwTs4wP4gaqmZ/NDpbyJJu4OM5Hf6VvySXgMeWIblgCgJwegNVpPtvmiOPc20/NHtyPqDQA22Jk08yRmbf95gy88ZBB9qd/Z6TRQyq0cxOMgHbt9jViG11BQBNvDTRnORjgcipP7JvFhhZHhG8liWcDdzQBShW4glfytL85OQUA6e9S2k9ze2c7w6fJAyNsZlHLD0/DirNpF9muC0twykZG6NuV+ueozS3eqXBZvKkYK3DEjAx3PFAFK1muYZzFLdOZVYHbznkdB+JrQ23CAxXMzuHHmgHC4Pce2KiFw81qTDsWRPlaTG5lxyCKnZbm7mV31C2ACYIKgnk8UASaTcLASzqzMSVZmXI5HH1HSuo0WeFmWdEQrvCZCAZPtWVbKbRoUlltXQFfmOF59BW3odskjBSYd6yFliV92B1BoA9O0ti8S5jUADA9/wqe4RJbeaMAnGFGO3uaTR0EsatsDADB54FacVsCXDDH070Aeepoz3TTIQ25mILj7v1zXSaHpdvp0SSMuCpw3sfetKaJgSRtUZOM9M1RlHnMQNzs5AIXoCKALtyrXNwC2BGACq9fxqVbJEVQOMLnAFTWqFm3MArEAH3qyFAHOQwxjPagDyL9pTUf7L+EWppuZJryWKzU56gtuI/wC+UavDf2cPiT/wiPiD+xtWnK6HqMgwzNhbec4AfngKeA34Htz3v7ZeqhdO8N6TG2fNllu5B7qAq/8Aob18uUAfpkEwzbh8xGAPeq8qbSrSZPGODXjH7MvxI/4SXQz4e1WfOtabF+5dzk3EA4B92XgH1GDzzXs14jGBypy2Bk++KAIYY3aTCHk4yc471pI22MbiSM4BHes203PCjHdnaGUEferQThxheR0PWgC4Bkd8Dil9O9CjjjvQoyenvQANTCOefungilPT1FN3/Lz09aAKsiK8TCTOecetQCMNkBB5a8hfXirjchsn2+tR7gSAUHy8DHSgDLNsd2whVQnJz1IqeHfhosDkY5q9sDKNoUEdec59qjMGVHIQgnkfTpQBW8sRjZEgbaOSPWrlhFsTBxgnPHf3pwUZOwYwM1NEoUBdoBA7UAPOM4NU792CYGNoGcepq22B83Ws6+kPQZwBjH9aAMW9lRdhOGyc5PQAVgXNxEctcxhYMnCkc59BWzMwjDPtBDnv2NYV2ouFiVhvkjcswHORQBHI0MrAngOvDA8ZHaqum25VpJpYxk4Dc9MelFxEDbbZGLB5CwC8ECrzRpHpgL5aTbtKIeooA4TxTcYvJpJiskkPKqmcnnivOPENxmSWK5LCKVhMwzyp/u/TNdp4wvhHJK8m1GRR5e3t7mvNvEl209wA5J2ncAR8x46sf6UAZ10cMHfaoxuXHU1QkfJyOpokkLMSxz1qLOSc0ASJ/KikTJ60UAfXov0fDg4UkcH2NSLeoyd8E8+1fN8fjvXIQM3AkUcEHvWjZfEu+hWP7Vb73UEMyv8Aez3x60AfQYnDJnIJzk4H6Uqyj5vmx7nnFeK2nxStlwskc6pt4cdQff1rbs/iJpc0ODeIsiHGW43e4oA9PDJJIcMu7tnt2qI28RRQ4AYHHrg1yFn4ssLhCiXsBcYA2sMn6VrW2uRSGMxyLLuHUHP40Aar2ULqVaNCueR/jVG50tHQjYOMEc/57U6LVImlY+YhJAOzuc9Pwp6XygLtJVv4h7UAU59FEp2P8gHQE4z64NUH0OW1nEqmQ4J5UZHA4reW8C7X4ZcYIPoeeKlFyEdUV2JH3s+lAHGzWbRhzNGxLYZRjAJ9TWXd2S3EkhLOm714GK9GaWOXAZQCASMjkiqz21s+SyKzZyQO9AHmosQlxI6XILnLDjJwDz/SmzCeJmAJG85QjoOOea7x9Ii8wtb20eTyc988VQntbNd32tDHggKAM5P+NAHKuIotoupZHUKQQGzgj+VKbPTWikcSzE5+UZz+VbNzYaXJIQ00m5h8uwfzzTLe0g89IonR+zDoD2P9KAMm2itpjcqsZ8wdA3Abj+VUZHkiRGhmgV8sBGy5P+cVv3NhtmKQEQhnAVlyxzjH4VWk0DUGuVcWocZK7sdO2T+tAGCwleORA4w2PNC8D2yfX2pjCCJIlXTjKGJG5jznt+ddlpnhDVZGUzxweWWyyv0YDpxXc6V4Ys7cRNJaoZcfM+Og6/lQBwHhnw1PrV3vvLN4bdQN2/tjpj8q9P0Hw1pmmktDbKZS33j04rXiURj5AABwSBxmmxKxnDFyA2QFUdPegDYs0AQAgKMYqwCAynB4H5GqtmpJG84GOnofU1d+6RgkKO4oAzL2JXysvC89TxVWOZVGyNBg4BIHU1c1GOPzCSM5G4Cs7LGEiIiP8O9AFyyndp5UUbgh3Kx61eldUYk5JzyT0rnrOQC+Ri5YAYPbmugiw69hnkCgD40/av1T7d8URaBgVsLKKIgdmbMhz74dfyFeMV72PhfrvxX+KPiLViTYeHzqEqfb5RnzURtiiJf4jhRz0Hrng4/7SPw90zwFqvh+LQopI7G4smRmkfc0kqP8zsfUh06YHoKAPL/Dmt33hzXLLV9JmMN7aSCSNu3uCO4IyCO4NfefgXxXYeNvB9trVg+0TfLNDnJhmH30P58eoIPesD4XaF4Z8c/Crwzf6zoWmX032NbaSWW2Qybosxk7sZBJTPWui8PeA9A8GyXsnhy0ksUugPPt1nd42YdCFYnBwSOMcGgDftRuCAtuzntjHsKvW4wdpJ5GR7+1V4sFUw3UduwqxCqxLtzlVPBoAtIRs465px4U0yE9KewyD60ARHk5z+lB4GM4zT8ckZpMHt9KAK+0KuRls9vamSoxX5MfXpnHNWTkHK4z60hB3YzlT29KAK6gAsdvJ7D17mlTBYgZ9cmnKME8YDDBFOIIDKSvPAPoKAAE8Y4PoRjipDjcQeuOlRqSvGRk8880qnAJyCo4z2oAC4Cg8AenrWVePsjJLbdp49sVbuJlGFPUgsD29KxryYBWR8EsMgjoeaAKN7ITM2wgI4yW759qxb0FJnltwAR1wecY6n8a07plnt2Kj5AOTnkH1ArOWDzpi7ElSuB26dqAK1lA03luu0LG2WzxtI5rL8UapBHFOsUoRP4mQ447j86f4n1+207TCI3ZQy7iQM/gT7814p4x8SG/321kHjiWTezscFyB6djQAviPXi800YlMmMYz0z7Vx1xO8ymVypdnbJz83QckenNNlbc+5iSW5JzVc8HmgBScnJ64oB4oIwfw7UgoAkjopI+tFAEhzjFNJPenMP1phoATNIcEdAfrR2pVUlhtGSenFAAoCsCpIxyCOtT291cWzbra5njPYq5FJFazyuUihdm5OAtXYdDv5ACYGRT0LelABH4g1eJgUv5sgY5OauxeMddiQr9uLgjqw5qODwxey54AO7bj+tWR4Tuf77Fs4AC5yKALlv8AEbW4iu4RSYGMHIGK1rT4p3SF/PtGYEgjD5x7VjQ+CLmVtolCtjOD16Z/Klt/BsjhiXOAm8dseuaAOvg+J9mwLESrKD8u8cYPGPatq08faZcFS10BjLYzjoOlcTH4Ednx5MgAXd6596sr4BMhKhUyF3Y6dfT19aAPQLTxVZz/ADLP2zgHkjqP61ow6tb3SYOyToVz65rh7PwXDbsm2NlK4Ytk4B7/AKV1thp8lkAsfMcbZBIBIzQBqtZrcqsiRAyZ+XC4yaI/DEs8g8+LajZOQcfl71q2FzcRtho1aIAFTj/PNbVveA5EinJOM+9AGTb+GrWHe67ncgAMw5z3NX00tQ6mFiAOMY6HFbscSy42nDL6H9KetuwJ575Oe1AGUtuEKqArJgBiegNW4YWaP5TwBzn+lWo4kj6MvC5//VT1IRCsZyWOc9KAI/sh8sMzAKMHANOgjt0fgsccj/Zz6UAEkZ4HTA606MxRyEtz3agC1E6SS53ceh46VZJB3E9uvpWfHc7SWMYCN0HqKlSbB+f5A3PP8qADUgCu4L846n27VlvGEYqHIG7cwxnPsK1bgF4jgk9s1mXChMEHBBy2fXvj8KAKkSxom4gyOGOF/wAfwrY0+UAIuCMY2A+lZMAb7QVGSpX73oasjMaRsOSv5Z9qAN63VUjVI1VVUYAUYAA7Yrwr9sPSTefD3TtSVcyaffBWPpHIpB/8eWOvbrGQ+Sm8bWYZPtXJ/GzSf7c+FHiezA3N9ja5UDruiIkUD6lAPxoA88/Y81f7Z8PtR0x2y9hfFlHpHIoI/wDHg9e43iAjc2MDlsdh618lfsc6v9k8a6zpbPtS9sfNA9XicY/8dd6+uJwJYWU43Y496AKiyZLfKSSMDtxUisNpHIJx8tQqF3iPdkgcnucVKjbpCyLkAcA0AXIiOcEYHUCpgeo7YqnEwXAHAOMg9fpU4kAAIOAfegCUg8kUhHIwcZHX3pAenanEcjFADWB2nHU0zg4J/wAipGGcepqI4yR2xx60AAAByCMkVExwpOOozT/m8w4wPY/zphAxluBnJFADWyoAI5xzn+GoLqdV3RhTwvB+tMuLosoVQcg5JxWTcXhVn4I24yc0AWLqY7XYkkKAOOxrEubtvNG5gMZKj39KbeXoLsob5mGV29qoSySeX28wHaoPbNAFK91uGBAqIomAwI/p1P0rk9c8UXD25t4pDHdSKflTA2f7QNJ4sims7mSSNmAZQ5OeD6iuGvbp454LyRl82JcJnoM9c/maAM28neS1+0S3Mjrny3Vup9eK5O5kLMW3Z549fxrT1GcO+6EbGG4A7s8dTWNKQT6ZAOMUARE9aa4xkHHSjru/Smt1/CgBTnGRSDkUEfL3oXoCRQBJGMY70UR847UUAdqnguVo2aVpAQN33etWYvBBLxD5m3tyMYIX1r29tIWRuFAPQYFTLpalQm0bR3xyOelAHjFr4GQxkbCwDHBbqBWpaeD4oyCAnlOoDqBypz1FerLpKxkeUm3Bzj1qUaehUjYUyAMY5HNAHB23hqG2wFXKhMjA7d+e9T2Ph9QmwxloyQRnoOP8K7tbEI/IBHJC9sUsdmoIwcgYJz1FAHFQ6CixKjgFd4OTxg//AKqvro0azJsXIBGGPBJ966oWLBQQBnkcjr9Kd9h4U7ec9+lAHNDTYQm3ywxj5yBzk9qt/wBlLxiBSCADgdR1rejtWVPlA2nnOOx9anS3WPOScZxjrxQBiw6WigMU+YcYPbjgH8KfDpaxgL94rye/y1vxjD4AI4xnr1p7RsrLJhVbBJHUfSgDCXTVG1mUccbXGc+lSrZxoquEIwAOvWtUxM5OMKTklcZA9KRbKQ/OFGDg46/WgCpa2g3bWUEDnj+IVcRDGpCZyBzxyanjtWiVi+eOQR6U0GXJ4PHzBsc9KAEjlaNj5Z2srdT0PFXo7gzRKcEtkfKR1rP8wLyyExgAn/CjzE2K6NIFQ/KVOM0AWmCkZYFcHkj/AD0pySNkYA45zUCXcc6NhR5h4KZ60xjJ8mUfgYIHb3oAtuyqgZpCMfxD0qWOPeMKFbAxknHHp71XtraeQYQ7VcAnIyAPWrAjVWKkksBw3p2oACsRXDSYG7H4VKWRVQxKGzyc9agSIAhihODnJOAKSVyBtBAAyucdu1AFpbn5l5zu45GKzbqX5nGfU8/ypXLu4K5OOcg8Cqt7Mzbo0Hyf3vU9+aAIYZWSdBIx2vzheoFasK74yA3CnoRxnNZUaldhbLlgVB7j3FaNu4Yr5TNIXPDYx07UAX40AGFBG0kZB6elWH8uW3mjnGY5E2MDyCp6iooyyIx6YOT7GiNiNwwu0nI560AfDnwombwf8dNLt5nK/Z9SfTpCePvFoTn8TmvuaSQq3zLxxzn8q+Hfj9Yy6B8Y9UuLceUZXivoTjuVBJ/77DV9f6dq0mpaXa3lq4eG7hjnTIzgMoYfpQBsxXCrdGOeTlTlWx+lXNgzk/exjPTNcrf3YXdvjOduQwPAqfTfEsJdIjuAIwN/UY7UAdGCQAG6+oqQMpCKFyAOh7VSTVbCaMkSbWPzdOhFSNeQbwyyqVBA68UAXSdrBTyAOaesp/EfpWet5CqsFlyeo9hSpeoxUKuc8kjvQBobwevTPWojKrADsRn3qlNcp5mBwu3kjtVee/hjXf5iYBxn0FAGgbhc5Uqc5AqlcXDYmZPmZQAB61lz6xAgbymDkdAB71lXur3H7sxII0JKnB6n+lAGpfXoiWTzT8xGQqnvXM3V+18wEC5GeW6fgabBbT3LhQxxuz5meB6mta306OCWR41IkC84GN3PBoApWFlKoie5CpLnovzBfxp99tExQlcAh1I/iA71sQRKIncl9x/hIrNuIUcltu1ADtGMn6UAcx4hso54JnkRZC0ZCn+6TXlfiKwjs41jy8cc64cHn5v/ANde36rEJIomcAKV5AHUjvXD67Yxtcn7QFdph8uSOCBwaAPEdSia0lRSMgJjjoazJGBJI6Gug123W1IgcFJUUkqeclu/41z8gwcAYGO9ADQMkADn9aiPfA49af6ZqPJ5FAD2I8pNpbPVgRgA+1IMECg8IOKfFG8sojiQvIxIVR1JoAEPNFLFjnPXp1ooA+3vsx+fjqdpx/OgW2088Ekjf6VOZBnHTJB9KBIHwO3T6UAVvsoAAfpnP5/0pXjUBCF+YZX6+9SFyoIzglvrTTMq5UDIHI9/agBI4hkBcncM/wD1qXyo2bcQQQe3Gab5yLGwGcZ60onChTkDOMj1oAkEYGBj5u5NPSAjIIOAoPNRrOOAxwM/KR3xUqXQUjJGCcY9KAGrbcYGTuXHPce1SJajGOc9vekS7Q7cEgHpn0qZLkcFBjnvQAsNuigZcA4x0p7JFtPIxnmoUnH8BBI45FJJOqooP3ScnHWgCbZECct0H0zSeYiKDj24PU1GZ1ICqMhR1I/OoDLmLdsGwHCk8n60AWftABBC7iq49qV54mBA4xUWNq/dI/nShFU4kwqn170AQXMZICohYNyRj2qNImjQboMjHTv+FXsiFlKSZBOFBNOduoDMcDn0z7UAZUSMH3CDaSecd/WrsPmE7HP3Tzjt6VN5krMpAQAj8/8AGoBJdSgBghPoOKALHnbQI0YhTwQTjNSFd7DDqB6n1qntZyQ0alRxk9afHESkgwQASVwe/wDhQA+SMuSpnIJPIzxjvSvCsTbd+UbHTqBTPK8tF3YYhSSuelR3EkshQLCPK6hhxQA8YUFQ3UkEdDUDWYMyM0hCoMhexpzsBndyWP3u4B9KRoyxJXLKRjAPIoAhmXyicKTJtwo7LU9sQZCroy7iGXBzmqksYVTFEHCbg29jzV21JlCADAVjz3oA0d4MMgUBgvLZ/KoI5irOj4ypyCOn0qdAqW4HmkjuT3qrOu1nbpkYyB0P+FAHI+MPh74b8T61DrGuaat9cxxCFd0jqqqGJ5VSM8seua3rC3gsrOOxs4Vhit1EUcaDASMDAA9sVdgypJbA3DBx3FHliN/mGOByDn8KAM6/iRig8sPwQfYmsKRlgvFTy/mccNjjI7V1U+3blANwByc+prNu7QySHhXwcjjn8KAMyWQL0OFI5x29aQiMxOQflY5HPX0p4idSQ8eApOd3cGpbRGKPGEB2r8pxwKAMO8v7y0JMTkxzNwhb7v1qKw1u6e4L+e4VB83bGeM1vzWKTLtkVSGBBPoawE8O38O8WpSWDAfc3B69KAL91qk279/cnoVHOM/hWaL9S8pkmkKxhW8xR8pPpT10y9M8cZiVcDBYnJJ9KuWOgzsy/athUnOAOpoAggkkCKqfvpM5zjGM/wBMVsW9iZZ1kmUCIsCEYe3ar9lpkVsVIjUYXauDV3y/kUSD5AeO3NAESoEVljVQHG58D9KnijOxRyEUEg96lROQTjv0HPNNc7CS3AUdfT3NAEdw+WQsylPuntWbcArKNjZJyc44FWbu4wchfu4wvUN71TaTDFSDkAn6DNAFTUW3pEGXO4YLZ6muJ8QQFG3W4DTwxE4Pda7XU33hFwQp+8e3HP4Vw+pqTqDMAH8xdpycAEjjmgDzXxQgmDzyjdJIvy5PKgdBXBzrhs9c9DXoGsRwSWcmZgk1uSuSevt74ya4O8AEp2gAelAFY9x7GmDknjmnE8dO1InfHp+VAAegp6O0cgdG2sARkehGCPyJphxx7cUvegB0QAUADAAxRSpRQB9rSXAlPIO4DqO4pouCqk4PHcetZh1DpuyAB1xnA/xpfN80gxg7CMjj/PNAGlHOUKYK5xzz1/zmkknDEFkODggDvWbFKwAIQFic5qSWYK5zlmAz8vSgC95ihPmQN6nNJNIicdEIOBms8XgYksjKD0p4nt2QspJIGTuPT3oAtmUDjLbsYHcHtT1YbQWHyDjmqD3CYwp+YcgD0oS4GAM4HX86ANDzITICz5XOPwpstzGIgUDkL0A61mkp5zLHIM+h6D/69VpyfNUi4YIflJx0oA1TfESFMHhc/WmtfuoZDGfL6bs+tZYSfKuoDR4I4PU+1CTMoVDv3Z/MUAbQfcgCOd3bng1LDfzRo3mgsMkcdetYM/ysELHAXOV4z6VLFOGjYGQDbjDD86AOie5DjlXYn3xn6VLEY3CZZsN1HUrXNJcyxsd0pbjvyPrT4dWnilClI2XAPPf8aAN6GaNWK7c7RkNj9KUSoI8oHHODVE6pbvtwwjDEFiegPpVgzZJMflsM4GGxQBoCTcqleD/CMdKdErkYdVyehXrmqCXQDtv+RgAARyCe9PmvGXYN24HuOtAGtHHE8eBnvwTyD6VIkSqdqupAGTuNYUd/G24Kzq3LH1JqYSbUY+YcEAjJ4xQBpCNFU7QCASOab5OMsArJ/EB3qnHcqQpEw57e3TNWDdSIoMezaOPqtAEF0YtgjkRgwO4EDj6VAnnGVNiII268YKmtBZvPLFjGTkjIHWpGiR4yGDY2gN65oAxnWdThg5iOec8degp0E7K6b2HlDIA7nHPNXbi0RLF1jLMCeOeBmorWNTI4MAOOGYcjp1oAltpY3jDqAyOCASasXKEopVlDDGQecioI0g27PuJGMgJT5Xjl8tvmBx27n0oAiZikrHGNw79sd6dJLtmHzZyOje9PkaMn7hc5zj1pZkXBIHBwcDsaAKszjcTsweOF5606IAk5UlRzn3qwIUZS0RHmAdTxxSiIlSSxO7HXpmgCu9ursowS6nOf6Uj2qu2R8rZJYr0aryxgkEIFzwwP+fapGhUkhuM9/wDCgDPa1UjcACSc9OlO+yndnHlp+daC7V9d2e/amuzBVI+vHpmgCkbSIxCQr1Ocjv603ydpOxRwcjPf3q47ls8D5RkAdaj3MwByDkfLigCuV+Zj93HOB6E0rhFcMc/Nz1/KmNONpG0kY25x0qGedEjXkq/HBNAEsjqh4AJHf61RlmbJATPXPPUGmyT4YBdxLe/I96pTzKFLNIBnIUE4xQBI0qrlmZi4GdvXNUEuyzKvAD5LZ421SubktFIGYfMS/B5IHXFU4pleOaSWSQInzHjigC5q95GMCMb2K7go4J9RXEarP5CTMQCE/e4HA6dK0tS1GGKdDG5lxEMMTjj2P1rz7W9VSS1kjcvKHjJWQ5GCDyP0oAxNfuY2idnjVZC2dhPK5PWuPmfL89cnNXbqdgrj+JgPm7is1zzkmgBG+6fSkj+6TzQT8tAPyLwAc9qAF5AHrQMZ60hPAoWgCWM0UJycDmigD6sa7CgGMYKnuvU/T1qeO6DA72PI3AL0rPkPzjdFyRnr3p0bsYmKxHYpxhv5igDUjvTGwG1cnke/apHmj3jccbgN319KybWVTMu1hlm4BHJ/+tT5vMeWTy0UnPAJ6HNAF5UTLDfxyAGNSGKKKJmccnoFPWsyJmZ9xfAGQ+R6dxUUTSxs+/BiB4A565oAuNGowBNgnnHp9KarrtaLzBn1z0qtIUD/ACrkhcKxOOR1FVlkiYeZtwV7EdcUAX2uY422kjPPzHuahFz5rMyYZTg47g471UiijVnctljtIB5yDzzTYYXcEAhT08xe59KALlxezQhRghSQdwP8qniuXdSrMQFGAMA7vemFU2N5pDgn5lxx0qOK8UztGxU7QO3WgC085LESKVZl4/HpmoXDxo6x5Cjj8fWmSXEaopkk3A5AalWQbQ2/5APlK+h9aAB59+FR9xXAINPVjLEQ+Nu7JANRxSxkluUB++D3PqKgncoZZPLLAHGF4JBNAFkuVEeUDJkDp265NTyzSRsHAyjdSfXP6VlW00pZWySucqCOg6cj19q0Umc5ebdFC3YjOT7e1AGxZakturidwQcBTjPNO/0hZTiUmLBYP6eornL9nEahN7hhkMhxuxz+dPhvJFlWMMFLAllJ7n2+lAG6moK6Qq0eETgsOuR3NSidkw8Y81XwNuckfUVz0F+nmtGjDYTtA9ff8DUK366dI5jkYk/d3fTnn2oA6oBkTzEibcTgo3ep4NVkMrp5O3aOc+lYVr4hE0RMm/8Adghjj0qHT/EAut3lvtRULEOOeD60AdLHdz58yMOgDAbQvFaGn387TvDcRggZ+YcY9K4yHWBIkkayvgjOM8k+1bNnPOiF5H8qNRkg8kmgDqLiRRCJOSG49vxqnp5RyWiBj3E8etVLPVVktykys3PIA4xSefM3mmzGIR1+X3oA0WmET/c5btUi3EfIkUKzfKWz09KznmSN45pGL7lLAfh1qnNqEjxg+QEII4z+tAG/JKsaZQ5OeuaZDOrMoxkDoR+ZrDXVd2UjQlwPkJ7/AFqeK7eOFi7KhOWXtn6UAarTpK2Y2UhflOPemxzcoFOV3AZrFtbyJ5OmWkyW29Miop72OMFWbnnAzzmgDonugoCZO8Ht0pIL8OSuTv54rmF1EOG8vewRhnnHNMa5BkLIygEZ5ODnvQB1hvSWG3lWqrHcSkldowp+6eDWLDdldsbRq6ZOCG6fWrLXasd0TE8bge2PQ0AXUuslg+UbkYB7Z6ikM6rGWZ/uNgjocetY093uO7arMmFJUYJFMW6Lyyo2ZEIyHHBHtQBqSXqshUCRgcglelULq+8zGzaMLycZwRVFpZI7eN4W2x57cn8apy3iiNTCPMkzjZnGeetAFu4uHldmEoDfdyep47VUluo2wjsshPy81QlvybiQbkD4znrg/wD1qwtS1fbhoI4y6tgsf41PUigDTub4WrFSSyIQM7ehPYVkatrMSCMGUhT8rKWwzZPQCsbWtamTEkS7oW+ZdwzwOgFcvfXIu1iaRXCqPMDkcL9D25oA1PEeqB0QxSjZb7gVJ++2c5rjNSumMoTzS8AwxHoSKXVbpJghcszFhuK9W9ay714hJKsSuAGxhjmgCvcOWL/NkZzyarvwq06Z8nvxUZwVXHc0AKegpM4wPSk5zxTehz2oAfTl7UwHr9aevTPOaAJEoojooA+sJLUhzucAdNxHWkSJfKPmMTxjGcfnWs1u/wDGmAOM44+v1qvLboGwQoU8Ad6AKEFpHgYwrKMBjzinQwFvlyNxztJFWhEqp9wk9RzwamhAWQllIxjp0oAxbmB2mGXbg4yOD/8AqpYsoPmbLZIOOlachcuNsfI7/XtWe8ZdivlkkMUO3j3oAZeW+c7+FLc/Wq86usaqu7y9w4x0HetiK3laFyi71xg7hzwOtQTwqEdfLOXwwXPUn+lAGahEzOwK78Z5GCfemxxZtzIGJBbcRuwTVlLbZIrAsFI2le1PmhYQkwrgD+6c8d6AM0lT5hSQ5fCMCSMe9W4ERYZWMrqCAuWwSPemHzYW/exo6yYBwOgH9aY0hlhffHtRXBLDjr/OgBtkjgFCqsrLw3XirVi5BeOQtsA+Qkbd3rUEUJhdPs4+XGRnr14qzb/NsDfPIvByMde1AEM6KpiJLFAxYYPUelLDApkMiyNhhtALZLZ68fWp3X/Qym0LgkjniqDyyWzRO4AJycD09/xoAfHAcKySkOMqWPr3q3a3EUyum7LoMFT61QtblpH2eX5pzkqBj64qaW5tLVhIIC02PlBPr2zQBMsyRAxXZC7TuVsYx7fnWfNHFdI8o35XIL55POfwpJtTS5MkZgJI4DqMjPbn0qtbXmXKXFs+0k/d/LBH60AV5yZJFeCUNsUHjrnOMmtGEs1tvvCjlPuMy8/TFUZZmtmZgioW+U47D6+tNkkm3GSUGRm+Vf8AZGKAJ4tQVJAwiZVbIxjH0z7U+0+wedJtjaFJF4DDJ+p9qyrgTAeVFFMxDBVcjp3qzZiaWB1kGwtwhYZ7Yxn60Ab0QjWcSRqruFAV1Hb6Vo2ztKssd5uLfdABxt9jXPWpe2bZbTIImBUoQc1rWsc1yHLmMjplW6kY5FAG4mAssETMrFfmz2xTkvBFabVldiWO4r1HpVKGS5FrjaJBt5I5IP1qgUnSYzyI8aYwRng0AdMpmeLzf9YgwDk4GPrVHV0+3C3ELmNA21QGwyg/0qWSdprEwwfuo5F5weQfas+GSKKYO7NsQfMW9BQAmsSJp8AhilLXSEZIOT0qnNq7S28K3ELG4jJ+VjyPUn2pkklnLq8V3K3mys2VUn7wxip9SvLKOd3Knfg+aO6qBx+FAGZBJqlmReWzssDH7oOQuexFTzatYGaCFpCZXyCwGPmHXFR3E27QTcWy797r8uf4T3FYqapPcSxyTRxxujl0YqOg6g/40AbF3fPC0rwStJEYyW9Rimx68JpA8MZMcXzYfg8iubn1pzfzLaEF3OURxgNnkj3FRW92txb+Zdyp9pkOFiztAYetAHarrEFyPMs1PyDLoRg59B61diuHgjcIiq0jDCs3bvivO9OvoEWSCaS4nvI+VEfAX3rbtby+kaYSoFjiwS05GSD6UAdW90yMQJQEJ3E+/pmoGuTMYp4mkL8bkAxuArNhvCkSpfrHJKhCoUPGD2I9aS8vYId+bxm2oF2qMBSen+FAGrcXHkhgy/IwLbQc8ViapcpB/pNuoIhUFwTg/QVivqAktiLRzK8TYKZ5XnnmsYatjfFLjMvIUN9/Pv6UAakt7M2/EKxICJPL68g9T6dRWTNKz3MUUqAuhJV1PGOvGKz9R1SZvshkmK+XI8TiPHzDHf14rJGrQvNb+WzJCyFZRuxx2x6UAdJFGktkJAGC4fq3BYdvxrA1O9EbwRTxmNXh2zxDoT2x9KzL12jty6yExyKdpyQyt2J9OKxbi88+RHfLKQM8+negBLy7SSKFEUKqcAjqfrVFm5OPf8aa7AFsA4qMt0+lAAxyeaXqoz61GSc07OFGaAF59PUUnbjtRnIXvSDnPPWgB+eCKVOgpmOKfGcdD0oAlj/WiiIZwMiigD7mktyc/MvAOQR3qpLZRNs3QjGQMr1q8+7fgZOQCeaiLMrKcfKD09KAKFxYhYwRE3fGD0GetRLaBIiGUgHH/wBetMuM7juB2Hj1AoEis2ATjtx7UAY01nskIWR3BHORg1QZJRzFjJGSPX2rpGZXAOQXb26VC2wBSy/cPYcZoAxw85GSykY2nA9fSmyRv8xhwOMkN2NaztE2BAhQsTu3DHPrVd0dsvCUZiudpOMmgDLe2G5FBXnsDnFAt8YxjG7PXpV1oJCqkIFIPO36cioRHucq8bkZ5Hp9KAM+e0aS4chgd+Sc1Aq8SKYiwxgBvWtXyGCLjIY+np6/WlW3APcbf73060AZxtZJ2QRgxbefm9h0p0NuSWO7oNzFRV6SBss/zNj5cDvVQsUAVGKoeCT1OelAFct5UuGbCsMkE9PpVNykkeMFlYbjt5796utaCRy/31xjk81C1i6gsqbZV6c8H3/pQBFbkgbF/cu2S2B0+lPaMK0pKhlxtzxyCM5pZJUSMLIsiSKwySOOnX9KpzW8rqGTHlsATg4OM0ASqYEjVdqMvIxjGB64/SoDd27ylHBB3AkqcD2zQYm8/rtAGdhGT65FUJpEePMZi8wnKk9Qff1oA0Hl0p0YyRmTPUg9D0p8i2/kGSJfMT5SM/lWOjElpPJV93J9GyOtPkvJwrqilFUqGQDp7fhQBZe9Ny4VYnBZsBmbjFSI5t5M3LqOBjHPf+lMt4pJ4w0ZR1YMdw9c9KcpUtH5sDBFJLDPQfjQBRvhPdSO1vM6gD5SvIznJFZsc0kc6Q+XNGiEMDzz64/OugkRkhWSyjJV2AHHzE5qe23m5C3iLg9sZ5HU/wD16AKVtPNA6PbTMpz3PB9se9Pvrme8DATlDGpyrHhP/rUanp8iyM6ICCWIZjwpFU1Ev9mOtzDukT5UYc5B6Z9aANq1drXTyy3BlKKJGIPIJ6YP1p322G/jWSAAMY9ro/BJFYCxQx6Y8Msr2oYjA6btpqCzmjku3hUOZgmwkDjnuT2/+vQA7UdPurnTTfWmILmNiw+bgr6VU1e/a3kklu1kEU0OxnXnLV0qyxnSkWRc4kWOVe6/5NZV9IjyxJJEJYg5j24xn0oAwtKutRit/Kt3LWKsrxBuMAg5H04rI1bU86oli8whhJyHHB+Yfd96663T+zbh4rlvMt5V2liOQCOn4VzutWNvLdWE7Ml48UmCFHJ7/wAqAMQSebPEkzP5sIIZVblcd8+4qKx1hLZr+5iikuYC6oEdOmT96r+o6bHqepXN8ojty5+TnCnH8jVKTzIpg4uonlLYaOAZ/H3oA1HNtJcvfJHNbTIVBJbhv/11oanfM6QPvKXLjlZDuGzsfqK5Cz+xw3d19pvLh2kHyK+Tk57j+VJdXUxzBvbzYiQHcEHpzQB3FpqbyS+Xck+W6siuTg465HvWZd6yVQwXA3wxNvdemR2OfauQuruVZ4VlmEixIVb/AGSe/vTLq4+0SyCV2e1hCupBwzD6UAdBJdI5aazljCnEuWY/KucEH3qpqkYitZlW7imORKnOD7rWW1zIUaeXyhZI4Qxp79BVW7uoLm6ee3iMDFQfLPIyP8RQBo6tOZJkCqI2IV41POPWqEiD7SEeMt5RMYQHBC9fxqs1zLKWYyqhB+VgOVx2+lQTXICMVbJ6jPbPWgC1qk4EhjQ5jwpX8KzJHUB0VRndnf7elNmkZhtJ5Hc96hPGQRyOCKAFds5NR56EfrTmxwO1MA6fSgBRncfSnNn5MfUU0dD9Kc+P3eB25oARTgKehoIwSB6cUAHauR/9egjDGgBwOOozjtSr0ppGB+NOSgCWPkYopY+RRQB9qC/R2wr/ACk84pFu1EfOMj39682TxZbOBi5iJJwRnnJ6fhViPxCgXb5igkYB7k96APR3vVLDo3H/AOugXI2ZJDFhlQP0NcTFrsbAESrkYyPQ9DU8etwkEq+CDtXPU4oA7COZQQ23JPB560xfL6At61zq6oihmyFXONuec5qYamD95uCOvrQBvDysA7854JI4zS+WhiDHaSD0Hv61iR6hvySADnqD+VWEvQDtDYYenb/69AGj5D+blJCikYBzUTwzFAWYdwfcVAl6pdiHXCjknvUv2wM2xeQBu+9QBC8Mm4MO4yDmoWE21BnB9OuKvNKGXKnB28Z9RQJuCCoYgcN/OgDPRJiQxfzN2cnpgU3zCOGiR8Dr/KtBkQ7QI8dxg4BpDGu9mYkZyBkdPagDKlkTHNswP+z+tBkiVAywtg4HPP1rUCxEYD7GIycn0pjx+Yp2hCvUnHWgDLuLjcAZoIyBwVY9TnikM0B8tjaqyE8jpj3rQe3Ux5ZRz/H1BqI2kaYCsuMHj096AKa3Vtlla1bHQEDJ96aY9MdSjWwVn+Qkp3NTyWzByTKFyuB8vIqN4z5jKCWYfKQKAIzounq5KuI8nIxyP/rdKS40yP5hHLncBhvX1onRUQfvXjXHfrnvSYVNixyDJyWOcHp0oARLN4wIlaPsRgdfaormJGTbcCVhu6k4wfenM80e1o3AyMhl5BP9KbDey5kS4UNjB+ZeCCOKACSO1QrHBIyEDGzd3x/OnR6bZMz7pWVMcknr+PpUFxbQXI8yWEqo4yDx7VTNpN5SpFKQpG1gr5+nFAF+4ilVZISqzRdyD29vwrO+yTG2czxiSMN8oA2lQO5ps1tdrcgQTT/cwATj8eadb219aqz73ZGYt87jpj0oAp31qd8QmlRW/hA5PA5BpmpaYv7q8tSY5GAVthwCP61ozMhv1/ePnBZEx971GajvbYmAAMxiL8LjlfWgDNupJLeR0sopT8yhkXkE+tVI4nuL6WaaFluA42IxwD3JxWjZwXaX6vApeIEYYjHTpSSNqM962y3WIA4LkDueCPXFAGZq8Md3qagiWF42wQPuyZ4yap6zEtpcE28YaQOoAiUk5471py6ffrEC+zeW5dnBJ/D0pt/dO8Bf+0Ft8gBwoGSB6GgDN1QKZVlaSCGBshoW+8rEd/xrk2tBZadL9mmWOeScKsijlcda6C81OzmjcRJNcO/yySrHliR0/OsC6bz3lH2KXy3OcTnGfTHpQBl3Vw0N1NNJNsugNgCJuLEc59qjvWne5juGYuCoPmHk59xUsrzKQZZIYn3HdEvPHbFZouoFjZcSMXYgtuwNp7fnQATiNnkZwwnc7iw6fQCqlzPLFvRgUl3c8c9KsRhXjYvKBheEzggn/Oazrt389/Mbe3GWz1oAczFonLBjjBOO57VHLMxYHdgnBPpj0qHzGGeTg9ahd89FAoAkkuGYnpwc+9MZzgHjJ61EMYPc0D7o7cUASM2XzzzimknBH40mSWwOlKc85HUUAKx5pM+h9zSEdKM80AOznJAxmlPJAz2pEAIOaVx834UAKo4A9vypM5Y4zTgMLnH8NNGQRz3oAce1OT69qYev5U9RQBJH0FFEfaigB3muv3XYfjUqahdRlSlxKCvAO7kVWPJAJxk4qNvTvQBqRa7qMYcC5c7vvZPUVfh8XapGqAy79h+UnrXNj2oB/P60AdrF491AIPMAZgRz2I+nr71p2vxEaIYCyECMrluck/4V5vnpS55oA9XtfiSiOMxsVPBGcY9/xrbsviBZylV+0JGzYBYg8H15rwwnil3UAfQ1n40tpufMXYH7kZxjg1sReIoQu5ZFCZA2jqoxXzEsjrjDEY96tRaldxfcuZcDoNxoA+n7fW1Lckspz+ArQttUVo2ZMZHOT347V8u2/iXVIUCi5ZlHqfbFbFv4+1GMjzVWQEdBxg4wcUAfSn9pCRd+Sc8MR2qSG8RpSDJkY5HXtXz9ZfE2VCvnxMu0YAHI6VuWXxKs5sZbyi+CS3G3nvQB7Uk6upDsDgDOB156UnmpkAHkccdz6V5hZ+OLGcO0dxGNpxuJ4PuK1rfxdbSRLJHJGqrxtZ8N69PyoA70MqEr5hznbjrTfMxkFVZenvXI2/iKBsseVIzkHPJNW4tbib5Q6YY/eXgCgDoPPl2kMoZAOQ3XrULyIc5twx6kqentVGPVIyxGRwpba3p65qQX8e0hmGMZPpg9zQBM5hLANETuPzYPrUEqabIxDxyjJzn0qSK7jJKjG0ccdCKElDIFJXGCfXNAFKWCwPKTyxhjhQegPenBVMSr58cqlQBu+XI+tDw70U5jPy5I/CkKEoFeKNjkDAHHSgCLykRQyn5yD8obr9KEjt85ZTHnrz3z0pGtwgdljUNkdCfx+lQhUKsrAqRypOT9DQBJPCkoby5myO+/oKRLcSq43M6pzuL8EegH5VGn2cRktIsYUHJHBz1P4ULKJFCwzoOvy4oAfJDsjRXRAsXV1l6+uakVi2I0WNhnIZXzzVb7WIyIv3hBGQRGCucd6SG/t4oSIxl1BXLLtz60AWtoVi7iYb1BxuyBWTLpIdy/2yZihLbS3SrLavbsiLL5Skt0V+g6ZPsaoXl1bTSfKgZDhsqSMjpigCreRIsxjh+Vsj5XTd1OCRWKLN0eQ3jwyJuJUKhBX6evFbZu7GEqxjuSAvXk9fWs6+uUVswCfAwQcHg9aAOdvLK6eNYYrr7KJCWj2oR0Of1rJu7KWPAlE14JB+9dmK7fTFb+s387SW2EBRTt+YkEVz2oXkEtv5pdt6EoVWXrz3FAFF4orQIHtljLA/vTksuOvNZpGYnm2uIkPBYgDrVybUm3SbI5F24TAfPbk1kz6hI0cccrbowTwU4oAjnkZ2LMoJbGWznNVZByRyeeSKa8ibiURQKYQzHCAk43EAdhyaACRsLgjHNRHoT2pSTnpzSdDn09aAEHTP0p5AKD3FN7EUoIwOtAAowfoOab0FOzz160LknHegAbJY/hSnCDzHAKg8gnrSMcsfyoU7SWwpOO4yKALF1bzWly9vcIElXBZQwbbkZxkd/ao2wS+ScjG3HT3zSIuCAM+9NHzFucdaAJOfLwPSkYYYegpQfmGT0xTQcmgBT97n2pwJJ44HTrTM81Ko5BoAljYjmihMEc0UAQtjGKaxJJz1pzHPWo24oAQmjPzUUg6+9ACnp1pSf8KaenFIeaAFz0ozSH26Uh5oAUE0uecjj29Kb34pDjtmgB4bp2pA3FN4wMdaBQA/efwphOR2NFDKVAJHBGR7igCTZJ5BmC7Yt2wNnGT6D1xQLiVTxI3p1qJSCUDswRc477c88D3NNz09aANKLV76NiyXUgY9easx+JNTTP78kE5IPQ1i54oJ4oA6yLx3rcYH+kAn1K5/yKuQ/EXVIhL8iMzgAt/OuIJ9qXd7UAeiQfEy6SNFMTYAwfmyMev1q/H8TkwpeKRGXIAHT/ADivKweOgpQTjgfjQB6/bfE60jJJdxtYAZT7wz0q2PiVYPG6PK7mQrhiNqrzXiuTTjjaMHNAHuA+Jmnltu790Qc57EHj86m/4WLpcxRPNwnJZiMY9BXhWfz9RSdD/LFAHu58d6bLu/fqCcZJwc1D/wAJhp0jA+eiSKVznjJIzXh+SMA5xS7icnnHegD26TxHaLGEW6XLD58SY2k8gflVaXW7DKD7WzxHG7c+d30rxosw/rS+YcAZIHpQB662uWiws4kjMQyu4EFuTT18RW6Rq0MiSDj5Gbt6H6V5B5jAcEjigysG6nNAHrtxr9uJWLSnYc8JJ82D/Ws//hIsTs1pqN2QQQI5FFeYeY2c5JJ5oMz44Y9aAO41bVXcZFwZTlST0I4zgVgS3gYyMzRlmOTleTWMZXwcscUwsT3oA0pLnJbJGM9QMZqF7glRk4A6DPFUi3GM5pM/L059aAJmfIzgfnUZ/p2ppYlQCeB0FHbrQA5tuEIdixB3AjGDnt68UmeKQ9frRzjFADh26UnYUDpxzR34oAOM9Kchxk0g9vendAB2HJoAb3JPFOU4UDHNBOVI6nOTQB8pPegB4Y7eg4yMgdfrTRjaCM9O9LkdPenwlBIhkj8xAQxUnGRkcf0oAYxC4xnilQA4PvTpMFy6rtUsSFznA9PwpE7EdqAFIG7KqVGeATnH409BzyeM0w5yB09KmUe5oAcuaKVKKAKz/hio84I7VI3XHSo26+9ACE+9IOvJo+o470Hk5AwM9KAAHJpD29qORig80AIeh+tGacMqDgkbhg+4ppHNAADzxR6UnFL2oATPFA96KMc0AH5cUnQHFObsKTGcj8QKAAY2992fwxTe9OA6kDpSYoATnFBoox1oAU5o7ZoI96D0H0oAB0oBOc55oXGKKAF6NwfypR39PSjPT2pCevc0AKGIIKkgjkGjJyeetJkUuaAFXkgGlOe2cH3603uOKPoaAAk5OaM8/hS7sjkA0nHUUAFGT69aADxyM0cgHpyMCgAz1xg0ZGBxTp5fNdfkCKqqiqOcADAye5phGMUAKxGO+KQ43cZxSEnOaOlAC8dOcUho6HtRj05oAUDLAcUmeOKORSj+VAB3GaPpR78dcYpUxu+bpQAg470oHTBxmg9SeozQrAY65oAd1bAz6CjaxiMm07A2wt2BxnFJ6dCCM4o7jpkUAIc4P1yaFoHf605GwufcUABPOT1pwbCknjPSmHOee/NOU+vQCgB2OeucU5eEI600e3elH8IJ96AHjngk8dKkXLDJqIdeuM+tSKxwM0ASoOaKRPaigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient incurred a fracture of the coronoid process following a hyperextension injury. The x-ray of elbow in the lateral projection reveals the fracture line through the tip of the coronoid process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Sandra O'Connor. Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, 3rd Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35108=[""].join("\n");
var outline_f34_18_35108=null;
var title_f34_18_35109="Outcomes of HCT by risk group";
var content_f34_18_35109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F88592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F88592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 646px\">",
"   <div class=\"ttl\">",
"    Outcomes of hematopoietic cell transplantation (HCT) stratified by overall disease/status risk group",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 626px; height: 608px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A disease risk index was created using data from 1539 patients who underwent allogeneic hematopoietic cell transplantation (HCT) at Dana-Farber Cancer Institute/Brigham and Women's Hospital from 2000 to 2009, and was validated in an independent cohort of 672 patients who underwent transplant at the Fred Hutchinson Cancer Research Center. Sixteen defined underlying diseases were categorized as low risk (eg, AML with favorable cytogenetics, CLL, CML, indolent B cell NHL), high risk (eg, AML or MDS with adverse cytogenetics, extranodal T cell lymphoma), or intermediate risk (eg, all others). Disease stage was categorized as low risk (eg, complete remission, first partial remission, untreated disease) or high risk (eg, induction failure, active relapse, accelerated or blast phase CML). These two ratings were then combined to define four risk groups with significantly different estimated rates of overall survival (A), progression-free survival (B), cumulative incidence of relapse (C), and non-relapse mortality (D) at four years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120:905. Copyright &copy; 2012 The American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35109=[""].join("\n");
var outline_f34_18_35109=null;
var title_f34_18_35110="Choroid plexus cysts";
var content_f34_18_35110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50051%7EOBGYN%2F74248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50051%7EOBGYN%2F74248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Multiple views of bilateral choroid plexus cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse image of the fetal head of an early second trimester fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 210px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow demonstrates a unilateral choroid plexus cyst. The cyst is anechoic and surrounded by the more brightly echogenic choroid plexus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35110=[""].join("\n");
var outline_f34_18_35110=null;
var title_f34_18_35111="Ultrasound white matter cysts";
var content_f34_18_35111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Ultrasound of white matter cysts in periventricular leukomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sonographic images demonstrate deep white matter cysts adjacent to the atria of the enlarged lateral ventricles (arrow on the coronal image marks the most apparent changes on the left side). Sagittal images nicely demonstrate these changes bilaterally (lower images). Periventricular cystic encephalomalacia is seen as a sequella of several perinatal insults. Hypoxic injury in premature infants results in periventricular \"watershed\" ischemia with some infants progressing to periventricular leukomalacia (PVL). The white matter adjacent to the frontal horns and atria of the lateral ventricles is especially prone to ischemia as these border zones lack autoregulation. Premature infants under the age of 32 weeks or less than 1500 grams are most commonly affected. The condition is associated with high mortality and significant neurologic mobidity, particularly spastic diplegia and intellectual deficit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from The Madigan Army Medical Center, file://www.mamc.amedd.army.mil/WILLIAMS/TF/Peds/Unknown6/ANS4.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35111=[""].join("\n");
var outline_f34_18_35111=null;
var title_f34_18_35112="Posaconazole: Pediatric drug information";
var content_f34_18_35112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Posaconazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"    see \"Posaconazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/7/20597?source=see_link\">",
"    see \"Posaconazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3339726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Noxafil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5222620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Posanol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4041077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Triazole",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F4041088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"      see \"Posaconazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Children &ge;13 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prophylaxis of invasive",
"     <i>",
"      Aspergillus",
"     </i>",
"     and",
"     <i>",
"      Candida",
"     </i>",
"     infections: 200 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of refractory invasive fungal infections: 800 mg/day in divided doses (ie, 400 mg 2 times/day or 200 mg 4 times/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of oropharyngeal candidiasis: Initial: 100 mg 2 times/day on day 1; maintenance: 100 mg once daily for 13 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of refractory oropharyngeal candidiasis: 400 mg 2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No adjustment is necessary; monitor for breakthrough fungal infection in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No adjustment necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3339777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Noxafil&reg;: 40 mg/mL (123 mL) [contains sodium benzoate; cherry flavor; delivers 105 mL of suspension]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3339728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4041089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Shake suspension before use. Administer with a full meal or with a liquid nutritional supplement. For patients who cannot tolerate a full meal or an oral liquid nutritional supplement, alternative antifungal therapy should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4041085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4041078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of invasive",
"     <i>",
"      Aspergillus",
"     </i>",
"     and",
"     <i>",
"      Candida",
"     </i>",
"     infections in high-risk, severely immunocompromised patients such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia secondary to chemotherapy; treatment of oropharyngeal candidiasis (including patients refractory to itraconazole and/or fluconazole); treatment of serious invasive fungal infections, including zygomycosis and coccidioidomycosis in patients intolerant of, or refractory to, conventional antifungal therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3339723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Noxafil&reg; may be confused with minoxidil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Noxafil [U.S. and multiple international markets] may be confused with Noxidil brand name for minoxidil [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F3339744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hyper-/hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fatigue, fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, hyperglycemia, hypocalcemia, hypokalemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, mucositis, nausea, oral candidiasis, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, neutropenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, musculoskeletal pain, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, epistaxis, pharyngitis, pneumonia, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bacteremia, CMV infection, diaphoresis, herpes simplex",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, adrenal insufficiency, allergic reaction, atrial fibrillation, cholestasis, ejection fraction decreased, hemolytic uremic syndrome, hepatic failure, hepatitis, hepatomegaly, hypersensitivity, jaundice, paresthesia, pulmonary embolus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, syncope, thrombotic thrombocytopenic purpura, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4041080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to posaconazole or any component; concurrent therapy with ergot alkaloids; coadministration with terfenadine, astemizole, cisapride, pimozide, halofantrine, or quinidine (posaconazole may increase plasma concentrations of these agents resulting in QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and rarely, torsade de pointes)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4041465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with hypersensitivity to other azole antifungal agents since cross-reaction may occur but has not yet been established. Use with caution in patients with proarrhythmic conditions since posaconazole has been associated with QT interval prolongation and torsade de pointes; do not administer with medications known to prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and are metabolized through the CYP3A4  system. Use with caution in patients with hepatic impairment or severe renal impairment (CL",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     ); monitor for breakthrough fungal infection in patients with severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4041081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hepatotoxicity including hepatitis, cholestasis, hepatic failure and elevations in ALT, AST, alkaline phosphatase, and total bilirubin have been reported. Liver function tests and bilirubin should be monitored at the start and during posaconazole therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Elevated cyclosporine levels resulting in nephrotoxicity, leukoencephalopathy, and death have been reported in patients on concurrent therapy with posaconazole. Dose adjustment and more frequent clinical monitoring of cyclosporine, tacrolimus, and sirolimus should be performed when posaconazole therapy is initiated in patients on these medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; use oral suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein-binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3339750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3339749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Posaconazole may enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).  Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Posaconazole may increase the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Posaconazole may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Posaconazole may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Posaconazole may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cinacalcet.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Posaconazole may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Posaconazole may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Posaconazole may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Posaconazole may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Posaconazole may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Posaconazole may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Posaconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlipiZIDE: Posaconazole may enhance the hypoglycemic effect of GlipiZIDE. Posaconazole may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Posaconazole. Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Posaconazole may enhance the QTc-prolonging effect of Methadone. Posaconazole may increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Posaconazole may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Posaconazole may increase the serum concentration of Ritonavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Posaconazole may increase the serum concentration of Sildenafil.  Management: Concurrent posaconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Posaconazole may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Posaconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Reduce tacrolimus dose to approximately one-third of original dose when starting posaconazole. Tacrolimus blood concentrations should be monitored closely during and at discontinuation of posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Posaconazole may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Posaconazole may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Posaconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Consider temsirolimus dose reductions or alternatives to posaconazole.  Monitor sirolimus concentrations in all patients receiving posaconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Posaconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 2.5 mg per 24 hours  in patients receiving concurrent therapy with strong CYP3A4 inhibitors, such as posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Posaconazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4041084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Posaconazole AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     are 3 times higher when administered with a nonfat meal and 4 times higher if administered with a high fat meal relative to a fasted state",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3339733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3339734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Posaconazole has been shown to be teratogenic in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if the benefit to the mother justifies potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4041090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic function tests and bilirubin, serum electrolytes, serum creatinine, ECG",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4041086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the enzyme 14 &alpha;-sterol demethylase, an essential enzyme in ergosterol biosynthesis resulting in the inhibition of fungal cell membrane formation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4041087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Food and/or liquid nutritional supplements increase absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1774 L; extensive extravascular distribution and penetration into body tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes hepatic glucuronidation to form glucuronide conjugates; substrate for p-glycoprotein efflux",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 35 hours (range: 20-66 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 71% (66% as unchanged drug) eliminated in feces; &lt;0.2% as unchanged drug excreted in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F4041091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/7/20597?source=see_link\">",
"      see \"Posaconazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician if severe diarrhea or vomiting, chest pain or palpitations, yellowing of eyes or skin, changes in color of urine or stool, weakness or tremor, or changes in vision occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4044648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dextrose content (oral suspension): 350 mg/mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/18/35112/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenberg RN, Mullane K, vanBurik JA, et al, &ldquo;Posaconazole As Salvage Therapy for Zygomycosis,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2006, 50(1):126-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/18/35112/abstract-text/16377677/pubmed\" id=\"16377677\" target=\"_blank\">",
"        16377677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gubbins PO, Krishna G, Sansone-Parsons A, et al, &ldquo;Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2006, 50(6):1993-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/18/35112/abstract-text/16723557/pubmed\" id=\"16723557\" target=\"_blank\">",
"        16723557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Raad I, Patterson TF, et al, &ldquo;Treatment of Invasive Aspergillosis With Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(1):2-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/18/35112/abstract-text/17143808/pubmed\" id=\"17143808\" target=\"_blank\">",
"        17143808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12997 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35112=[""].join("\n");
var outline_f34_18_35112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5222620\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041077\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041088\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339777\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339728\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041089\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041085\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041078\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339723\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339744\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041080\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041465\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041081\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339750\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339749\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041084\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339733\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339734\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041090\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041086\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041087\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4041091\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4044648\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12997\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12997|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=related_link\">",
"      Posaconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/7/20597?source=related_link\">",
"      Posaconazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_18_35113="Overview of causes of genital tract bleeding in women";
var content_f34_18_35113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of causes of genital tract bleeding in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/18/35113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/18/35113/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/18/35113/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/18/35113/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/18/35113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/18/35113/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/18/35113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal bleeding noted in the genital area is often attributed to a uterine source, but may arise from disease at any anatomic site in the lower genital tract (vulva, vagina, cervix) or upper genital tract (uterine corpus, fallopian tubes, ovaries). The source of bleeding may also be a nongynecologic organ, such as the urethra, bladder, or bowel. The differential diagnosis of genital tract bleeding is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef74527 \" href=\"mobipreview.htm?25/45/26334\">",
"     table 1",
"    </a>",
"    ). It is useful to separate these causes according to age group (",
"    <a class=\"graphic graphic_table graphicRef61684 \" href=\"mobipreview.htm?30/12/30924\">",
"     table 2",
"    </a>",
"    ) and site (see below).",
"   </p>",
"   <p>",
"    An overview of the differential diagnosis of genital tract bleeding in women will be reviewed here. The evaluation and management of women with this complaint are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/25/20887?source=see_link\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UTERINE BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of a particular etiology of uterine bleeding depends upon the age of the patient and the pattern of bleeding (cyclic or noncyclic).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is a common symptom of a variety of disorders related to pregnancy. All reproductive age women with vaginal bleeding should have a pregnancy test as part of their initial evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Menstruation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterus is the only organ for which bleeding can be a normal physiologic phenomenon (menstruation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal menstrual bleeding is characterized by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration between two and seven days",
"     </li>",
"     <li>",
"      Flow less than 80 mL",
"     </li>",
"     <li>",
"      Occurring in cycles of 24 to 35 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moliminal symptoms are often present and include an increase in thin cervical mucus secretions at mid-cycle and premenstrual symptoms such as menstrual cramps, breast tenderness, fluid retention, and appetite or mood changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26724?source=see_link\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive menstrual blood flow is termed menorrhagia. Menorrhagia may be due to local disturbances in prostaglandins (elevated endomyometrial vasodilatory prostaglandins and decreased vasoconstrictive prostaglandins), or may be related to any of the uterine etiologies described below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In premenopausal nonpregnant women, anovulation is a common cause of abnormal uterine bleeding (AUB). Anovulatory bleeding is characterized by noncyclical bleeding of variable flow and duration. Molimina are typically absent.",
"   </p>",
"   <p>",
"    Many women with chronic anovulation have an adequate amount of biologically active estrogen since androgens can be converted peripherally to estrogens in the absence of normal ovarian function; however, their anovulatory cycles lack the progesterone secretion normally present in the luteal phase. This puts them at risk of developing endometrial hyperplasia and endometrial cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes of anovulation are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79628 \" href=\"mobipreview.htm?12/36/12876\">",
"     table 3",
"    </a>",
"    ). Anovulation should be suspected in the following settings:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulatory cycles are the most common cause of AUB in adolescent girls due to a slowly maturing hypothalamic-pituitary axis during the first two to three postmenarchal years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25975?source=see_link&amp;anchor=H3#H3\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Abnormal uterine bleeding (AUB) in adolescents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11160?source=see_link\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Menopausal transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulation is also a common cause of AUB in women in the menopausal transition. Ovulatory cycles and the normal cyclic production of estrogen and progesterone become disturbed as women approach menopause. Ovulation occurs intermittently, interspersed with anovulatory (estrogen only) cycles of varying length. As a result, menses become irregular. The duration and volume of blood loss can be short and light, but prolonged heavy bleeding can occur during longer periods of anovulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Polycystic ovary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic anovulation in reproductive-age women is most often attributable to an endogenous disorder, such as the polycystic ovary syndrome (PCOS), which is characterized by oligomenorrhea (irregular infrequent menstrual cycles) and hyperandrogenism (hirsutism, acne, and male pattern balding). Obesity and insulin resistance are common.",
"   </p>",
"   <p>",
"    Women with PCOS have an adequate amount of biologically active estrogen since androgens can be converted peripherally to estrogens even in the absence of normal ovarian function, but low levels of progesterone. Thus, constant mitogenic stimulation of the endometrium leads to endometrial hyperplasia, intermittent estrogen unscheduled (breakthrough) bleeding, and menorrhagia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine disorders may be associated with hormonal changes that affect ovulation. These disorders are uncommon causes of AUB, with the exception of polycystic ovary syndrome, which occurs in 6 percent of reproductive age women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both hypo- and hyper- thyroid activity are associated with AUB. Women with hypothyroidism, even when subclinical, may have heavy or prolonged uterine bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/3\">",
"     3",
"    </a>",
"    ]. Hypothyroidism can cause hyperprolactinemia; this usually results in amenorrhea and galactorrhea, but women may develop anovulatory bleeding prior to amenorrhea. Hyperthyroidism may cause anovulation due to alterations in sex hormone binding globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Menstrual irregularities are common in women with Cushing's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/5\">",
"     5",
"    </a>",
"    ]. Menstrual abnormalities correlate with increased serum cortisol and decreased serum estradiol concentrations, but not with serum androgen concentrations. The menstrual irregularities may be due to suppression of secretion of gonadotropin-releasing hormone by hypercortisolemia. High doses of corticosteroids have a similar effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormone secreting adrenal and ovarian tumors are rare causes of anovulation and menstrual irregularities. (See individual topic reviews).",
"   </p>",
"   <p>",
"    Endocrine changes leading to anovulation may also be caused by strenuous",
"    <span class=\"nowrap\">",
"     exercise/activity",
"    </span>",
"    (eg, running, ballet dancing), sudden weight change, or significant stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level or activity of sex hormones may be affected by disorders unrelated to endocrine glands, such as advanced liver or renal disease, that alter hormone metabolism or binding. Anovulation and AUB may result.",
"   </p>",
"   <p>",
"    Neoplasia and other disorders of the hypothalamus and pituitary often cause anovulation, but amenorrhea is more common than AUB because estrogen levels are low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anatomic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of women who complain of abnormal uterine bleeding have uterine abnormalities. This was illustrated in a study of 370 women aged 22 to 82 years with abnormal uterine bleeding unresponsive to treatment with progestin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/6\">",
"     6",
"    </a>",
"    ]. Hysteroscopy revealed an abnormal uterine cavity in two-thirds of these women: endometrial hyperplasia (23 percent), polyps (22 percent), submucous myomata (11 percent), synechiae (6 percent), endometrial atrophy (2 percent), and adenocarcinoma (1 percent).",
"   </p>",
"   <p>",
"    When anatomic abnormalities are the cause of abnormal bleeding, cyclic menses with molimina typically occur. However, the duration and flow of the menstrual period may be altered or there may be bleeding between menstrual periods. Anatomic abnormalities can often be diagnosed by imaging studies, but excision is sometimes required for confirmation of the diagnosis and treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Polyp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine polyps are usually benign endometrial growths of unknown etiology that are a common cause of abnormal uterine bleeding in women in the menopausal transition and early postmenopausal women. Irregular bleeding is the most frequent symptom, occurring in about one-half of symptomatic cases. Bleeding after straining or heavy lifting is common. Less frequent symptoms include heavy or prolonged bleeding, postmenopausal bleeding, prolapse through the cervical os, and unscheduled (breakthrough) bleeding during hormonal therapy. Polyps can be stimulated by estrogen replacement or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . The uterus is typically normal on bimanual examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fibroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas, also known as fibroids, are the most common pelvic tumors in women, occurring in approximately 25 percent of those who are of reproductive age. There are three uterine locations for fibroids: submucosal, intramural, and subserosal (",
"    <a class=\"graphic graphic_figure graphicRef53241 \" href=\"mobipreview.htm?30/16/30978\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intramural and submucosal fibroids distort the endometrial cavity, resulting in heavy or prolonged menstrual periods. Intermenstrual bleeding can also occur, but this is less likely and other lesions of cervix or uterus must be considered. The uterus often feels enlarged and asymmetric on bimanual examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Adenomyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomyosis is a disorder in which endometrial glands and stroma are present within the uterine musculature. The ectopic endometrial tissue appears to induce hypertrophy and hyperplasia of the surrounding myometrium, which results in a diffusely enlarged uterus and heavy, prolonged, painful menstrual periods. The diagnosis may be suspected by ultrasound or magnetic resonance imaging, but can only be confirmed by pathologic examination following hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hysterotomy scar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial abnormalities related to previous hysterotomy (particularly cesarean delivery) can lead to postmenstrual or intermenstrual bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other structural abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described sarcoidosis of the endometrium detected during the evaluation and treatment of AUB.",
"   </p>",
"   <p>",
"    A rare cause of heavy uterine bleeding is a congenital or acquired uterine arteriovenous malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/11\">",
"     11",
"    </a>",
"    ]. This lesion should be suspected when an invasive procedure (eg, endometrial biopsy, curettage) for unexplained uterine bleeding seems to aggravate the problem. Color Doppler studies can confirm the presence of abnormal blood flow, but pelvic arteriography is the standard for diagnosis. Uterine arteriovenous malformations have traditionally been treated with hysterectomy, but uterine artery embolization is often effective and may preserve fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30408?source=see_link\">",
"     \"Interventional radiology in management of gynecological disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterus &mdash; Adenocarcinoma of the endometrium is the most common gynecologic cancer in women over 45 years of age; it is rarely seen before age 35. All women who experience postmenopausal uterine bleeding in the absence of estrogen therapy must be evaluated for endometrial cancer since age is a significant risk factor for this disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=see_link\">",
"       \"Postmenopausal uterine bleeding\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sarcomas of the uterus constitute only 3 to 5 percent of all uterine tumors. These cancers arise from the stroma of the endometrium (endometrial stromal sarcomas) or the myometrium. They may look and feel like benign leiomyomas; diagnosis requires a hysterectomy. Women with leiomyosarcomas usually present with heavy prolonged bleeding or postmenopausal bleeding and a uterine mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other &mdash; Bleeding from fallopian tube cancer can track through the uterus, but this is a rare cause of uterine bleeding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link&amp;anchor=H9533947#H9533947\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Subacute presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal uterine bleeding can also be a symptom of ovarian cancer or gestational trophoblastic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, the endometrium is the site of metastatic disease from nongynecologic malignancy (eg, melanoma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Endometritis and pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometritis may be acute or chronic. Premenopausal women with chronic endometritis usually present with abnormal uterine bleeding, which may consist of intermenstrual bleeding, spotting, postcoital bleeding, or heavy prolonged periods. Vague, crampy lower abdominal pain may accompany the bleeding. The most common finding on physical examination is uterine tenderness or cervical motion tenderness. Women with acute endometritis frequently have fever, while it is less common in women with the chronic process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17431?source=see_link\">",
"     \"Endometritis unrelated to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute endometritis occurs postpartum in women with recent complications of pregnancy: spontaneous or induced abortion, premature rupture of membranes, intrauterine procedures, retained products of conception, or cesarean delivery. Symptoms include fever, uterine tenderness, foul lochia, and leukocytosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endometritis may also occur after placement of an intrauterine contraception or with pelvic inflammatory disease. Lower abdominal pain is the cardinal presenting symptom of pelvic inflammatory disease. The onset of pain during or shortly after menses is particularly suggestive of this disorder. The abdominal pain is usually bilateral and rarely of more than two weeks' duration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, endometritis in postmenopausal women is commonly associated with underlying malignancy. In the setting of cervical stenosis, blood can accumulate in the uterus (hematometra) and become secondarily infected (pyometra).",
"   </p>",
"   <p>",
"    Inflammation of neighboring organs, such as diverticulitis, can occasionally cause corresponding inflammation of the female upper genital tract. A ruptured sigmoid diverticulum may fistulize into the uterus and present as uterine bleeding, discharge, and endometritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Bleeding diatheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with bleeding diatheses usually present with abnormal uterine bleeding, particularly increased flow, but other genital tract bleeding may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/12\">",
"     12",
"    </a>",
"    ]. In one series of women age 18 to 45 years, bleeding disorders were diagnosed in 11 percent of patients with menorrhagia (von Willebrand disease",
"    <span class=\"nowrap\">",
"     [8/121],",
"    </span>",
"    factor deficiencies",
"    <span class=\"nowrap\">",
"     [2/121],",
"    </span>",
"    platelet abnormality",
"    <span class=\"nowrap\">",
"     [3/121]),",
"    </span>",
"    but only in 3 percent of controls without abnormal uterine bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/13\">",
"     13",
"    </a>",
"    ]. In another series, 19 percent of adolescents with abnormal uterine bleeding had a coagulation disorder, with an even higher risk in those with hemoglobin less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or requiring hospitalization (25 and 50 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/14\">",
"     14",
"    </a>",
"    ]. Abnormal genital bleeding in women and adolescents with bleeding diatheses may be associated with other mucosal bleeding (eg, epistaxis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/41/1690?source=see_link\">",
"     \"Approach to the adult with epistaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      von Willebrand's disease is a relatively common inherited bleeding disorder that is characterized by a deficiency of a plasma protein that stabilizes factor VIII. It should be suspected in young women who present with menorrhagia from the onset of menarche, particularly if there is a family history of coagulopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24794?source=see_link\">",
"       \"Clinical presentation and diagnosis of von Willebrand disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombocytopenia due to immune thrombocytopenia (ITP), hypersplenism, or systemic diseases, such as chronic renal failure, may cause menorrhagia. Uremia also causes anovulatory menstrual bleeding.",
"     </li>",
"     <li>",
"      Women with acute leukemia or who are undergoing chemotherapy for malignancy may develop a bleeding diathesis and heavy, prolonged uterine bleeding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37285?source=see_link\">",
"       \"Heavy or irregular uterine bleeding during chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advanced liver disease may cause reduced synthesis of vitamin K-dependent clotting factors, fibrinogen, and antithrombins.",
"     </li>",
"     <li>",
"      Anticoagulants enhance the volume of blood loss from menstruation or AUB. Menorrhagia has been reported in women taking SSRIs, presumably related to the effect of these agents on platelets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link&amp;anchor=H12543449#H12543449\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraceptive techniques that can cause abnormal vaginal bleeding include combination hormonal contraceptives, intrauterine contraception, and progestin-only contraceptives.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination hormonal contraceptives &mdash; Intermenstrual (breakthrough) bleeding is the most common side effect of combination hormonal contraceptives. Its occurrence does not indicate a decrease in efficacy (unless the patient has been noncompliant), but reflects tissue breakdown as the endometrium adjusts to a new thin state in which it is fragile and atrophic. Unscheduled (breakthrough) bleeding is related to a relatively high progesterone-to-estrogen ratio and was less of a problem when high doses of estrogen were used because estrogen stabilizes the endometrium. The frequency of bleeding is independent of the type of progestin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/16,17\">",
"       16,17",
"      </a>",
"      ], and is increased in women who smoke cigarettes, probably due to the accelerated metabolism of estrogen caused by smoking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/18\">",
"       18",
"      </a>",
"      ]. Women should be cautioned that missing pills results in an increase in unscheduled bleeding, as well as a decrease in contraceptive efficacy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progestin-only contraceptives &mdash; Prolonged bleeding and spotting are common complications of progestin-only contraceptives, such as depot",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (Depo-Provera), the levonorgestrel-releasing intrauterine contraceptive, implantable progestin rods (eg, Implanon), and progestin-only pills. Bleeding tends to be an early complication of these methods; many women develop amenorrhea with continued use. The mechanism of progesterone-breakthrough bleeding is endometrial atrophy and ulceration due to insufficient estrogen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"       \"Overview of contraception\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Copper IUC &mdash; Copper IUCs cause a foreign body reaction in the uterus that creates an inflammatory response. The endometrium may hypertrophy at the site of inflammation with normal cyclic estrogen stimulation, resulting in intermenstrual bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of intrauterine contraception\", section on 'TCu380A (copper) IUD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal women who take postmenopausal hormone therapy may develop uterine bleeding; the frequency depends upon the regimen used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=see_link&amp;anchor=H24#H24\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Doses and bleeding patterns with estrogen regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that can cause hyperprolactinemia may also cause abnormal uterine bleeding (",
"    <a class=\"graphic graphic_table graphicRef75914 \" href=\"mobipreview.htm?2/58/2988\">",
"     table 4",
"    </a>",
"    ). Although severe hyperprolactinemia results in amenorrhea, mild degrees of hyperprolactinemia may cause oligomenorrhea and menstrual abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy-induced thrombocytopenia can cause menorrhagia, while antipsychotic drugs may lead to anovulation and irregular bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ruptured ovarian cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms include pain and light uterine bleeding (due to a drop in ovarian hormone levels). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CERVICAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to abnormal bleeding from the corpus, which is often heavy and associated with menses, cervical lesions typically cause sporadic spotting, which commonly occurs postcoitally. In addition, cervical lesions can be easily visualized on speculum examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic bleeding, postcoital spotting, and vaginal discharge that is watery, mucoid, or purulent and malodorous are common signs of cervical cancer. Therefore, women with these symptoms should not have cervical cytology postponed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct extension from other pelvic tumors, such as uterine cancer, is the most common source of cervical involvement by metastatic tumors. Choriocarcinoma has a relatively high rate of cervical involvement. Rarely leukemias, lymphomas, and other nongynecological cancers involve the cervix.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cervicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postcoital bleeding is common in women with cervicitis due to nonspecific inflammatory changes or ulcerative sexually transmitted diseases. A strawberry red cervix with bleeding on contact is pathognomonic for Trichomonas vaginalis infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical polyps commonly cause postcoital spotting and sporadic bleeding. The majority are benign endocervical polyps, which can be seen on visual examination of the cervix and endocervix. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=see_link\">",
"     \"Congenital cervical anomalies and benign cervical lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ectropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectropion is the normal physiologic presence of endocervical glandular tissue on the exocervix. This tissue is friable and readily bleeds upon contact, such as during intercourse or cervical cancer screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Ectropion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Pelvic organ prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in pelvic floor support can lead to herniation of the anterior, posterior, or apical portion of the vagina. If part or all of the vagina and cervix is exteriorized, bleeding can occur secondary to ulceration, trauma and infection. This type of bleeding often occurs after straining. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=see_link\">",
"     \"An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic endometriosis can be found in the cervix, especially if the patient has a history of cervical procedures (such as cone biopsy). These endometriotic implants will bleed during menses. Diagnosis is made by biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated necrotizing arteritis is a rare lesion, usually localized to the cervix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/19\">",
"     19",
"    </a>",
"    ]. Clinical manifestations include menorrhagia or postmenopausal bleeding. Isolated vasculitis involving the cervix, as well as other sites in the female genital tract, is another rare lesion that may be associated with bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     VAGINAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with cervical lesions, vaginal lesions typically cause sporadic or postcoital bleeding and can be easily visualized on speculum examination. Trauma is an exception; vaginal trauma can be associated with major internal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    external hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Vaginitis and vaginal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal infection or inflammation may lead to significant irritation of the vaginal lining, which then bleeds. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrophic vaginitis is an estrogen deficiency state, which occurs in premenarchal girls, postpartum lactating women, and postmenopausal women. Bleeding or spotting may occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ulcerative diseases with vaginal involvement can cause postcoital bleeding. Genital ulcers may be caused by infection, but non-infection related etiologies should also be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Primary and metastatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary vaginal cancer constitutes 1 to 2 percent of gynecological malignancies. The majority of patients present with vaginal bleeding, either postmenopausal or postcoital. Other symptoms include a watery, blood-tinged, or malodorous vaginal discharge or a vaginal mass. The upper posterior vaginal wall is the most frequent site of vaginal cancer. It is important to carefully palpate the lateral, anterior, and posterior vaginal walls since the lesion may be obscured by the speculum blades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31208?source=see_link\">",
"     \"Vaginal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Up to 20 percent of children under age 10 with vaginal bleeding have a reproductive tract neoplasm, such as sarcoma botryoides. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=see_link\">",
"     \"Vulvovaginal complaints in the prepubertal child\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advanced bladder or colorectal cancer may invade the vagina and cause vaginal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/22\">",
"     22",
"    </a>",
"    ], and the vagina may be the site of metastatic disease from distant organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding can be a late effect of radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/23\">",
"     23",
"    </a>",
"    ]. Obliterative endarteritis and the vascular narrowing of aging and arteriosclerosis lead to devascularization of the radiated tissues. Tissue necrosis causes viscus perforation, tissue sloughing, and bleeding. Hemorrhagic cystitis and proctitis can lead to significant blood loss. Vaginal vault necrosis may cause uncontrolled bleeding and pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Vaginal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from the vagina or vulva can occur from genital tract trauma related to intercourse (eg, tearing of an intact hymen during intercourse), foreign bodies that cause ulceration (eg, neglected tampon, pessary, sexual aids), sexual assault, pelvic trauma (eg, from a motor vehicle accident), and straddle-type injuries that result in lacerations or abrasions of the labia (eg, falling on a bicycle rail, fence, or table edge). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44071?source=see_link\">",
"     \"Evaluation and management of lower genital tract trauma in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Female circumcision or infundibulation reduces the vaginal opening. Vaginal bleeding and lacerations can occur when intercourse is attempted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34133?source=see_link\">",
"     \"Female genital cutting (circumcision)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicovaginal or rectovaginal fistulas related to childbirth, gynecologic surgery, or complications of cancer and cancer therapy can present with vaginal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44792?source=see_link\">",
"     \"Urogenital tract fistulas in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Benign growths",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gartner's duct cysts, polyps, and aberrant glandular tissue (termed vaginal adenosis) rarely lead to vaginal bleeding in the absence of friction and trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Toxic epidermal necrolysis and Stevens-Johnson syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic epidermal necrolysis and Stevens-Johnson syndrome may be caused by a variety of drugs, particularly antibiotics. The vulvar and vaginal regions are commonly involved in this sudden and extensive destruction of the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35113/abstract/24\">",
"     24",
"    </a>",
"    ]. Bleeding may occur along with significant ulceration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     VULVAR BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with cervical and vaginal lesions, vulvar lesions typically cause sporadic bleeding and can be easily visualized on physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted diseases can cause characteristic lesions on the vulva, some of which may produce a bloody discharge or bleed easily on contact. Examples include the syphilitic chancre (although this usually produces more serous than bloody drainage), herpes simplex virus, Haemophilus ducreyi (Chancroid), granuloma inguinale (Donovanosis), and lymphogranuloma venereum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Benign lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign lesions, such as sebaceous (epidermal) cysts, condylomata, and angiokeratoma, may bleed due to trauma related to friction from clothing or scratching. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37349?source=see_link\">",
"     \"Diagnostic evaluation of vulvar lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20618?source=see_link\">",
"     \"Differential diagnosis of vulvar lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Malignant and premalignant lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar malignancies account for 3 to 5 percent of gynecologic cancers. Early vulvar cancer is asymptomatic; bleeding occurs when a lesion is extensive enough to ulcerate.",
"   </p>",
"   <p>",
"    Vulvar cancer and vulvar intraepithelial neoplasia are often misdiagnosed. Delay may be related to patient embarrassment, denial, reluctance to be examined, or the tendency of health care practitioners to prescribe topical medications to a patient with vulvar complaints without performing a physical examination. All ulcers associated with skin thickening or mass must be biopsied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Vulvar trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vulva may bleed from trauma due to forceful sexual",
"    <span class=\"nowrap\">",
"     activity/assault",
"    </span>",
"    or accidents (sports or exercise related, motor vehicle). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44071?source=see_link\">",
"     \"Evaluation and management of lower genital tract trauma in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     NONGENITAL TRACT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases of the urethra (eg, urethritis, diverticulum, urethral prolapse [caruncle]), bladder (eg, cancer, stone, or infection), and bowel (eg, inflammatory bowel disease, hemorrhoids) may cause bleeding that is misdiagnosed as genital tract bleeding. These disorders should be considered in women with bleeding unrelated to the menstrual cycle, especially when there is no obvious genital tract etiology.",
"   </p>",
"   <p>",
"    Systemic diseases that may present with vulvar involvement include Crohn's disease, Behcet's syndrome, pemphigoid, erosive lichen sclerosus, and lymphoma.",
"   </p>",
"   <p>",
"    Trauma is a common cause genital tract bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/18/22820?source=see_link\">",
"       \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/35/23094?source=see_link\">",
"       \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=see_link\">",
"       \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The source of abnormal bleeding may be from a problem anywhere in the lower genital tract (vulva, vagina, cervix), upper genital tract (uterine corpus, fallopian tubes, ovaries), or from nearby organs (urethra, bladder, bowel). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The likelihood of a particular etiology for uterine bleeding depends upon the patient's reproductive age (premenarchal, adolescent, menopausal status), the pattern of bleeding (heavy, light, prolonged, cyclic or noncyclic), and the occurrence of associated symptoms (eg, pain, fever) and medical conditions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Uterine bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bleeding is a common symptom of a variety of disorders related to pregnancy; therefore, all reproductive age women with uterine bleeding should have a pregnancy test as part of their initial evaluation. Other common causes of abnormal uterine bleeding include heavy menses, anovulation, anatomic abnormalities (eg, polyps, fibroids, adenomyosis), and side effects of contraceptives. Bleeding is the cardinal symptom of endometrial cancer.",
"     </li>",
"     <li>",
"      Vulvar, vaginal, and cervical bleeding can usually be visualized by physical examination. Causes include trauma, infection, neoplasia, and genital manifestations of systemic disease. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Cervical bleeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Vaginal bleeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H42\">",
"       'Vulvar bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diseases of the urethra (eg, urethritis, diverticulum), bladder (eg, cancer, stone, infection), and bowel (eg, inflammatory bowel disease, hemorrhoids) may cause bleeding that is misdiagnosed as genital tract bleeding. (See",
"      <a class=\"local\" href=\"#H47\">",
"       'Nongenital tract disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/2\">",
"      Parker MA, Sneddon AE, Arbon P. The menstrual disorder of teenagers (MDOT) study: determining typical menstrual patterns and menstrual disturbance in a large population-based study of Australian teenagers. BJOG 2010; 117:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/3\">",
"      Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf) 1999; 50:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/4\">",
"      Aoki Y, Belin RM, Clickner R, et al. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 2007; 17:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/5\">",
"      Putignano P, Bertolini M, Losa M, Cavagnini F. Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome. J Endocrinol Invest 2003; 26:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/6\">",
"      Kowalczyk D, Guzikowski W, Wicek J, Sioma-Markowska U. Clinical value of real time 3D sonohysterography and 2D sonohysterography in comparison to hysteroscopy with subsequent histopathological examination in perimenopausal women with abnormal uterine bleeding. Neuro Endocrinol Lett 2012; 33:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/7\">",
"      Tahara M, Shimizu T, Shimoura H. Preliminary report of treatment with oral contraceptive pills for intermenstrual vaginal bleeding secondary to a cesarean section scar. Fertil Steril 2006; 86:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/8\">",
"      Monteagudo A, Carreno C, Timor-Tritsch IE. Saline infusion sonohysterography in nonpregnant women with previous cesarean delivery: the \"niche\" in the scar. J Ultrasound Med 2001; 20:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/9\">",
"      Fabres C, Arriagada P, Fern&aacute;ndez C, et al. Surgical treatment and follow-up of women with intermenstrual bleeding due to cesarean section scar defect. J Minim Invasive Gynecol 2005; 12:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/10\">",
"      Van Horenbeeck A, Temmerman M, Dhont M. Cesarean scar dehiscence and irregular uterine bleeding. Obstet Gynecol 2003; 102:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/11\">",
"      Molvi SN, Dash K, Rastogi H, Khanna SB. Transcatheter embolization of uterine arteriovenous malformation: report of 2 cases and review of literature. J Minim Invasive Gynecol 2011; 18:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/12\">",
"      James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005; 11:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/13\">",
"      Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/14\">",
"      Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause 2011; 18:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/15\">",
"      Do SSRIs cause gastrointestinal bleeding? Drug Ther Bull 2004; 42:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/16\">",
"      Archer DF. Vascular dysfunction as a cause of endometrial bleeding. Gynecol Endocrinol 2012; 28:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/17\">",
"      Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005; :CD002126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/18\">",
"      Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996; 174:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/19\">",
"      Francke ML, Mihaescu A, Chaubert P. Isolated necrotizing arteritis of the female genital tract: a clinicopathologic and immunohistochemical study of 11 cases. Int J Gynecol Pathol 1998; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/20\">",
"      Abu-Farsakh H, Mody D, Brown RW, Truong LD. Isolated vasculitis involving the female genital tract: clinicopathologic spectrum and phenotyping of inflammatory cells. Mod Pathol 1994; 7:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/21\">",
"      Al-Kurdi M, Monaghan JM. Thirty-two years experience in management of primary tumours of the vagina. Br J Obstet Gynaecol 1981; 88:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/22\">",
"      Brand A, Scurry J, Planner R, Leung S. Primary and recurrent colorectal cancer masquerading as gynaecological malignancy. Aust N Z J Obstet Gynaecol 1996; 36:165.",
"     </a>",
"    </li>",
"    <li>",
"     Hopewell, JW. The importance of vascular damage in the development of late radiation effects of normal tissues. In: Meyn, RE, Withers, HR (Eds), Radiation Biology in Cancer Research. Raven Press, New York 1980. p.449.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35113/abstract/24\">",
"      Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91:283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5440 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35113=[""].join("\n");
var outline_f34_18_35113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UTERINE BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Menstruation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anovulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Menopausal transition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anatomic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Polyp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fibroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hysterotomy scar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other structural abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Endometritis and pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Bleeding diatheses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CERVICAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cervicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ectropion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Pelvic organ prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      VAGINAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Vaginitis and vaginal ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Primary and metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Vaginal trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Benign growths",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Toxic epidermal necrolysis and Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      VULVAR BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Benign lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Malignant and premalignant lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Vulvar trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      NONGENITAL TRACT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5440|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/16/30978\" title=\"figure 1\">",
"      Fibroid anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5440|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/45/26334\" title=\"table 1\">",
"      Causes genital tract bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/12/30924\" title=\"table 2\">",
"      Causes genital bleeding by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/36/12876\" title=\"table 3\">",
"      Causes anovulation oligoovulati",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/58/2988\" title=\"table 4\">",
"      Drugs cause hyperprolactinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40473?source=related_link\">",
"      An overview of the epidemiology, risk factors, clinical manifestations, and management of pelvic organ prolapse in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/41/1690?source=related_link\">",
"      Approach to the adult with epistaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25975?source=related_link\">",
"      Definition and evaluation of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37349?source=related_link\">",
"      Diagnostic evaluation of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11160?source=related_link\">",
"      Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20618?source=related_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17431?source=related_link\">",
"      Endometritis unrelated to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44071?source=related_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18086?source=related_link\">",
"      Evaluation of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/6/26724?source=related_link\">",
"      Evaluation of the menstrual cycle and timing of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34133?source=related_link\">",
"      Female genital cutting (circumcision)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37285?source=related_link\">",
"      Heavy or irregular uterine bleeding during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17529?source=related_link\">",
"      Management of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/35/23094?source=related_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44792?source=related_link\">",
"      Urogenital tract fistulas in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_18_35114="Prevention and treatment of neonatal pain";
var content_f34_18_35114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of neonatal pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/18/35114/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/18/35114/contributors\">",
"     KJS Anand, MBBS, DPhil, FAAP, FCCM, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/18/35114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/18/35114/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/18/35114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/18/35114/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/18/35114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in neonatal research demonstrate that newborns experience pain and controlling newborn pain has short-term and long-term benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/1\">",
"     1",
"    </a>",
"    ]. Care providers are expected to prevent infants from experiencing pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Varying degrees of neonatal discomfort or pain may occur during routine patient care (eg, gavage tube placement, bladder catheterization, or physical examination) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/5\">",
"     5",
"    </a>",
"    ], moderately invasive procedures (eg, suctioning, phlebotomy, or peripheral intravenous line placement), or more invasive procedures (eg, chest tube placement, circumcision, or central venous line placement).",
"   </p>",
"   <p>",
"    Pain is most common and intense in infants admitted to the neonatal intensive care unit (NICU). Infants admitted to the NICU frequently experience acute pain from skin-breaking procedures, established pain following surgery, and prolonged (chronic) pain from diseases like necrotizing enterocolitis or meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=see_link\">",
"     \"Assessment of neonatal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2006, the American Academy of Pediatrics and the Canadian Pediatric Society",
"    <span class=\"nowrap\">",
"     (AAP/CPS)",
"    </span>",
"    published new guidelines recommending that each health care facility that treats neonates establish a neonatal pain control program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/2\">",
"     2",
"    </a>",
"    ]. These recommendations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Routine assessments for the detection of pain",
"     </li>",
"     <li>",
"      Reduce the number of painful procedures",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Prevent/reduce",
"      </span>",
"      acute pain from invasive procedures performed at the bedside",
"     </li>",
"     <li>",
"      Anticipate and treat postoperative pain following surgery",
"     </li>",
"     <li>",
"      Avoid chronic",
"      <span class=\"nowrap\">",
"       pain/stress",
"      </span>",
"      during neonatal intensive care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prevention, control, and treatment of neonatal pain will be reviewed here. The assessment of neonatal pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=see_link\">",
"     \"Assessment of neonatal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ethical approach to neonatal intensive care must include evidence-based and effective measures to reduce, control, or prevent pain in newborns, which includes: [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preemptive analgesia for any anticipated painful procedure.",
"     </li>",
"     <li>",
"      Elimination of unnecessary noxious stimuli or painful procedures.",
"     </li>",
"     <li>",
"      Active involvement of the parents in helping their baby cope with the procedure.",
"     </li>",
"     <li>",
"      A combination of nonpharmacologic methods and pharmacologic agents to prevent and reduce neonatal pain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Analgesia for specific procedures'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANALG",
"1ff8",
"ESIA FOR SPECIFIC PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive analgesia before and during elective painful procedures should be provided to all neonates. Analgesia often includes a combination of non-pharmacologic and pharmacologic techniques.",
"   </p>",
"   <p>",
"    In our institution, we use a combination of measures for frequently performed neonatal procedures in a stepwise manner with increasing analgesia as the degree of anticipated procedural pain increases (",
"    <a class=\"graphic graphic_figure graphicRef60821 \" href=\"mobipreview.htm?37/59/38846\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. This approach is similar to the World Health Organization analgesic ladder for pain management in adults and guidelines published by the Italian Society of Neonatology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of pain in children\", section on 'Principles of management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1 &ndash; Nonpharmacologic measures including pacifier use, administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      , swaddling, kangaroo care, and sensorial saturation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nonpharmacologic analgesia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Step 2 &ndash; Topical anesthetics (ie, topical",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/43/34486?source=see_link\">",
"       lidocaine-prilocaine",
"      </a>",
"      cream, amethocaine gel,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37648?source=see_link\">",
"       tetracaine",
"      </a>",
"      gel). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Topical anesthetics'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Step 3 &ndash; Oral, intravenous, or rectal administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acetaminophen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Step 4 &ndash; Slow intravenous infusion of opioids (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Step 5 &ndash; Subcutaneous infiltration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      or specific nerve blocks.",
"     </li>",
"     <li>",
"      Step 6 &ndash; Deep sedation (eg, combination of opioids, sedatives, and other drugs) or general anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The application of these steps to specific invasive procedures at the bedside depends upon the clinician's choice and hospital-specific policies and procedures.",
"   </p>",
"   <p>",
"    Our analgesic management is detailed in the accompanying table for common procedures performed in the NICU (",
"    <a class=\"graphic graphic_table graphicRef75338 \" href=\"mobipreview.htm?3/2/3118\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114448720\">",
"    <span class=\"h2\">",
"     Retinopathy of prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials show minimal or no effects of topical anesthetic (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/19/36146?source=see_link\">",
"     proparacaine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    or glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/14\">",
"     14",
"    </a>",
"    ], or comfort care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/15\">",
"     15",
"    </a>",
"    ] in reducing the pain and distress associated with retinopathy of prematurity screening. Therefore, we recommend deep sedation with short-acting drugs like",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/56/31622?source=see_link\">",
"     remifentanil",
"    </a>",
"    for this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=see_link&amp;anchor=H18#H18\">",
"     \"Retinopathy of prematurity\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     REDUCTION OF PAINFUL EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective method to reduce neonatal pain or discomfort is to reduce the number of procedures performed and episodes of patient handling. NICUs and nurseries should develop strategies that limit handling and procedures but do not compromise the care of the infants.",
"   </p>",
"   <p>",
"    With forethought and planning, the number of bedside disruptions and procedures can be reduced as follows, commonly referred to as \"clustered care\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/2,6,17\">",
"     2,6,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease the number of bedside disruptions by timing routine medical interventions (daily physical examinations by clinician) with other care procedures (eg, diaper change or suctioning).",
"     </li>",
"     <li>",
"      Anticipate needed blood studies to minimize the frequency of blood studies. For example, nonchemical photometric devices can perform several analyses (eg, pH, PaO2, electrolytes, calcium, and bilirubin) from a single small blood sample, thereby reducing the number of venipunctures or heelsticks required for laboratory testing.",
"     </li>",
"     <li>",
"      For newborns who need more than two to three heelsticks a day, a peripheral arterial catheter can be placed for frequent blood sampling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a central venous catheter in patients who need intravenous access. These procedures should be performed with appropriate analgesia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Analgesia for specific procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If clinically appropriate, use noninvasive monitoring such as transcutaneous monitoring (eg, oxygen saturation or bilirubin levels), or near infra-red spectroscopy (NIRS) to avoid the need for blood sampling.",
"     </li>",
"     <li>",
"      Consider the use of noninvasive therapeutic approaches for achieving analgesia in newborns [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following nonpharmacologic approaches can effectively reduce pain and discomfort from minor procedures in both preterm and term neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      or glucose",
"     </li>",
"     <li>",
"      Breastfeeding",
"     </li>",
"     <li>",
"      Non-nutritive sucking",
"     </li>",
"     <li>",
"      Skin to skin contact (eg, kangaroo care)",
"     </li>",
"     <li>",
"      Swaddling including facilitated tucking (defined as maintaining the arms and legs in a flexed position)",
"     </li>",
"     <li>",
"      Sensorial saturation &ndash; Use of touch, massage, voice, smell, and sight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonpharmacologic approaches are generally more effective when used in combination than when used alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. As discussed above, in our practice we use combinations of nonpharmacologic and pharmacologic measures depending upon the clini",
"1ff8",
"cal setting (",
"    <a class=\"graphic graphic_table graphicRef75338 \" href=\"mobipreview.htm?3/2/3118\">",
"     table 1",
"    </a>",
"    ). Combinations of nonpharmacologic measures (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    and skin-to-skin contact) have additive or synergistic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/23\">",
"     23",
"    </a>",
"    ]. In some settings, these combinations may eliminate pharmacologic use, or reduce drug dosage or the frequency of doses required, and consequently, the risk of pharmacologic side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/20-22,25\">",
"     20-22,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oral sucrose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    and other sweet-tasting liquids, such as glucose or saccharin, appear to be effective analgesics in both term and preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. This was illustrated in a systematic review of randomized controlled trials that included infants with gestational ages from 25 to 42 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/29\">",
"     29",
"    </a>",
"    ]. In neonates undergoing skin-breaking procedures (eg, heelstick or venipuncture), sucrose was associated with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced crying &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       Sucrose",
"      </a>",
"      compared with placebo reduced total crying time.",
"     </li>",
"     <li>",
"      Dampened physiologic responses &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       Sucrose",
"      </a>",
"      compared with placebo reduced the changes in heart rate, oxygen saturation, or vagal tone at heel lance in the majority of studies. However, results were variable across studies.",
"     </li>",
"     <li>",
"      Reduced facial expressions &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       Sucrose",
"      </a>",
"      compared with placebo was associated with a lower pain score on unidimensional pain measures based on facial expression or the presence of crying.",
"     </li>",
"     <li>",
"      Improved composite pain scores &ndash; Studies that used multidimensional pain assessment tools reported lower pain scores in the groups who received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      before or after the heelstick, as compared with controls. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=see_link&amp;anchor=H8#H8\">",
"       \"Assessment of neonatal pain\", section on 'Pain assessment tools'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It remains unclear whether",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    suppresses the neurophysiologic responses to pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 44 term infants, patients assigned to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      therapy versus placebo had lower pain scores (using the Premature Infant Pain Profile) following a heelstick, but there were no differences in brain and spinal cord activity using brief electroencephalographic (EEG) and electromyographic (EMG) recordings in the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/30\">",
"       30",
"      </a>",
"      ]. Several concerns about the study design and analysis have been raised including the small sample size, exclusion of more than 30 percent of the enrolled subjects in the sucrose group (9 of 29 patients), limitations regarding the electrophysiological monitoring to specific domains and amplitudes, and the timing of the EMG and EEG within one second after the heelstick, and the uncertainty of whether the time-limited EEG (one second) and EMG (two seconds) recordings actually measure pain (which the neonate was not able to express), or reduction of the nociception response (which the neonate did not perceive as pain) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/31-35\">",
"       31-35",
"      </a>",
"      ]. These reservations have limited the applicability of these findings.",
"     </li>",
"     <li>",
"      In contrast, another trial reported",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      given prior to a heelstick suppressed the electroencephalographic changes occurring in the right frontal lobe of control infants who received water [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon animal studies, it was proposed that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    mediated its effect by activating endogenous opioid mechanisms in the brainstem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. In human infants, however, one study showed no changes in plasma beta-endorphin levels with sucrose analgesia, while another study demonstrated that intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/4/20551?source=see_link\">",
"     naloxone",
"    </a>",
"    appeared to potentiate the effects of sucrose administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Current evidence suggests that the analgesic effects of sucrose or glucose are mediated through activation of opioid and nonopioid systems in the brainstem.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     Sucrose",
"    </a>",
"    may not provide enough analgesia to reduce the pain caused by intramuscular injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/42\">",
"     42",
"    </a>",
"    ]. However, sucrose in combination with topical anesthetic appears to reduce pain from eye examinations screening for retinopathy of prematurity (ROP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. A meta-analysis of five studies demonstrated infants who received sucrose had lower pain scores than those assigned placebo therapy during ROP screening. However, scores remained high even with sucrose therapy indicating the need for better pain reduction strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucose appears to be as effective as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    in providing analgesia in preterm infants undergoing minor invasive procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;No optimal dose for oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    has been established and dosing to treat neonatal pain ranges from 0.012 to 0.12 g (0.05 to 0.5 mL of a 24 percent sucrose solution) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/2,37,48-50\">",
"     2,37,48-50",
"    </a>",
"    ]. Current data indicates that sucrose is not effective after three months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     Sucrose",
"    </a>",
"    can be administered orally via a syringe or onto the tongue by allowing the infant to suck on a pacifier that has been previously dipped in 24 percent sucrose solution.",
"   </p>",
"   <p>",
"    Although repeated",
"1ff8",
" doses are effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/49,53\">",
"     49,53",
"    </a>",
"    ], one study has reported adverse neurodevelopmental effects in preterm infants less than 32 weeks gestation who received more than 10 doses over a 24 hour time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/50,54\">",
"     50,54",
"    </a>",
"    ]. A review also questioned the long-term developmental effects of repeated",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    exposure in preterm neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we administer oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    as a 24 percent sucrose solution via pacifier, given two minutes before painful procedures and repeat the sucrose administration as needed for pain relief. For intubated infants, we place sucrose directly on the infant's tongue based upon postconceptual age (PCA) as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      24 to 26 weeks PCA &ndash; 0.1 mL",
"     </li>",
"     <li>",
"      27 to 31 weeks PCA &ndash; 0.25 mL",
"     </li>",
"     <li>",
"      32 to 26 weeks PCA &ndash; 0.5 mL",
"     </li>",
"     <li>",
"      37 to 44 weeks PCA &ndash; 1 mL",
"     </li>",
"     <li>",
"      45 to 60 weeks PCA &ndash; 2 mL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We monitor for changes in vital signs as well as any clinical signs of choking or gagging.",
"   </p>",
"   <p>",
"    We use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    for minor procedures such as heelstick, venipuncture, venous catheterization, nasogastric insertion, arterial puncture, bladder catheterization, intramuscular or subcutaneous injections, eye examination for ROP assessment, dressing change, or tape removal. Sucrose is combined with other analgesic agents for moderately painful procedures such as lumbar puncture, circumcision, chest tube insertion, percutaneous central venous catheter insertion, or intraosseous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/42,48,56\">",
"     42,48,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     Sucrose",
"    </a>",
"    may be used for distress unrelated to invasive procedures to reduce crying activity and heat loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/51,57\">",
"     51,57",
"    </a>",
"    ], but an evaluation and documentation of its effectiveness is essential when sucrose is used outside the procedural pain setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Breastfeeding or breast milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding or oral administration of breast milk appears to have similar analgesic effects as those elicited by oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    . This was an illustrated meta-analyses that included trials of breastfeeding or supplemental breast milk in neonates undergoing painful procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/58\">",
"     58",
"    </a>",
"    ]. One major limitation of this meta-analysis was a significant variability in study design among trials. Infants who were breastfed or received breast milk were compared to control groups receiving placebo or no intervention, or interventions such as sucrose, holding by mother, non-nutritive sucking, or swaddling. The following main findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates in the breastfeeding group had reduced crying and smaller increases in heart rate during acute painful procedures compared to infants in the control groups. Validated pain scores such as the PIPP (Premature Infant Pain Profile), DAN (Douleur Aigue Nouveau-ne), NIPS (Neonatal Infant Pain Scale), or NFCS (Neonatal Facial Coding System) were also lower in the breast feeding group.",
"     </li>",
"     <li>",
"      Results varied when breastfeeding was compared with either oral glucose or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      administration. In some studies, pain scores were lower in the breastfeeding group, whereas in others, there was no difference between the breastfeeding and the oral",
"      <span class=\"nowrap\">",
"       glucose/sucrose",
"      </span>",
"      groups.",
"     </li>",
"     <li>",
"      Supplemental breast milk that was given orally to the infant appeared to be more effective in controlling procedural pain (decreased changes in heart rate, facial expressions (NFCS), and decreased crying) when compared with placebo, but less effective than oral glucose or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials showed that breastfeeding has greater analgesic effects compared with non-nutritive sucking on a pacifier, with or without",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], but it is unclear whether combining breastfeeding and sugar solution increases their analgesic effects. In one study, there were additive analgesic effects when the two were combined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/61\">",
"     61",
"    </a>",
"    ]; however, another trial found no additional benefits of combining breastfeeding with sucrose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breastfeeding is a developmentally superior alternative to oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    or glucose for pain control in infants, but it may not be applicable to intubated or very preterm neonates undergoing painful procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/60\">",
"     60",
"    </a>",
"    ]. If oral sucrose or glucose, or breastfeeding is unavailable, supplemental breast milk is a reasonable option for providing neonatal analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/63\">",
"     63",
"    </a>",
"    ]. Currently, there are no studies that have evaluated the safety or effectiveness of repeated administration of breastfeeding or supplemental breast milk for pain relief in neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-nutritive sucking",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis, non-nutritive suckling was shown to be effective in reducing pain-related distress reactivity in both preterm and term infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants treated with non-nutritive sucking with pacifiers have lower increases in heart rate and decreased duration of crying in response to a painful stimuli compared to those who received no intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/64\">",
"     64",
"    </a>",
"    ], swaddling alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/65\">",
"     65",
"    </a>",
"    ], rocking alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/66\">",
"     66",
"    </a>",
"    ], or sensory stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/62\">",
"     62",
"    </a>",
"    ]. However, pain relief was poorer in infants who received pacifiers only as compared to those receiving",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    dipped pacifiers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/64\">",
"     64",
"    </a>",
"    ]. As a result, oral sucrose or breastfeeding is preferred to non-nutritive sucking or swaddling for infants undergoing minor painful procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/59,61,62\">",
"     59,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other measure",
"1ff8",
"s",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Swaddling or facilitated tucking &ndash; Restricting the movement of an infant's limbs activates proprioceptive, tactile, and thermal systems, facilitates self-soothing behaviors (eg, hand-to-mouth movement, and non-nutritive sucking), and is developmentally supportive. This can be achieved by swaddling in a blanket or manually by facilitated tucking (holding the infant's extremities flexed and contained close to the trunk).",
"      <br/>",
"      <br/>",
"      In the previously mentioned meta-analysis, swaddling or facilitated tucking was shown to be effective for both pain reactivity and pain-related regulation in both preterm and term infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/19\">",
"       19",
"      </a>",
"      ]. Both approaches compared to no intervention reduce pain responses to invasive procedures (eg, endotracheal suctioning and heelstick) in term [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/65,67,68\">",
"       65,67,68",
"      </a>",
"      ] and preterm infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/68-73\">",
"       68-73",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A multicenter randomized trial comparing interventions for repeated heelsticks showed that facilitated tucking alone was significantly less effective in relieving repeated procedural pain than",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      , but in combination with sucrose it seemed to have added value, with lower pain scores occurring in the recovery phase, compared with either treatment given alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Of note, swaddling has been associated with an increased risk of developmental dysplasia of the hip (DDH). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/199?source=see_link&amp;anchor=H3#H3\">",
"       \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin to skin contact &ndash; Skin to skin contact, which includes kangaroo care (with infant resting between the mother's breasts) stimulates ventral tactile and proprioceptive systems and reduces neonatal pain responses. Several randomized trials have demonstrated that kangaroo care reduced pain compared to standard within the crib positioning when undergoing heelsticks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/74-77\">",
"       74-77",
"      </a>",
"      ]. In a clinical trial, 95 preterm neonates (gestational age 28 to 36 weeks) were randomly assigned to receive skin-to-skin contact or 25 percent glucose (1 mL), or no treatment during heel lancing. Skin-to-skin contact reduced changes in heart rate (p = 0.0001), oxygen saturation (p = 0.0012), facial pain expressions (brow bulge, eye squeeze, nasolabial furrowing; p = 0.0001), and lowered their Premature Infant Pain Profile (PIPP) scores (p = 0.0001) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sensorial saturation &ndash; Sensorial saturation is the use of sensory input (eg, touch, massage, taste, voice, smell, and sight) during a painful procedure. Several studies from the same research group have shown reduction of pain in infants who received a combination of sensorial saturation and oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      during painful procedures compared to oral sucrose alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/20,79,80\">",
"       20,79,80",
"      </a>",
"      ]. This approach is labor-intensive and has not been replicated in other settings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of the above interventions, including 51 studies with 3396 participants, showed that non-nutritive sucking and kangaroo care were effective in term and preterm neonates,",
"    <span class=\"nowrap\">",
"     swaddling/facilitated",
"    </span>",
"    tucking was effective in preterm neonates, and",
"    <span class=\"nowrap\">",
"     rocking/holding",
"    </span>",
"    in term neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LOCAL ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local analgesics, such as topical anesthetics and injectable",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    , can reduce procedural pain in neonates and are widely used. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Topical anesthetics'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Topical anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several topical anesthetics are available, including EMLA&reg; cream, an eutectic mixture of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    (2.5 percent) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    (2.5 percent) in a cream base, Ametop&reg; or Pontocaine&reg; (2 or 4 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37648?source=see_link\">",
"     tetracaine",
"    </a>",
"    cream, respectively), L.M.X-4&reg; or L.M.X-5&reg; (4 or 5 percent liposomal lidocaine cream, respectively), and S-caine&reg;, a eutectic mixture of lidocaine (7 percent) and tetracaine (7 percent). EMLA is the most frequently used preparation, and the one most extensively studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     EMLA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of EMLA for procedural pain in newborns were evaluated in two systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The procedures assessed were circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/81\">",
"     81",
"    </a>",
"    ], heelstick, venipuncture, arterial puncture, lumbar puncture, and percutaneous insertion of venous catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/83\">",
"     83",
"    </a>",
"    ]. The results were summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measures of pain during circumcision such as facial grimacing, duration of crying time, increased heart rates, and oxygen desaturations were significantly reduced with the use of EMLA compared to placebo.",
"     </li>",
"     <li>",
"      EMLA reduced the pain of venipuncture. It appeared to be more successful for venipuncture than arterial puncture.",
"     </li>",
"     <li>",
"      EMLA had no effect on lumbar puncture pain in one randomized trial.",
"     </li>",
"     <li>",
"      EMLA did not diminish pain associated with heelstick and may prolong the procedure because it produces vasoconstriction at the site of application.",
"     </li>",
"     <li>",
"      The effect of EMLA on the pain associated with percutaneous venous catheter placement was equivocal, with attenuation of increases in heart rate and respiratory rate, but no effects on blood pressure or oxygen saturation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent randomized trial of neonates undergoing lumbar puncture, EMLA reduced pain (detected by changes in heart rate and oxygen saturation, and facial expressions) compared to placebo at both needle insertion and withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small clinical trial, the combination of ELMA cream and oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    was more effective in providing analgesia than placebo cream and oral sucrose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effect is mild, transient skin irritation, which is related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    contain",
"1ff8",
"ed in the formulation. Methemoglobinemia is a serious but rare side effect, and is more likely to occur in patients with a predisposing condition, such as glucose-6-phosphate dehydrogenase deficiency, or following the use of inappropriately excessive doses. In the above meta-analyses, application of EMLA appeared to be safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/81,83\">",
"     81,83",
"    </a>",
"    ]. Methemoglobin concentration as a percent of hemoglobin concentration was similar in EMLA and control groups, and no study reported clinically significant levels. Plasma concentrations of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    (four studies) and prilocaine (three studies) in treated infants were less than 0.3 and 0.1",
"    <span class=\"nowrap\">",
"     &micro;g/mL",
"    </span>",
"    respectively, significantly below their toxic concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To attain adequate local anesthesia, 1 to 2 g of EMLA cream should be applied and covered with an occlusive dressing for 45 to 60 minutes. The safety of repeated doses, up to four times a day, has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, if time permits for application, we use EMLA cream to reduce pain associated with venous, arterial, and lumbar punctures, and intravenous or arterial catheter insertion, in addition to the administration of oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    . EMLA is not effective in reducing pain from heelsticks because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    causes vasoconstriction, and squeezing the heel for blood collection is the most painful part of the procedure.",
"   </p>",
"   <p>",
"    The use of EMLA as a topical anesthetic is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H11#H11\">",
"     \"Topical anesthetics in children\", section on 'EMLA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     Lidocaine",
"    </a>",
"    can be injected locally to reduce the pain associated with venous or arterial puncture, percutaneous venous or arterial catheter placement, lumbar puncture, and circumcision. Lidocaine infiltration is also used during surgical operations to reduce the postoperative hyperalgesia and the need for postoperative analgesia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     Lidocaine",
"    </a>",
"    is usually administered as either a 0.5 (5",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    or 1 percent solution (10",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    at a maximum dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    In neonates, the combination of lidocaine with epinephrine should be avoided to minimize the risk of tissue necrosis and arrhythmias. Needle-free devices may be able to inject lidocaine subcutaneously, but these have not been tested in newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For circumcisions, 1 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    is administered either as a dorsal penile nerve block or circumferential subcutaneous local anesthesia (ring block) as the most effective therapy to reduce circumcision pain. Infants should also receive oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"     sucrose",
"    </a>",
"    prior and during the circumcision, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for postprocedure pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link&amp;anchor=H8#H8\">",
"     \"Techniques for neonatal circumcision\", section on 'Pain control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    as a local anesthetic is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link&amp;anchor=H2#H2\">",
"     \"Infiltration of local anesthetics\", section on 'Lidocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SYSTEMIC ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic pharmacologic agents that have been used in neonates to reduce pain and stress include nonopioid analgesics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    ), nonsteroidal anti-inflammatory agents, opioid analgesics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    ), and sedatives (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Opioids are the most effective therapy for moderate to severe pain in patients of all ages. They provide both analgesia and sedation, have a wide therapeutic window, and also attenuate physiologic stress responses.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     Morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    are the most commonly used opioids in neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    (paracetmaol) is used in the management of mild to moderate procedural and post-operative pain. In both preterm and term infants, the clearance of acetaminophen is slower than older children, so oral dosing is required less frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/86-88\">",
"     86-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In neonates, recommended oral doses are 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given every six to eight hours and 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given rectally at the same time intervals. The maximum oral doses are 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours in infants &gt;32 weeks postconception age and 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 hours for infants between 28 and 32 weeks postconception age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/89\">",
"     89",
"    </a>",
"    ]. These doses are primarily based upon antipyretic dose-response studies and may not be adequate for pain control.",
"   </p>",
"   <p>",
"    In infants, both rectal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/87,90,91\">",
"     87,90,91",
"    </a>",
"    ] and intravenous formulations of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/92\">",
"     92",
"    </a>",
"    ] have been studied. There are minimal adverse effects in infants, and in contrast to its use in older children and adults, acetaminophen rarely, if ever, causes hepatic or renal toxicity in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/93,94\">",
"     9",
"1ff8",
"3,94",
"    </a>",
"    ]. In addition, intravenous administration of acetaminophen does not increase the risk of hypothermia in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rectal dose is 20 to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given every six to eight hours.",
"     </li>",
"     <li>",
"      Although data have been limited regarding the intravenous dosing for neonates, the following dosing schedule for infants with a postmenstrual age (PMA) between 32 and 44 weeks has been proposed based on a pharmacokinetic analysis in 158 infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/96\">",
"       96",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Loading dose of 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Maintenance doses of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      starting six hours after the initial dose, and every six hours thereafter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    alone is not effective to reduce acute pain from circumcision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/97\">",
"     97",
"    </a>",
"    ] or heelsticks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/98\">",
"     98",
"    </a>",
"    ], but when combined with other analgesic interventions it can be effective for postoperative or other types of prolonged pain. As an example, in a Dutch trial, the use of intravenous acetaminophen reduced the cumulative",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    dose given to neonates and infants following major (noncardiac) or abdominal surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nonsteroidal anti-inflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nonsteroidal anti-inflammatory drugs (NSAIDs) are used extensively in older children and adults, there has been reluctance to use these agents because of their well-known adverse effects in newborn infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. In studies that evaluated",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    for treatment of patent ductus arteriosus in preterm infants, use of NSAIDs was associated with gastrointestinal bleeding, platelet dysfunction, and decreased glomerular filtration rate. As a result, NSAIDs are not generally used for analgesia because effective and safer agents are available. Use of NSAIDs during pregnancy may cause premature closure of the ductus arteriosus in utero, associated with severe pulmonary hypertension in the newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link&amp;anchor=H10685801#H10685801\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\", section on 'Prostaglandin E2'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=see_link&amp;anchor=H17050117#H17050117\">",
"     \"Management of patent ductus arteriosus in premature infants\", section on 'Cyclooxygenase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5495576\">",
"    <span class=\"h2\">",
"     Opioid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are the most effective therapy for moderate to severe pain in patients of all ages. They provide both analgesia and sedation, have a wide therapeutic window, and also attenuate physiologic stress responses.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     Morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    are the most commonly used opioids in neonates, although more potent (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/6/96?source=see_link\">",
"     sufentanil",
"    </a>",
"    ), shorter acting (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/53/2903?source=see_link\">",
"     alfentanil",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/56/31622?source=see_link\">",
"     remifentanil",
"    </a>",
"    ), or mixed opioids (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/7/26743?source=see_link\">",
"     tramadol",
"    </a>",
"    ) are being used with increasing frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     Morphine",
"    </a>",
"    is the most commonly used opioid for analgesia in the neonate. It has been used as a continuous infusion in ventilated infants or infants following major surgery, or intermittently to reduce the acute pain associated with invasive procedures. Whether it is an effective and safe neonatal analgesic in these clinical settings, however, remains under active investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Ventilated neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    may improve ventilator synchrony [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/105\">",
"     105",
"    </a>",
"    ] and sedate ventilated neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/106,107\">",
"     106,107",
"    </a>",
"    ], the following data suggest that routine continuous morphine infusions in ventilated preterm infants provide little or no clinical benefits compared to placebo.",
"   </p>",
"   <p>",
"    A multicenter-blinded prospective trial (the NEOPAIN trial) evaluated the outcomes of 898 ventilated preterm infants (gestational age &le;32 weeks) who were randomly assigned to continuous infusion of either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. Open-label morphine was allowed and was administered based upon the clinical judgment of blinded care providers in each of the participating NICUs. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no differences in the rates of mortality, severe intraventricular hemorrhage (IVH), or periventricular leukomalacia (PVL) between the two groups.",
"     </li>",
"     <li>",
"      Infants assigned to the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      group compared to placebo appeared to have lower levels of pain as assessed by smaller increases in heart and respiratory rates, and lower scores on multidimensional neonatal pain assessment using the Premature Infant Pain Profile (PIPP). These differences were small, but reached statistical significance because of the large sample size.",
"     </li>",
"     <li>",
"      Although a higher proportion of control infants received open-label",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      , almost half of the patients in each group did not receive open-label morphine.",
"     </li>",
"     <li>",
"      Infants treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      were more likely to develop hypotension [",
"      <a class=\"abstract\" href=\"./prevention-and-treatment-of-neonatal",
"1ff8",
"-pain/abstract/110\">",
"       110",
"      </a>",
"      ], required longer duration of mechanical ventilation, and took longer to tolerate full-volume nasogastric feeds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/108,109\">",
"       108,109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      did not increase the rate of gastrointestinal complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/109\">",
"       109",
"      </a>",
"      ]. However, the morphine group had a delay in starting feeds and attaining full feeds. Other factors that were associated with a delay in starting feeds included lower birth weight, a higher score of neonatal morbidities, and the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A smaller randomized Dutch clinical trial demonstrated that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    had no additional analgesic effect compared to placebo using multiple measures of pain assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/111\">",
"     111",
"    </a>",
"    ]. In this trial of 150 preterm infants, there was a decrease in the rate of IVH in the morphine-treated group, but there was no difference in the likelihood of poor neurologic outcome between the two groups.",
"   </p>",
"   <p>",
"    A systematic review on the use of opioids (primarily",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    ) in ventilated infants selected 13 studies for analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/112\">",
"     112",
"    </a>",
"    ]. There was, however, significant variability of study design resulting in differences in the quality of the included studies. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pooled data from four high-quality studies (which used a validated pain assessment tool, PIPP, and included the above two trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/108,111\">",
"       108,111",
"      </a>",
"      ]) demonstrated a trend towards reduced pain scores in the group of patients that received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      compared to controls (-1.71, 95% CI -3.18 to -0.24).",
"     </li>",
"     <li>",
"      Other analyses demonstrated no differences in the rates of mortality (five trials), duration of mechanical ventilation (ten trials), and neurodevelopment outcomes evaluated at five to six years of age (two trials).",
"     </li>",
"     <li>",
"      There were no differences in secondary outcomes (eg, rates of necrotizing enterocolitis, bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, and hypotension requiring medical intervention), except patients in the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      group took longer to reach full enteral feeds, especially very preterm infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the above studies, in preterm infants it appears that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     Morphine",
"    </a>",
"    analgesia may be associated with significant side effects, including hypotension, delayed feeding, and it does not alter long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/108,113,114\">",
"     108,113,114",
"    </a>",
"    ]. The routine use of morphine infusions is, therefore, not recommended for ventilated preterm neonates.",
"   </p>",
"   <p>",
"    In ventilated term infants,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    analgesia may not be associated with the same risk of adverse effects as seen in preterm infants, but still may be cause an increase duration of ventilation. This was illustrated in a retrospective study of 62 ventilated term newborns that found postoperative morphine infusions prolonged the need for mechanical ventilation, but were not associated with apnea, hypotension, or other complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Postoperative and procedural pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies and trials comparing intermittent bolus versus continuous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    administration of morphine suggest that morphine is safe and effective in reducing postoperative pain in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/116-120\">",
"     116-120",
"    </a>",
"    ]. However, there are currently no data from randomized trials comparing the safety of efficacy of postoperative morphine analgesia to placebo in preterm neonates.",
"   </p>",
"   <p>",
"    Data also are conflicting regarding",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    's ability to reduce acute pain from procedures as demonstrated by the following randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/108,111,121,122\">",
"     108,111,121,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study, ventilated neonates who required central venous line placement were randomly assigned topical anesthesia alone (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37648?source=see_link\">",
"       tetracaine",
"      </a>",
"      ),",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      alone, or both tetracaine and morphine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/121\">",
"       121",
"      </a>",
"      ]. Infants who received no analgesic therapy because of parental choice were used as a no treatment group. Assessment of pain was based upon changes in heart rate and the duration of facial grimacing during different phases of the procedure. Morphine alone and morphine plus tetracaine groups had lower pain scores than the no treatment or tetracaine alone groups. However, patients who received morphine required an increase in ventilatory support within the first 12 hours following the procedure.",
"     </li>",
"     <li>",
"      The second study, nested within the NEOPAIN trial, evaluated the response to heelstick in preterm infants who were randomly assigned to continuous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      infusion or placebo therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/122\">",
"       122",
"      </a>",
"      ]. Responses to pain using assessment tools based upon behavioral and physiological indicators demonstrated no difference in pain scores between the two groups.",
"     </li>",
"     <li>",
"      The third trial of ventilated preterm neonates assigned to either",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      or placebo therapy found no difference in the responses to tracheal suctioning between the two groups using multiple methods for pain assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/111\">",
"       111",
"      </a>",
"      ]. A detailed analysis of morphine pharmacodynamics in ventilated preterm neonates also found no relationship between measured plasma morphine levels and the responses to tracheal suctioning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/123\">",
"       123",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=see_link&amp;anchor=H8#H8\">",
"       \"Assessment of neonatal pain\", section on 'Pain assessment tools'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     B",
"1ff8",
"irth asphyxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    analgesia may be beneficial in term infants following birth asphyxia. This was illustrated in an observational study of 52 term infants who had significant hypoxic-ischemic insults documented by elevated serum lactate levels or low five minute Apgar scored and underwent magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/124\">",
"     124",
"    </a>",
"    ]. MRI demonstrated less brain injury in infants who were treated with opioids than those who did not receive opioid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Fentanyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    is used because of its ability to provide rapid analgesia with minimal hemodynamic effects. There are no large trials of the use of fentanyl in neonates similar to those for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    . Small randomized controlled trials have reported reduced stress hormone levels (eg, catecholamines and glucocorticoids), fewer episodes of hypoxia, and lower behavioral stress scores in ventilated infants treated with fentanyl compared to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. Although infants who received fentanyl required greater ventilatory support, there were no differences in clinical outcomes between the fentanyl- and placebo-treated groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/125,127\">",
"     125,127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     Fentanyl",
"    </a>",
"    or its shorter-acting derivatives (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/53/2903?source=see_link\">",
"     alfentanil",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/56/31622?source=see_link\">",
"     remifentanil",
"    </a>",
"    ) are often used for achieving analgesia prior to tracheal intubation in preterm and term newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/128-131\">",
"     128-131",
"    </a>",
"    ]. A randomized controlled trial in 20 preterm newborns found that the overall intubating conditions were significantly improved in those receiving remifentanil rather than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    prior to endotracheal intubation. However, there were no complications observed following either intravenous morphine or remifentanil use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In accordance with the American Academy of Pediatrics and the Canadian Pediatric Society",
"    <span class=\"nowrap\">",
"     (AAP/CPS)",
"    </span>",
"    guidelines, we do",
"    <strong>",
"     not routinely",
"    </strong>",
"    use continuous infusions of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    in ventilated preterm neonates. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/2\">",
"     2",
"    </a>",
"    ] We reserve the use of fentanyl when a rapidly acting opioid is required for analgesia in a controlled setting that can adequately address any associated potential side effects (eg, bradycardia, chest wall rigidity). Other indications include fentanyl analgesia for postoperative pain (particularly following cardiac surgery), or for patients with pulmonary hypertension (primary, or secondary to meconium aspiration, diaphragmatic hernia, or congenital heart disease). Further studies of fentanyl analgesia for ventilated preterm neonates, and for term and preterm neonates exposed to postoperative pain or procedural pain, are required to evaluate its safety and efficacy in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88253533\">",
"    <span class=\"h4\">",
"     Compared to other opioid agents",
"    </span>",
"   </p>",
"   <p>",
"    Compared to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    analgesia is associated with less sedative or hypotensive effects, reduced effects on gastrointestinal motility or urinary retention, but greater opioid tolerance and withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/132-135\">",
"     132-135",
"    </a>",
"    ]. In one randomized trial comparing infusions of fentanyl (1.5",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per hour) versus morphine (20",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per hour) in ventilated neonates, similar pain scores, catecholamine responses, and vital signs were reported in the two groups. There were no adverse respiratory effects or difficulties in weaning from ventilation in either group, but lower beta-endorphin levels and decreased incidence of gastrointestinal dysmotility occurred in the fentanyl group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a trial of postoperative preterm infants,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/7/26743?source=see_link\">",
"     tramadol",
"    </a>",
"    were equally effective for pain relief, and there were no differences between the two regarding the duration of mechanical ventilation and the time to reach enteral feeds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5495647\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above discussion and clinical experience in our institution, we feel that routine use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    infusions in ventilated preterm infants cannot be recommended at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/112\">",
"     112",
"    </a>",
"    ], except for neonates undergoing tracheal intubation, central line placement, or surgery. Morphine analgesia may be used in ventilated term neonates following surgery, birth asphyxia, or those requiring moderately invasive procedures like central venous catheterization, tracheal intubation, or chest tube placement.",
"   </p>",
"   <p>",
"    Extreme caution must be exercised if using opioid therapy in ventilated preterm neonates born at 23 to 26 weeks gestation or those with pre-existing hypotension at baseline because of the increased risk for associated adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/110,137\">",
"     110,137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181258568\">",
"    <span class=\"h2\">",
"     Ketamine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     Ketamine",
"    </a>",
"    , an N-methyl-D-aspartate (NMDA) receptor antagonist, was introduced as a &ldquo;dissociative anesthetic&rdquo; but is widely used for procedural, operative, or postoperative analgesia and sedation in neonates and small infants. Ketamine is the only analgesic that produces intense sedation and amnesia, while maintaining respiratory drive, producing bronchodilation, and improving hemodynamic function with mild increases in heart rate and blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/138\">",
"     138",
"    </a>",
"    ]. Although, in rodents and other animal models, prolonged exposure to high doses of ketamine was associated with increased apoptotic",
"    <span class=\"nowrap\">",
"     and",
"1ff8",
"/or",
"    </span>",
"    necrotic cell death in the developing brain, the clinical relevance of these data remain questionable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/139-141\">",
"     139-141",
"    </a>",
"    ]. In newborn rats, the use of ketamine analgesia in the setting of inflammatory pain reduced cell death in the developing brain areas and improved the animals&rsquo; long-term neurobehavioral outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    In preterm neonates undergoing central venous catheterization, no significant hemodynamic changes were associated with use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    during the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/144\">",
"     144",
"    </a>",
"    ]. High doses of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of ketamine were associated with reduced heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/145\">",
"     145",
"    </a>",
"    ], and even higher doses of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    reduced blood pressure without impairing cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At our institution, we use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose intravenously) for neonates with hemodynamic instability, such as those with congenital heart disease, congenital diaphragmatic hernia, or those requiring ECMO cannulation. Further research is needed to establish the safety and efficacy of ketamine",
"    <span class=\"nowrap\">",
"     analgesia/sedation",
"    </span>",
"    for ventilated neonates or for other clinical indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Sedatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;These drugs (eg, benzodiazepines, barbiturates, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    ) provide sedation, anxiolysis, muscle relaxation, and amnesia. However, sedatives do not provide analgesia and may even mask the clinical signs of pain in some neonates.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    is a short-acting benzodiazepine, but may cause prolonged sedative effects in sick preterm neonates. Three randomized trials have examined its use in ventilated preterm neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/146-148\">",
"     146-148",
"    </a>",
"    ]. However, differences in study design did not allow combining these results into a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/149\">",
"     149",
"    </a>",
"    ]. Two studies reported increased sedation with midazolam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/147,148\">",
"     147,148",
"    </a>",
"    ], and the third study reported an increase in poor neurologic outcomes among preterm neonates who received midazolam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/146\">",
"     146",
"    </a>",
"    ]. In addition, a randomized trial evaluating midazolam as pre-medication for endotracheal intubation was terminated early because of significant oxygen desaturations in treated versus control infants (86 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/150\">",
"     150",
"    </a>",
"    ]. Based upon these results, the use of midazolam is not recommended in preterm neonates.",
"   </p>",
"   <p>",
"    In one animal study,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    increased the need for analgesia and provided poor sedation in newborn rats, which had comparable neurological maturity to preterm human neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that prolonged use of neonatal sedative",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analgesic drugs may not have clinical long-term neurological and behavioral sequelae as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis of data from a French population-based study (EPIPAGE cohort) of very preterm infants (gestational age below 33 weeks of age), there was no difference in the five-year neurological outcome between patients who received sedative",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      opioid drugs for more than seven days as neonates compared to those without prolonged neonatal exposure to sedation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      analgesia (RR 1.0, 95% CI 0.8 to 1.2), after adjusting for gestational age and a propensity score (which included neonatal, pregnancy, and birth confounding factors) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/152\">",
"       152",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another follow-up study of preterm survivors at five or six years, although there were no differences in cognition, behavior, movement and thyroid function between those randomly assigned to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      and those assigned to placebo, although there was a trend towards better performance in the morphine group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a follow-up study of five-year-olds who had participated in the previously discussed neonatal Dutch trial of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      for pain control, multivariate analysis found no difference between children who had received morphine as a neonate compared with control children when treatment condition, open-label morphine consumption, and a propensity score for clinically relevant concomitant factors were controlled [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/153\">",
"       153",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neonatal pain and stress may alter the regulation of cortisol secretion in preterm infants with elevated basal cortisol levels and dampened stress reactivity until at least 18 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/154,155\">",
"     154,155",
"    </a>",
"    ]. In these infants, high cortisol levels during infancy may contribute to greater risks of impaired neurodevelopment and poorer attention, modulated to some extent by maternal mood and caregiving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/18/35114/abstract/155-157\">",
"     155-157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further follow-up studies are needed to determine if there are significant long-term effects of neonatal sedative",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analgesic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates experience pain in a similar manner to older children and adults. Pain is most common and intense in infants who are cared for in the neonatal intensive care unit (NICU).",
"     </li>",
"     <li>",
"      Each health care facility that treats neonates should establish a neonatal pain control program that includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Routine assessments for the detection of pain (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=see_link\">",
"       \"Assessment of neonatal pain\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reduction of the number of painful procedures and episodes of patient handling (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Reduction of painful events'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Guidelines and protocols to",
"      <span class=\"nowrap\">",
"       prevent/reduce",
"      </span>",
"      pain due to handling and procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analgesia should be provided preemptively for any painful procedure. Nonpharmacologic meas",
"1ff8",
"ures (oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      , breastfeeding, nonnutritive sucking, swaddling or facilitated tucking, and skin-to-skin contact) and pharmacologic agents (EMLA,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      , and opioids) are used for neonatal pain control. Therapy including combination of interventions is dependent upon the specific procedure performed (",
"      <a class=\"graphic graphic_table graphicRef75338 \" href=\"mobipreview.htm?3/2/3118\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We employ the following step-wise approach in the management of neonatal pain depending on the clinical setting, which is based on published data and our clinical experience.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that facilitated tucking or skin-to-skin contact be used to improve analgesia for any painful procedure, when feasible (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neonates undergoing a brief needlestick (eg, heelstick, venipuncture), we recommend oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Alternatives include breastfeeding, breast milk, or glucose. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Oral sucrose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neonates undergoing a more prolonged or painful skin breaking procedure (arterial puncture, arterial or venous line placement, or lumbar puncture), in addition to oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      , we suggest the use of a topical anesthetic cream (eg, EMLA&reg;) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Topical anesthetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For male neonatal circumcision, in addition to oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/13/43218?source=see_link\">",
"       sucrose",
"      </a>",
"      , we suggest ring block or dorsal penile nerve block rather than topical anesthetic cream (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link&amp;anchor=H8#H8\">",
"       \"Techniques for neonatal circumcision\", section on 'Pain control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For neonates who undergo more invasive procedures, such as central line placement, we suggest that nonpharmacologic measures be combined with",
"      <span class=\"nowrap\">",
"       local/topical",
"      </span>",
"      anesthesia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systemic analgesia to provide adequate analgesia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Systemic analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that neonates receive postoperative analgesia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This is generally accomplished with a combination of nonpharmacologic approaches,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , and opioid therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Systemic analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend against the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      for routine sedation in ventilated neonates (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Analgesia in such patients should be based on an individual assessment of their analgesic requirements. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Morphine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/1\">",
"      Anand KJ, Aranda JV, Berde CB, et al. Summary proceedings from the neonatal pain-control group. Pediatrics 2006; 117:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/2\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn, American Academy of Pediatrics Section on Surgery, Canadian Paediatric Society Fetus and Newborn Committee, et al. Prevention and management of pain in the neonate: an update. Pediatrics 2006; 118:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/3\">",
"      Franck LS, Allen A, Cox S, Winter I. Parents' views about infant pain in neonatal intensive care. Clin J Pain 2005; 21:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/4\">",
"      Franck LS, Cox S, Allen A, Winter I. Parental concern and distress about infant pain. Arch Dis Child Fetal Neonatal Ed 2004; 89:F71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/5\">",
"      Pereira-Da-Silva L, Bergmans KI, van Kerkhoven LA, et al. Reducing discomfort while measuring crown-heel length in neonates. Acta Paediatr 2006; 95:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/6\">",
"      Sharek PJ, Powers R, Koehn A, Anand KJ. Evaluation and development of potentially better practices to improve pain management of neonates. Pediatrics 2006; 118 Suppl 2:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/7\">",
"      Anand KJ, International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. Arch Pediatr Adolesc Med 2001; 155:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/8\">",
"      Bellieni CV, Buonocore G. Neonatal pain treatment: ethical to be effective. J Perinatol 2008; 28:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/9\">",
"      Anand KJ, Hall RW. Pharmacological therapy for analgesia and sedation in the newborn. Arch Dis Child Fetal Neonatal Ed 2006; 91:F448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/10\">",
"      Lago P, Garetti E, Merazzi D, et al. Guidelines for procedural pain in the newborn. Acta Paediatr 2009; 98:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/11\">",
"      Anand KJ. Analgesia for skin-breaking procedures in newborns and children: what works best? CMAJ 2008; 179:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/12\">",
"      Cogen MS, Parker JS, Sleep TE, et al. Masked trial of topical anesthesia for retinopathy of prematurity eye examinations. J AAPOS 2011; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/13\">",
"      Marsh VA, Young WO, Dunaway KK, et al. Efficacy of topical anesthetics to reduce pain in premature infants during eye examinations for retinopathy of prematurity. Ann Pharmacother 2005; 39:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/14\">",
"      Olsson E, Eriksson M. Oral glucose for pain relief during eye examinations for retinopathy of prematurity. J Clin Nurs 2011; 20:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstra 1ff8 ct\" href=\"mobipreview.htm?34/18/35114/abstract/15\">",
"      Rush R, Rush S, Ighani F, et al. The effects of comfort care on the pain response in preterm infants undergoing screening for retinopathy of prematurity. Retina 2005; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/16\">",
"      Sammartino M, Bocci MG, Ferro G, et al. Efficacy and safety of continuous intravenous infusion of remifentanil in preterm infants undergoing laser therapy in retinopathy of prematurity: clinical experience. Paediatr Anaesth 2003; 13:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/17\">",
"      Aranda JV, Carlo W, Hummel P, et al. Analgesia and sedation during mechanical ventilation in neonates. Clin Ther 2005; 27:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/18\">",
"      Zempsky WT, Bean-Lijewski J, Kauffman RE, et al. Needle-free powder lidocaine delivery system provides rapid effective analgesia for venipuncture or cannulation pain in children: randomized, double-blind Comparison of Venipuncture and Venous Cannulation Pain After Fast-Onset Needle-Free Powder Lidocaine or Placebo Treatment trial. Pediatrics 2008; 121:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/19\">",
"      Pillai Riddell RR, Racine NM, Turcotte K, et al. Non-pharmacological management of infant and young child procedural pain. Cochrane Database Syst Rev 2011; :CD006275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/20\">",
"      Bellieni CV, Cordelli DM, Marchi S, et al. Sensorial saturation for neonatal analgesia. Clin J Pain 2007; 23:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/21\">",
"      Golianu B, Krane E, Seybold J, et al. Non-pharmacological techniques for pain management in neonates. Semin Perinatol 2007; 31:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/22\">",
"      Taddio A, Pollock N, Gilbert-MacLeod C, et al. Combined analgesia and local anesthesia to minimize pain during circumcision. Arch Pediatr Adolesc Med 2000; 154:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/23\">",
"      Chermont AG, Falc&atilde;o LF, de Souza Silva EH, et al. Skin-to-skin contact and/or oral 25% dextrose for procedural pain relief for term newborn infants. Pediatrics 2009; 124:e1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/24\">",
"      O'Sullivan A, O'Connor M, Brosnahan D, et al. Sweeten, soother and swaddle for retinopathy of prematurity screening: a randomised placebo controlled trial. Arch Dis Child Fetal Neonatal Ed 2010; 95:F419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/25\">",
"      Okan F, Coban A, Ince Z, et al. Analgesia in preterm newborns: the comparative effects of sucrose and glucose. Eur J Pediatr 2007; 166:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/26\">",
"      Harrison D, Bueno M, Yamada J, et al. Analgesic effects of sweet-tasting solutions for infants: current state of equipoise. Pediatrics 2010; 126:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/27\">",
"      Stevens B, Yamada J, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev 2010; :CD001069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/28\">",
"      Cignacco EL, Sellam G, Stoffel L, et al. Oral sucrose and \"facilitated tucking\" for repeated pain relief in preterms: a randomized controlled trial. Pediatrics 2012; 129:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/29\">",
"      Stevens B, Yamada J, Lee GY, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev 2013; 1:CD001069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/30\">",
"      Slater R, Cornelissen L, Fabrizi L, et al. Oral sucrose as an analgesic drug for procedural pain in newborn infants: a randomised controlled trial. Lancet 2010; 376:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/31\">",
"      Vanhatalo S. Oral sucrose for procedural pain in infants. Lancet 2011; 377:26; author reply 27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/32\">",
"      Linhares MB, Gaspardo CM, Martinez FE. Oral sucrose for procedural pain in infants. Lancet 2011; 377:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/33\">",
"      Stevens B, Craig K, Johnston C, et al. Oral sucrose for procedural pain in infants. Lancet 2011; 377:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/34\">",
"      Steed D, Port L, Connell TG, et al. Oral sucrose for procedural pain in infants. Lancet 2011; 377:25; author reply 27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/35\">",
"      Heaton PA, Fernando AM, Herd D. Oral sucrose for procedural pain in infants. Lancet 2011; 377:25; author reply 27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/36\">",
"      Fernandez M, Blass EM, Hernandez-Reif M, et al. Sucrose attenuates a negative electroencephalographic response to an aversive stimulus for newborns. J Dev Behav Pediatr 2003; 24:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/37\">",
"      Blass EM, Shah A. Pain-reducing properties of sucrose in human newborns. Chem Senses 1995; 20:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/38\">",
"      Blass EM, Shide DJ. Endogenous cholecystokinin reduces vocalization in isolated 10-day-old rats. Behav Neurosci 1993; 107:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/39\">",
"      Ren K, Blass EM, Zhou Q, Dubner R. Suckling and sucrose ingestion suppress persistent hyperalgesia and spinal Fos expression after forepaw inflammation in infant rats. Proc Natl Acad Sci U S A 1997; 94:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/40\">",
"      Gradin M, Schollin J. The role of endogenous opioids in mediating pain reduction by orally administered glucose among newborns. Pediatrics 2005; 115:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/41\">",
"      Taddio A, Shah V, Shah P, Katz J. Beta-endorphin concentration after administration of sucrose in preterm infants. Arch Pediatr Adolesc Med 2003; 157:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/42\">",
"      Taddio A, Shah V, Hancock R, et al. Effectiveness of sucrose analgesia in newborns undergoing painful medical procedures. CMAJ 2008; 179:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/43\">",
"      Gal P, Kissling GE, Young WO, et al. Efficacy of sucrose to reduce pain in premature infants during eye examinations for retinopathy of prematurity. Ann Pharmacother 2005; 39:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/44\">",
"      Mitchell A, Stevens B, Mungan N, et al. Analgesic effects of oral sucrose and pacifier during eye examinations for retinopathy of prematurity. Pain Manag Nurs 2004; 5:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./prevention-and-treatment-of-neonatal-",
"1ff8",
"pain/abstract/45\">",
"      Grabska J, Walden P, Lerer T, et al. Can oral sucrose reduce the pain and distress associated with screening for retinopathy of prematurity? J Perinatol 2005; 25:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/46\">",
"      Boyle EM, Freer Y, Khan-Orakzai Z, et al. Sucrose and non-nutritive sucking for the relief of pain in screening for retinopathy of prematurity: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2006; 91:F166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/47\">",
"      Sun X, Lemyre B, Barrowman N, O'Connor M. Pain management during eye examinations for retinopathy of prematurity in preterm infants: a systematic review. Acta Paediatr 2010; 99:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/48\">",
"      Stevens B, Yamada J, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev 2004; :CD001069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/49\">",
"      Johnston CC, Stremler R, Horton L, Friedman A. Effect of repeated doses of sucrose during heel stick procedure in preterm neonates. Biol Neonate 1999; 75:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/50\">",
"      Johnston CC, Filion F, Snider L, et al. Routine sucrose analgesia during the first week of life in neonates younger than 31 weeks' postconceptional age. Pediatrics 2002; 110:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/51\">",
"      Blass EM, Camp CA. Changing determinants of crying termination in 6- to 12-week-old human infants. Dev Psychobiol 2003; 42:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/52\">",
"      Curtis SJ, Jou H, Ali S, et al. A randomized controlled trial of sucrose and/or pacifier as analgesia for infants receiving venipuncture in a pediatric emergency department. BMC Pediatr 2007; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/53\">",
"      Stevens B, Yamada J, Beyene J, et al. Consistent management of repeated procedural pain with sucrose in preterm neonates: Is it effective and safe for repeated use over time? Clin J Pain 2005; 21:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/54\">",
"      Johnston CC, Filion F, Snider L, et al. How much sucrose is too much sucrose? Pediatrics 2007; 119:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/55\">",
"      Holsti L, Grunau RE. Considerations for using sucrose to reduce procedural pain in preterm infants. Pediatrics 2010; 125:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/56\">",
"      Lefrak L, Burch K, Caravantes R, et al. Sucrose analgesia: identifying potentially better practices. Pediatrics 2006; 118 Suppl 2:S197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/57\">",
"      Rao M, Blass EM, Brignol MM, et al. Reduced heat loss following sucrose ingestion in premature and normal human newborns. Early Hum Dev 1997; 48:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/58\">",
"      Shah PS, Herbozo C, Aliwalas LL, Shah VS. Breastfeeding or breast milk for procedural pain in neonates. Cochrane Database Syst Rev 2012; 12:CD004950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/59\">",
"      Abdulkader HM, Freer Y, Fleetwood-Walker SM, McIntosh N. Effect of suckling on the peripheral sensitivity of full-term newborn infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/60\">",
"      Weissman A, Aranovitch M, Blazer S, Zimmer EZ. Heel-lancing in newborns: behavioral and spectral analysis assessment of pain control methods. Pediatrics 2009; 124:e921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/61\">",
"      Shann F. Suckling and sugar reduce pain in babies. Lancet 2007; 369:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/62\">",
"      Brovedani P, Montico M, Shardlow A, et al. Suckling and sugar for pain reduction in babies. Lancet 2007; 369:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/63\">",
"      Shendurnikar N, Gandhi K. Analgesic effects of breastfeeding on heel lancing. Indian Pediatr 2005; 42:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/64\">",
"      Stevens B, Johnston C, Franck L, et al. The efficacy of developmentally sensitive interventions and sucrose for relieving procedural pain in very low birth weight neonates. Nurs Res 1999; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/65\">",
"      Campos RG. Soothing pain-elicited distress in infants with swaddling and pacifiers. Child Dev 1989; 60:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/66\">",
"      Campos RG. Rocking and pacifiers: two comforting interventions for heelstick pain. Res Nurs Health 1994; 17:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/67\">",
"      Geyer J, Ellsbury D, Kleiber C, et al. An evidence-based multidisciplinary protocol for neonatal circumcision pain management. J Obstet Gynecol Neonatal Nurs 2002; 31:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/68\">",
"      Cignacco E, Hamers JP, Stoffel L, et al. The efficacy of non-pharmacological interventions in the management of procedural pain in preterm and term neonates. A systematic literature review. Eur J Pain 2007; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/69\">",
"      Corff KE, Seideman R, Venkataraman PS, et al. Facilitated tucking: a nonpharmacologic comfort measure for pain in preterm neonates. J Obstet Gynecol Neonatal Nurs 1995; 24:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/70\">",
"      Axelin A, Salanter&auml; S, Lehtonen L. 'Facilitated tucking by parents' in pain management of preterm infants-a randomized crossover trial. Early Hum Dev 2006; 82:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/71\">",
"      Fearon I, Kisilevsky BS, Hains SM, et al. Swaddling after heel lance: age-specific effects on behavioral recovery in preterm infants. J Dev Behav Pediatr 1997; 18:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/72\">",
"      Huang CM, Tung WS, Kuo LL, Ying-Ju C. Comparison of pain responses of premature infants to the heelstick between containment and swaddling. J Nurs Res 2004; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/73\">",
"      Ward-Larson C, Horn RA, Gosnell F. The efficacy of facilitated tucking for relieving procedural pain of endotracheal suctioning in very low birthweight infants. MCN Am J Matern Child Nurs 2004; 29:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/74\">",
"      Gray L, Watt L, Blass EM. Skin-to-skin contact is analgesic in healthy newborns. Pediatrics 2000; 105:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract 1ff8 \" href=\"mobipreview.htm?34/18/35114/abstract/75\">",
"      Johnston CC, Stevens B, Pinelli J, et al. Kangaroo care is effective in diminishing pain response in preterm neonates. Arch Pediatr Adolesc Med 2003; 157:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/76\">",
"      Ludington-Hoe SM, Hosseini R, Torowicz DL. Skin-to-skin contact (Kangaroo Care) analgesia for preterm infant heel stick. AACN Clin Issues 2005; 16:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/77\">",
"      Ferber SG, Makhoul IR. Neurobehavioural assessment of skin-to-skin effects on reaction to pain in preterm infants: a randomized, controlled within-subject trial. Acta Paediatr 2008; 97:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/78\">",
"      Freire NB, Garcia JB, Lamy ZC. Evaluation of analgesic effect of skin-to-skin contact compared to oral glucose in preterm neonates. Pain 2008; 139:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/79\">",
"      Bellieni CV, Bagnoli F, Perrone S, et al. Effect of multisensory stimulation on analgesia in term neonates: a randomized controlled trial. Pediatr Res 2002; 51:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/80\">",
"      Bellieni CV, Buonocore G, Nenci A, et al. Sensorial saturation: an effective analgesic tool for heel-prick in preterm infants: a prospective randomized trial. Biol Neonate 2001; 80:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/81\">",
"      Taddio A, Ohlsson K, Ohlsson A. Lidocaine-prilocaine cream for analgesia during circumcision in newborn boys. Cochrane Database Syst Rev 2000; :CD000496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/82\">",
"      Kaur G, Gupta P, Kumar A. A randomized trial of eutectic mixture of local anesthetics during lumbar puncture in newborns. Arch Pediatr Adolesc Med 2003; 157:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/83\">",
"      Taddio A, Ohlsson A, Einarson TR, et al. A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. Pediatrics 1998; 101:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/84\">",
"      Biran V, Gourrier E, Cimerman P, et al. Analgesic effects of EMLA cream and oral sucrose during venipuncture in preterm infants. Pediatrics 2011; 128:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/85\">",
"      Essink-Tebbes CM, Wuis EW, Liem KD, et al. Safety of lidocaine-prilocaine cream application four times a day in premature neonates: a pilot study. Eur J Pediatr 1999; 158:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/86\">",
"      Arana A, Morton NS, Hansen TG. Treatment with paracetamol in infants. Acta Anaesthesiol Scand 2001; 45:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/87\">",
"      Anderson BJ, van Lingen RA, Hansen TG, et al. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 2002; 96:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/88\">",
"      Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000; 50:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/89\">",
"      Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med 2002; 347:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/90\">",
"      van Lingen RA, Deinum HT, Quak CM, et al. Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. Clin Pharmacol Ther 1999; 66:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/91\">",
"      van Lingen RA, Deinum JT, Quak JM, et al. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80:F59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/92\">",
"      Anderson BJ, Pons G, Autret-Leca E, et al. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth 2005; 15:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/93\">",
"      Truog R, Anand KJ. Management of pain in the postoperative neonate. Clin Perinatol 1989; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/94\">",
"      Anderson BJ, Holford NH, Armishaw JC, Aicken R. Predicting concentrations in children presenting with acetaminophen overdose. J Pediatr 1999; 135:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/95\">",
"      Hopchet L, Kulo A, Rayyan M, et al. Does intravenous paracetamol administration affect body temperature in neonates? Arch Dis Child 2011; 96:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/96\">",
"      Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 2011; 96:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/97\">",
"      Howard CR, Howard FM, Weitzman ML. Acetaminophen analgesia in neonatal circumcision: the effect on pain. Pediatrics 1994; 93:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/98\">",
"      Shah V, Taddio A, Ohlsson A. Randomised controlled trial of paracetamol for heel prick pain in neonates. Arch Dis Child Fetal Neonatal Ed 1998; 79:F209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/99\">",
"      Ceelie I, de Wildt SN, van Dijk M, et al. Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial. JAMA 2013; 309:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/100\">",
"      Bhatt-Mehta V, Rosen DA. Management of acute pain in children. Clin Pharm 1991; 10:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/101\">",
"      Zenker M, Klinge J, Kr&uuml;ger C, et al. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. J Perinat Med 1998; 26:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/102\">",
"      Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001; 107:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/103\">",
"      Schmidt B, Adelmann C, St&uuml;tzer H, et al. Comparison of sufentanil versus fentanyl in ventilated term neonates. Klin Padiatr 2010; 222:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/104\">",
"      Penney CL, Gauldie J, Evelegh M, et al. Polycarbonate membranes: a novel surface for solid-phase determinations with utility in field format serological assays. J Immunol Methods 1989; 123:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./prevention",
"1ff8",
"-and-treatment-of-neonatal-pain/abstract/105\">",
"      Dyke MP, Kohan R, Evans S. Morphine increases synchronous ventilation in preterm infants. J Paediatr Child Health 1995; 31:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/106\">",
"      Quinn MW, Wild J, Dean HG, et al. Randomised double-blind controlled trial of effect of morphine on catecholamine concentrations in ventilated pre-term babies. Lancet 1993; 342:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/107\">",
"      Wood CM, Rushforth JA, Hartley R, et al. Randomised double blind trial of morphine versus diamorphine for sedation of preterm neonates. Arch Dis Child Fetal Neonatal Ed 1998; 79:F34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/108\">",
"      Anand KJ, Hall RW, Desai N, et al. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. Lancet 2004; 363:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/109\">",
"      Menon G, Boyle EM, Bergqvist LL, et al. Morphine analgesia and gastrointestinal morbidity in preterm infants: secondary results from the NEOPAIN trial. Arch Dis Child Fetal Neonatal Ed 2008; 93:F362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/110\">",
"      Hall RW, Kronsberg SS, Barton BA, et al. Morphine, hypotension, and adverse outcomes among preterm neonates: who's to blame? Secondary results from the NEOPAIN trial. Pediatrics 2005; 115:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/111\">",
"      Simons SH, van Dijk M, van Lingen RA, et al. Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial. JAMA 2003; 290:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/112\">",
"      Bell&ugrave; R, de Waal K, Zanini R. Opioids for neonates receiving mechanical ventilation: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2010; 95:F241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/113\">",
"      Black AM, Bandya S, Clark D, et al. Effect of caffeine and morphine on the developing pre-mature brain. Brain Res 2008; 1219:136.v.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/114\">",
"      MacGregor R, Evans D, Sugden D, et al. Outcome at 5-6 years of prematurely born children who received morphine as neonates. Arch Dis Child Fetal Neonatal Ed 1998; 79:F40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/115\">",
"      El Sayed MF, Taddio A, Fallah S, et al. Safety profile of morphine following surgery in neonates. J Perinatol 2007; 27:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/116\">",
"      Bouwmeester NJ, Hop WC, van Dijk M, et al. Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med 2003; 29:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/117\">",
"      van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, et al. Efficacy of continuous versus intermittent morphine administration after major surgery in 0-3-year-old infants; a double-blind randomized controlled trial. Pain 2002; 98:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/118\">",
"      Rouss K, Gerber A, Albisetti M, et al. Long-term subcutaneous morphine administration after surgery in newborns. J Perinat Med 2007; 35:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/119\">",
"      van der Marel CD, Peters JW, Bouwmeester NJ, et al. Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants. Br J Anaesth 2007; 98:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/120\">",
"      Lynn AM, Nespeca MK, Bratton SL, Shen DD. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. Pain 2000; 88:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/121\">",
"      Taddio A, Lee C, Yip A, et al. Intravenous morphine and topical tetracaine for treatment of pain in [corrected] neonates undergoing central line placement. JAMA 2006; 295:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/122\">",
"      Carbajal R, Lenclen R, Jugie M, et al. Morphine does not provide adequate analgesia for acute procedural pain among preterm neonates. Pediatrics 2005; 115:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/123\">",
"      Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 101:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/124\">",
"      Angeles DM, Wycliffe N, Michelson D, et al. Use of opioids in asphyxiated term neonates: effects on neuroimaging and clinical outcome. Pediatr Res 2005; 57:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/125\">",
"      Orsini AJ, Leef KH, Costarino A, et al. Routine use of fentanyl infusions for pain and stress reduction in infants with respiratory distress syndrome. J Pediatr 1996; 129:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/126\">",
"      Guinsburg R, Kopelman BI, Anand KJ, et al. Physiological, hormonal, and behavioral responses to a single fentanyl dose in intubated and ventilated preterm neonates. J Pediatr 1998; 132:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/127\">",
"      Lago P, Benini F, Agosto C, Zacchello F. Randomised controlled trial of low dose fentanyl infusion in preterm infants with hyaline membrane disease. Arch Dis Child Fetal Neonatal Ed 1998; 79:F194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/128\">",
"      Pereira e Silva Y, Gomez RS, Marcatto Jde O, et al. Morphine versus remifentanil for intubating preterm neonates. Arch Dis Child Fetal Neonatal Ed 2007; 92:F293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/129\">",
"      Roberts KD, Leone TA, Edwards WH, et al. Premedication for nonemergent neonatal intubations: a randomized, controlled trial comparing atropine and fentanyl to atropine, fentanyl, and mivacurium. Pediatrics 2006; 118:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/130\">",
"      Pokela ML, Koivisto M. Physiological changes, plasma beta-endorphin and cortisol responses to tracheal intubation in neonates. Acta Paediatr 1994; 83:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/131\">",
"      Kim JH, Kim KH, Woo HY, Shim JY. Maternal cytokine production during pregnancy and the development of childhood wheezing and allergic disease in offspring three years of age. J Asthma 2008; 45:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/132\">",
"      Saarenmaa E, Huttunen P, Lepp&auml;luoto J, et al. Advantages of fentanyl over morphine in analgesia for ventilated newborn infants after birth: A randomized trial. J Pediatr 1999; 134:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./prevention-and-treatment-of-neonatal",
"1ff8",
"-pain/abstract/133\">",
"      Ionides SP, Weiss MG, Angelopoulos M, et al. Plasma beta-endorphin concentrations and analgesia-muscle relaxation in the newborn infant supported by mechanical ventilation. J Pediatr 1994; 125:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/134\">",
"      Franck LS, Vilardi J, Durand D, Powers R. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation. Am J Crit Care 1998; 7:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/135\">",
"      Anand KJ, Willson DF, Berger J, et al. Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics 2010; 125:e1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/136\">",
"      Alencar AJ, Sanudo A, Sampaio VM, et al. Efficacy of tramadol versus fentanyl for postoperative analgesia in neonates. Arch Dis Child Fetal Neonatal Ed 2012; 97:F24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/137\">",
"      Hall RW, Boyle E, Young T. Do ventilated neonates require pain management? Semin Perinatol 2007; 31:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/138\">",
"      Hall RW, Shbarou RM. Drugs of choice for sedation and analgesia in the neonatal ICU. Clin Perinatol 2009; 36:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/139\">",
"      Anand KJ. Anesthetic neurotoxicity in newborns: should we change clinical practice? Anesthesiology 2007; 107:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/140\">",
"      Bhutta AT, Venkatesan AK, Rovnaghi CR, Anand KJ. Anaesthetic neurotoxicity in rodents: is the ketamine controversy real? Acta Paediatr 2007; 96:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/141\">",
"      Rappaport B, Mellon RD, Simone A, Woodcock J. Defining safe use of anesthesia in children. N Engl J Med 2011; 364:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/142\">",
"      Anand KJ, Garg S, Rovnaghi CR, et al. Ketamine reduces the cell death following inflammatory pain in newborn rat brain. Pediatr Res 2007; 62:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/143\">",
"      Rovnaghi CR, Garg S, Hall RW, et al. Ketamine analgesia for inflammatory pain in neonatal rats: a factorial randomized trial examining long-term effects. Behav Brain Funct 2008; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/144\">",
"      B&eacute;tr&eacute;mieux P, Carr&eacute; P, Pladys P, et al. Doppler ultrasound assessment of the effects of ketamine on neonatal cerebral circulation. Dev Pharmacol Ther 1993; 20:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/145\">",
"      Saarenmaa E, Neuvonen PJ, Huttunen P, Fellman V. Ketamine for procedural pain relief in newborn infants. Arch Dis Child Fetal Neonatal Ed 2001; 85:F53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/146\">",
"      Anand KJ, Barton BA, McIntosh N, et al. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. Neonatal Outcome and Prolonged Analgesia in Neonates. Arch Pediatr Adolesc Med 1999; 153:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/147\">",
"      Arya V, Ramji S. Midazolam sedation in mechanically ventilated newborns: a double blind randomized placebo controlled trial. Indian Pediatr 2001; 38:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/148\">",
"      Jacqz-Aigrain E, Daoud P, Burtin P, et al. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet 1994; 344:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/149\">",
"      Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. Cochrane Database Syst Rev 2003; :CD002052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/150\">",
"      Attardi DM, Paul DA, Tuttle DJ, Greenspan JS. Premedication for intubation in neonates. Arch Dis Child Fetal Neonatal Ed 2000; 83:F161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/151\">",
"      Koch SC, Fitzgerald M, Hathway GJ. Midazolam potentiates nociceptive behavior, sensitizes cutaneous reflexes, and is devoid of sedative action in neonatal rats. Anesthesiology 2008; 108:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/152\">",
"      Roz&eacute; JC, Denizot S, Carbajal R, et al. Prolonged sedation and/or analgesia and 5-year neurodevelopment outcome in very preterm infants: results from the EPIPAGE cohort. Arch Pediatr Adolesc Med 2008; 162:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/153\">",
"      de Graaf J, van Lingen RA, Simons SH, et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates on children's functioning: five-year follow-up of a randomized controlled trial. Pain 2011; 152:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/154\">",
"      Grunau RE, Haley DW, Whitfield MF, et al. Altered basal cortisol levels at 3, 6, 8 and 18 months in infants born at extremely low gestational age. J Pediatr 2007; 150:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/155\">",
"      Grunau RE, Holsti L, Haley DW, et al. Neonatal procedural pain exposure predicts lower cortisol and behavioral reactivity in preterm infants in the NICU. Pain 2005; 113:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/156\">",
"      Tu MT, Grunau RE, Petrie-Thomas J, et al. Maternal stress and behavior modulate relationships between neonatal stress, attention, and basal cortisol at 8 months in preterm infants. Dev Psychobiol 2007; 49:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/18/35114/abstract/157\">",
"      Oberlander TF, Weinberg J, Papsdorf M, et al. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 2008; 3:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5018 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-85BFFBD9BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35114=[""].join("\n");
var outline_f34_18_35114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SU",
"1df5",
"MMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANALGESIA FOR SPECIFIC PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114448720\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      REDUCTION OF PAINFUL EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NONPHARMACOLOGIC ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oral sucrose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Breastfeeding or breast milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-nutritive sucking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LOCAL ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Topical anesthetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - EMLA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SYSTEMIC ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nonsteroidal anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5495576\">",
"      Opioid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Morphine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ventilated neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Postoperative and procedural pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Birth asphyxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Fentanyl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88253533\">",
"      Compared to other opioid agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5495647\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181258568\">",
"      Ketamine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Sedatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5018|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/59/38846\" title=\"figure 1\">",
"      Neonate step pain therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3118\" title=\"table 1\">",
"      Newborn procedure analgesia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31863?source=related_link\">",
"      Assessment of neonatal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/199?source=related_link\">",
"      Epidemiology and pathogenesis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/1002?source=related_link\">",
"      Management of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=related_link\">",
"      Techniques for neonatal circumcision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_18_35115="Death during induction AML";
var content_f34_18_35115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mortality during induction chemotherapy in acute myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" style=\"width: 549px; height: 124px;\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Performance status*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Death by day +28 (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-59",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-69",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70-79",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;79",
"       </td>",
"       <td>",
"        &lt;3",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-69",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;69",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"       <td>",
"        57",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Zubrod (ECOG) performance status at the onset of treatment. A score of &lt;3 is seen in a patient who is either asymptomatic or symptomatic and is in bed &lt;50 percent of the time. A score of 3 or greater means that the patient is symptomatic and in bed &gt;50 percent of the time.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Estey, EH. Cancer 2001; 92:1059.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35115=[""].join("\n");
var outline_f34_18_35115=null;
var title_f34_18_35116="Comparison of coronary diagnostic techniques";
var content_f34_18_35116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of coronary diagnostic techniques",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Angioscopy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Coronary arteriography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intravascular ultrasound",
"       </td>",
"       <td class=\"subtitle1\">",
"        Optical coherence tomography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Color tone",
"       </td>",
"       <td>",
"        Color",
"       </td>",
"       <td>",
"        Black and white",
"       </td>",
"       <td>",
"        Black and white",
"       </td>",
"       <td>",
"        False color (eg, sepia) or black and white",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Picture expression",
"       </td>",
"       <td>",
"        3-dimension",
"       </td>",
"       <td>",
"        2-dimension",
"       </td>",
"       <td>",
"        2-dimension",
"       </td>",
"       <td>",
"        2-dimension and 3-dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High resolution",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quantification",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General picture",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        Tissue characterization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intraluminal",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intramural",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thrombus",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Calcification",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Plaque characterization",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"       <td class=\"sublist_other\">",
"        ++",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ++: excellent; +: good; -: poor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35116=[""].join("\n");
var outline_f34_18_35116=null;
var title_f34_18_35117="ANC hospitalization infection";
var content_f34_18_35117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neutropenia and hospitalization for infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incidence rate (per 10,000 days at risk) and 95 percent confidence intervals (vertical bars) for bacterial infection requiring hospitalization among 2047 HIV-infected patients for each absolute neutrophil count (ANC). The rate increased progressively at ANCs below 750/&micro;L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jacobson, MA, Liu, RC, Davies, D, Cohen, PT, Arch Intern Med 1997; 157:1825.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35117=[""].join("\n");
var outline_f34_18_35117=null;
var title_f34_18_35118="Rx incompatible crossmatch";
var content_f34_18_35118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Clinical management of patients with incompatible crossmatch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35118=[""].join("\n");
var outline_f34_18_35118=null;
var title_f34_18_35119="Positive predict value ETT";
var content_f34_18_35119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81630%7ECARD%2F50189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81630%7ECARD%2F50189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Estimated positive predictive value of exercise test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 168px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The positive predictive value of an ECG exercise test is related to the pretest probability of coronary heart disease (CHD), ie, the prevalence of CHD in the population studied.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calculation of probability of coronary artery disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 371px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The probability of coronary artery disease (CAD) based upon a positive exercise test depends upon the pre-test probability of CAD, ie, the prevalence of CAD in the population studied. The solid black bar indicates the results for a negative test (-ST) while the red bars indicate the results for a positive test (+ST). The results of a postive exercise test are less predictive in an asymptomatic population with a low pre-test probability of CAD while they are very predictive in patients with typical angina who have a high pretest probability of CAD. The posttest probability of CAD is optimal in patients with an intermediate prevalence of CAD, eg, the 45 year old with atypical chest pain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Patterson RE, Horowitz SF. J Am Coll Cardiol 1989; 13:1653.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_18_35119=[""].join("\n");
var outline_f34_18_35119=null;
